Amino acid derivatives

Abstract

A compound of the formula (1): 1

Description

FIELD OF THE INVENTION

[0001] The present invention relates to an amino acid derivative of the formula (I), a process for the preparation thereof, and a pharmaceutical composition comprising it as an active ingredient.

[0002] More particularly, it relates to amino acid derivatives of the formula (I) 2

[0003] (wherein all the symbols are the same meanings as hereinafter described.), non-toxic salts thereof, and the hydrates thereof, processes for the preparation thereof, and N-type calcium channel blocker comprising them.

BACKGROUND OF THE INVENTION

[0004] Calcium ion has been known as an intracellular messenger for signal transduction, and it is suggested that various physiological events are triggered by the elevation of intracellular calcium concentration. Calcium influx from extracellular fluid is one of the mechanisms for the elevation of intracellular calcium concentration. The gate of calcium influx is the voltage-dependent calcium channels. The voltage-dependent calcium channel is opened by the polarization of plasma membrane, and calcium ion influxes from extracellular fluid into the cell selectively through the channel according to the electrochemical gradient. The voltage-dependent calcium channels are classified into N-, L-, P-, Q- and T-type at present. It is known that L- and T-type calcium channels are distributed in the various tissues ubiquitously, and especially, L-type calcium channel is enriched in the smooth muscle cells or the cardiac muscle cells. On the other hand, N- and P-type calcium channels are mainly located in the nervous system and related to the neurotransmitter release. This neurotransmitter is stored in synaptic vesicles of nerve terminals at resting state. When action potential by signal transmission on nerve is conducted in pre-synaptic fiber and reaches to the nerve terminal, the voltage-dependent calcium channels are activated and then, calcium ion influxes into the nerve terminals. By these mechanisms, synaptic vesicles are fused with pre-synaptic membrane, and neurotransmitters in the vesicles are released. The released neurotransmitters are related to signal transmission in synapse due to binding to their receptors in post-synaptic membrane. From the above, an N-type calcium channel blocker is thought to be effective on various diseases induced by an excessive release of neurotransmitter. For example, it may be useful as agent for the prevention and/or treatment of cerebral infarct (J. Cereb. Blood Flow Metab., Vol. 17, 421-429, 1997), transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress (Science., 239, 57-61, 1988), neurosis or epilepsy etc. or agent for the treatment of pain (for example, acute pain, chronic pain, pain after operation, cancer pain, neuralgia, pain caused by infection etc.) (Pain, 60, 83-90, 1995).

[0005] The venoms isolated from the genus Conus, ω-conotoxin GVIA, MVIIA, are well known as N-type calcium channel blockers.

[0006] But, these ω-conotoxins are peptidic compounds, so it is expected that they have various problems (for example, they are not absorbed into the living body easily.). Therefore, there is a demand for arrangement of these blockers to non-peptidic compounds namely to small-molecule. There are some reports relate to small-molecule as follows:

[0007] For example, it is described in the specification of Japanese Patent Kokai Hei 8-217671 that glycine derivatives of the formula (A)

R1ACH(OCOR2A) CH2CONHCH2CO2H (A)

[0008] (wherein R1A and R2A are, same or different, C1-19 straight or branched alkyl, or C2-19 straight or branched alkenyl.) and salts thereof are N-type calcium channel blocker.

[0009] It is described In the specification of EP 805147 that the compounds of the formula (B) 3

[0010] (wherein R1B is alkyl, R2B is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl, R3 is hydrogen, CN, XB is bond or SO2, R4B, R5B, R6B, R8B, R9B and R10B are each hydrogen or alkyl, AB is CH or YBCO (in which YB is bond.), R7B is C-a substituent of amino acid or ester thereof, R6B and R7B together form C3-5 alkylene chain optionally substituted by C1-alkyl or hydroxy, or CH2—ZB—CH2 (in which ZB is CO, S, SO, SO2.), R7B and R8B together form C3-5 alkylene chain optionally substituted by C1-4 alkyl or hydroxy, BB is CON(R218), mB is 0˜2, R11B is hydrogen or alkyl, R12B is hydrogen, alkyl, optionally substituted aryl or optionally substituted heteroaryl, R13B is alkyl, optionally substituted aryl, or optionally substituted heteroaryl, R12B and R13B together form C3-8 cycloalkyl.), the salts thereof, or the ester thereof are calcium channel modulator (necessary part is extracted in the explanation of the group.).

[0011] Also, it is described in the specification of Japanese Patent Kokai Sho 61-200950 that the compound of the formula (C) 4

[0012] (wherein RC and R1C each independently, is lower alkyl, aryl-lower alkyl or phenyl optionally substituted by one or more electron-withdrawing or electron-donating group, R2C and R3C each independently, is hydrogen, lower alkyl, aryl-lower alkyl or phenyl optionally substituted with one or more electron-withdrawing or electron-donating group, and nC is 1˜4.) and pharmaceutically acceptable salts thereof are anti-convulsant agent.

DISCLOSURE OF THE INVENTION

[0013] As the result of energetic investigations in order to find compounds possessing an N-type calcium channel blockery action, the present inventors have found that the purpose has been accomplished by the compound of the formula (I). Most of compounds of the formula (I) are new.

[0014] The present invention relates to:

[0015] 1) an N-type calcium channel blocker comprising, as an active ingredient, an amino acid derivative of the formula (I) 5

[0016] [wherein R1 is

[0017] 1) C1-15 alkyl,

[0018] 2) C1-8 alkoxy,

[0019] 3) phenyl,

[0020] 4) C3-8 cycloalkyl,

[0021] 5) hetero ring,

[0022] 6) C1-4 alkyl substituted by phenyl, C3-8 cycloalkyl, or hetero ring,

[0023] 7) C1-4 alkoxy substituted by phenyl, C3-8 cycloalkyl, or hetero ring, or

[0024] 8) C2-4 alkenyl substituted by phenyl, C3-8 cycloalkyl, or hetero ring (with proviso that, all phenyl, C3-8 cycloalkyl and hetero ring in R1 group may be substituted by 1˜3 of substituent selected from the following (i)˜(xi);

[0025] (i) C1-4 alkyl,

[0026] (ii) C1-4 alkoxy,

[0027] (iii) phenyl,

[0028] (iv) phenoxy,

[0029] (v) benzyloxy,

[0030] (vi) —SR5 (in which R5 is hydrogen or C1-4 alkyl.),

[0031] (vii) C2-5 acyl,

[0032] (viii) halogen,

[0033] (ix) C1-4 alkoxycarbonyl,

[0034] (x) nitro,

[0035] (xi) —NR6R7 (in which R5 and R7 each independently, is hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl, or R6 and R7 taken together with the nitrogen atom to which they are attached may represent 5˜7 membered saturated hetero ring containing another one nitrogen atom or one oxygen atom.).);

[0036] A is bond, —CO— or —SO2—;

[0037] R2 is hydrogen or C1-4 alkyl optionally substituted by one phenyl;

[0038] D is C1-4 alkylene or C2-4 alkenylene;

[0039] E is

[0040] 1) —COO—,

[0041] 2) —OCO—,

[0042] 3) —CONR8— (in which R8 is hydrogen or C1-4 alkyl.),

[0043] 4) —NR9CO— (in which R9 is hydrogen or C1-4 alkyl.),

[0044] 5) —O—,

[0045] 7) —SO—,

[0046] 8) —SO2—,

[0047] 9) —NR10— (in which R10 is hydrogen or C1-4 alkyl.),

[0048] 10) —CO—,

[0049] 11) —SO2NR11— (in which R11 is hydrogen or C1-4 alkyl.), or

[0050] 12) —NR12SO2— (in which R12 is hydrogen or C1-4 alkyl.);

[0051] R is

[0052] 1) carbocyclic ring,

[0053] 2) hetero ring, or

[0054] 3) C1-4 alkyl substituted by carbocyclic ring or hetero ring (with proviso that, all carbocyclic ring and hetero ring in R3, may be substituted by 1˜3 of substituent selected from the following (i)˜(xi);

[0055] (i) C1-4 alkyl,

[0056] (ii) C1-4 alkoxy,

[0057] (iii) phenyl,

[0058] (iv) phenoxy,

[0059] (v) benzyloxy,

[0060] (vi) —SR13 (in which R13 is hydrogen or C1-4 alkyl.),

[0061] (vii) C2-5 acyl,

[0062] (viii) halogen,

[0063] (ix) C0-4 alkoxycarbonyl,

[0064] (x) nitro,

[0065] (xi) —NR14R15 (in which R14 and R15 each independently, is hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl, or R14 and R15 taken together with the nitrogen atom to which they are attached may represent 5˜7 membered saturated hetero ring containing another one nitrogen atom or one oxygen atom.).);

[0066] J is —O— or —NR16— (in which R16 is hydrogen or C1-4 alkyl.);

[0067] R4 is

[0068] 1) C1-8 alkyl,

[0069] 2) carbocyclic ring,

[0070] 3) hetero ring,

[0071] 4) C1-8 alkyl substituted by 1˜3 of substituent selected from the following (i)˜(v);

[0072] (i) carbocyclic ring,

[0073] (ii) hetero ring,

[0074] (iii) COOR17 (in which R17 is hydrogen or C1-4 alkyl substituted by one phenyl (in which phenyl may be substituted by C1-4 alkoxy.),

[0075] (iv) SR18 (in which R18 is hydrogen or C1-4 alkyl.),

[0076] (v) OR19 (in which R19 is hydrogen or C1-4 alkyl.), or

[0077] when J represents —NR16— group, R4 and R16 taken together with the nitrogen atom to which they are attached may represent hetero ring (with proviso that, all carbocyclic ring and hetero ring, and hetero ring represented by R4 and R16 taken together with the nitrogen atom to which they are attached may be substituted by 1˜3 of substituent selected from the following (i)˜(xi);

[0078] (i) C1-4 alkyl,

[0079] (ii) C1-4 alkoxy,

[0080] (iii) phenyl,

[0081] (iv) phenoxy,

[0082] (v) benzyloxy,

[0083] (vi) —SR20 (in which R20 is hydrogen or C1-4 alkyl.),

[0084] (vii) C2-5 acyl,

[0085] (viii) halogen,

[0086] (ix) C1-4 alkoxycarbonyl,

[0087] (x) nitro,

[0088] (xi) —NR21R22 (in which R21 and R22 each independently, is hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl, or R21 and R22 taken together with the nitrogen atom to which they are attached may represent 5˜7 membered saturated hetero ring containing another one nitrogen atom or one oxygen atom.).).],

[0089] non-toxic salt thereof, or a hydrate thereof, and

[0090] 2) an amino acid derivative of the formula (I) 6

[0091] [wherein R1 is

[0092] 1) C1-15 alkyl,

[0093] 2) C1-8 alkoxy,

[0094] 3) phenyl,

[0095] 4) C3-8 cycloalkyl,

[0096] 5) hetero ring,

[0097] 6) C1-4 alkyl substituted by phenyl, C3-8 cycloalkyl, or hetero ring,

[0098] 7) C1-4 alkoxy substituted by phenyl, C3-8 cycloalkyl, or hetero ring, or

[0099] 8) C2-4 alkenyl substituted by phenyl, C3-8 cycloalkyl, or hetero ring (with proviso that, all phenyl, C3-8 cycloalkyl and hetero ring in R1 group may be substituted by 1˜3 of substituent selected from the following (i)˜(xi);

[0100] (i) C1-4 alkyl,

[0101] (ii) C1-4 alkoxy,

[0102] (iii) phenyl,

[0103] (iv) phenoxy,

[0104] (v) benzyloxy,

[0105] (vi) —SR5 (in which R5 is hydrogen or C1-4 alkyl.),

[0106] (vii) C2-5 acyl,

[0107] (viii) halogen,

[0108] (ix) C1-4 alkoxycarbonyl,

[0109] (x) nitro,

[0110] (xi) —NR6R7 (in which R6 and R7 each independently, is hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl, or R6 and R7 taken together with the nitrogen atom to which they are attached may represent 5˜7 membered saturated hetero ring containing another one nitrogen atom or one oxygen atom.).);

[0111] A is bond, —CO— or —SO2—;

[0112] R2 is hydrogen or C1-4 alkyl optionally substituted by one phenyl;

[0113] D is C1-4 alkylene or C2-4 alkenylene;

[0114] E is

[0115] 1) —COO—,

[0116] 2) —OCO—,

[0117] 3) —CONR8— (in which R8 is hydrogen or C1-4 alkyl.),

[0118] 4) —NR9CO— (in which R9 is hydrogen or C1-4 alkyl.),

[0119] 5) —O—,

[0120] 6) —S—,

[0121] 7) —SO—,

[0122] 8) —SO2—,

[0123] 9) —NR10— (in which R10 is hydrogen or C1-4 alkyl.),

[0124] 10) —CO—,

[0125] 11) —SO2NR11— (in which R11 is hydrogen or C1-4 alkyl.), or

[0126] 12) —NR2SO2— (in which R12 is hydrogen or C1-4 alkyl.);

[0127] R3 is

[0128] 1) carbocyclic ring,

[0129] 2) hetero ring, or

[0130] 3) C1-4 alkyl substituted by carbocyclic ring or hetero ring (with proviso that, all carbocyclic ring and hetero ring in R3, may be substituted by 1˜3 of substituent selected from the following (i)˜(xi);

[0131] (i) C1-4 alkyl,

[0132] (ii) C1-4 alkoxy,

[0133] (iii) phenyl,

[0134] (iv) phenoxy,

[0135] (v) benzyloxy,

[0136] (vi) —SR13 (in which R13 is hydrogen or C1-4 alkyl.),

[0137] (vii) C2-5 acyl,

[0138] (viii) halogen,

[0139] (ix) C1-4 alkoxycarbonyl,

[0140] (x) nitro,

[0141] (xi) —NR14R15 (in which R14 and R15 each independently, is hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl, or R14 and R15 taken together with the nitrogen atom to which they are attached may represent 5˜7 membered saturated hetero ring containing another one nitrogen atom or one oxygen atom.).);

[0142] J is —O— or —NR16— (in which R16 is hydrogen or C1-4 alkyl.);

[0143] R4 is

[0144] 1) C1-8 alkyl,

[0145] 2) carbocyclic ring,

[0146] 3) hetero ring,

[0147] 4) C1-8 alkyl substituted by 1˜3 of substituent selected from the following (i)˜(v);

[0148] (i) carbocyclic ring,

[0149] (ii) hetero ring,

[0150] (iii) COOR17 (in which R17 is hydrogen or C1-4 alkyl substituted by one phenyl (in which phenyl may be substituted by C1-4 alkoxy.),

[0151] (iv) SR18 (in which R18 is hydrogen or C1-4 alkyl.),

[0152] (v) OR19 (in which R19 is hydrogen or C1-4 alkyl.), or

[0153] when J represents —NR16— group, R4 and R16 taken together with the nitrogen atom to which they are attached may represent hetero ring (with proviso that, all carbocyclic ring and hetero ring, and hetero ring represented by R4 and R16 taken together with the nitrogen atom to which they are attached may be substituted by 1˜3 of substituent selected from the following (i)˜(xi);

[0154] (i) C1-4 alkyl,

[0155] (ii) C1-4 alkoxy,

[0156] (iii) phenyl,

[0157] (iv) phenoxy,

[0158] (v) benzyloxy,

[0159] (vi) —SR20 (in which R20 is hydrogen or C1-4 alkyl.),

[0160] (vii) C2-5 acyl,

[0161] (viii) halogen,

[0162] (ix) C1-4 alkoxycarbonyl,

[0163] (x) nitro,

[0164] (xi) —NR21R22 (in which R21 and R22 each independently, is hydrogen, C1-4 alkyl or C1-4 alkoxycarbonyl, or R21 and R22 taken together with the nitrogen atom to which they are attached may represent 5-7 membered saturated hetero ring containing another one nitrogen atom or one oxygen atom.).).

[0165] With proviso that, the following compounds (1)-(37) are excluded:

[0166] (1) N-(2-amino-5-nitrophenyl)-3-benzyloxy-2-t-butoxycarbonylaminopropanamide,

[0167] (2) N-phenyl-3-benzyloxy-2-butoxycarbonylaminopropanamide,

[0168] (3) N-(2-aminophenyl)-3-benzyloxy-2-t-butoxycarbonylaminopropanamide,

[0169] (4) N-(4-nitrophenyl)-3-benzyloxy-2-t-butoxycarbonylaminopropanamide,

[0170] (5) N-(adamantan-2-yl)-3-benzyloxy-2-t-butoxycarbonylaminopropanamide,

[0171] (6) N-(pyridin-4-yl)-3-benzyloxy-2-t-butoxycarbonylaminopropanamide,

[0172] (7) N-(2-aminophenyl)-3-benzyloxy-2-t-butoxycarbonylaminobutanamide,

[0173] (8) N-(4-nitrophenyl)-3-benzyloxy-2-t-butoxycarbonylaminobutanamide,

[0174] (9) N-(3-bromo-4,5-dihydroisoxazol-5-ylmethyl)-3-benzyloxy-2-t-butoxycarbonylaminobutanamide,

[0175] (10) N-methyl-N-(2,6-dimethoxy-4-methylphenyl)-3-benzyloxy-2-t-butoxycarbonylaminopropanamide,

[0176] (11) N-(4-nitrophenyl)-3-benzylthio-2-t-butoxycarbonylaminopropanamide,

[0177] (12) N-(quinolin-6-yl)-3-benzylthio-2-t-butoxycarbonylaminopropanamide,

[0178] (13) N-(2-aminophenyl)-3-benzylthio-2-t-butoxycarbonylaminopropanamide,

[0179] (14) N-(adamantan-2-yl)-3-(3-ethoxycarbonylpyridin-2-ylthio)-2-t-butoxycarbonylaminopropanamide,

[0180] (15) N-methyl-N-(2-ethoxyphenyl)-3-(3-methoxycarbonylpyridin-2-yl)-2-t-butoxycarbonylaminopropanamide,

[0181] (16) N-(4-methoxycarbonylphenyl)-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0182] (17) N-(3-bromo-4,5-dihydroisoxazol-5-ylmethyl)-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0183] (18) N-(2-methylphenyl)-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0184] (19) N-(3-methylphenyl)-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0185] (20) N-(4-methylphenyl)-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0186] (21) N-phenyl-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0187] (22) N-(naphthalen-2-yl)-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0188] (23) N-(naphthalen-1-yl)-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0189] (24) N-benzyl-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0190] (25) N-(4-chlorophenyl)-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0191] (26) N-(4-bromophenyl)-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0192] (27) N-(4-nitrophenyl)-3-benzylthio-2-benzyloxycarbonylaminopropanamide,

[0193] (28) N-(1,2,3,4-tetrahydronaphthalen-2-yl)-3-benzylthio-2-(4-chlorobenzyloxycarbonylamino)propanamide,

[0194] (29) N-methyl-N-(2-ethoxyphenyl)-3-(3-methoxycarbonylpyridin-2-ylthio)-2-(3,4-dichlorophenylcarbonylamino)propanamide,

[0195] (30) 3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 4-nitrobenzyl ester,

[0196] (31) 3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester,

[0197] (32) 3-cycloheptyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester,

[0198] (33) 3-cyclooctyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester,

[0199] (34) 3-(2-isopropyl-5-methylcyclohexyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.benzyl ester,

[0200] (35) N-(benzyloxycarbonylmethyl)-3-(2-isopropyl-5-methylcyclohexyloxycarbonyl)-2-t-butoxycarbonylaminopropanamide,

[0201] (36) 3-cyclohexyloxycarbonyl-2-benzyloxycarbonylaminopropanoic acid.benzyl ester, and

[0202] (37) N-phenyl-2,3-bis(benzoylamino)propanamide.],

[0203] non-toxic salt thereof, or a hydrate thereof, and

[0204] 3) processes for the preparation of an amino acid derivative of the formula (I) and a non-toxic salt thereof.

DETAILED EXPLANATION OF THE INVENTION

[0205] Unless otherwise specified, all isomers are included in the present invention. For example, alkyl, alkoxy, alkylene and alkenylene group include straight-chain or branched-chain ones. The double bond in alkenylene includes structure of configurations E, Z and EZ mixtures. The isomers (optical isomers) generated by asymmetric carbon atom(s) in branched alkyl, alkoxy, alkylene and alkenylene group are also included within the present invention.

[0206] In the formula (I), C1-15 alkyl group represented by R1 means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl and the isomers thereof.

[0207] In the formula (I), C1-8 alkoxy group represented by R1 means methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy and the isomers thereof.

[0208] In the formula (i), C3-8 cycloalkyl group represented by R1 or C3-8 cycloalkyl group as a substituent of C1-4 alkyl, C1-4 alkoxy or C2-4 alkenyl in R1 group means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

[0209] In the formula (I), C1-4 alkyl group represented by R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R18, R19, R20, R21 or R22 means methyl, ethyl, propyl, butyl and the isomers thereof.

[0210] In the formula (I), C1-4 alkyl group as a substituent of phenyl, C3-8 cycloalkyl or hetero ring in R1 group, C1-4 alkyl group as a substituent of carbocyclic ring or hetero ring in R3 or R4 group, or C1-4 alkyl group as a substituent of hetero ring represented by R4 and R16 taken together with the nitrogen atom to which they are attached means methyl, ethyl, propyl, butyl and the isomers thereof.

[0211] In the formula (I), C1-4 alkyl substituted by phenyl, cycloalkyl or hetero ring represented by R1 group means methyl, ethyl, propyl, butyl and the isomers thereof substituted by phenyl, C3-8 cycloalkyl or hetero ring.

[0212] In the formula (I), C1-4 alkyl optionally substituted by one phenyl represented by R2 group means methyl, ethyl, propyl, butyl and the isomers thereof optionally substituted by one phenyl.

[0213] In the formula (I), C1-4 alkyl substituted by one phenyl represented by R17 group means methyl, ethyl, propyl, butyl and the isomers thereof substituted by one phenyl.

[0214] In the formula (I), C1-4 alkyl substituted by carbocyclic ring or hetero ring represented by R3 group means methyl, ethyl, propyl, butyl and the isomers thereof substituted by carbocyclic ring or hetero ring.

[0215] In the formula (I), C1-4 alkoxy substituted by phenyl, C3-8 cycloalkyl or hetero ring means methoxy, ethoxy, propoxy, butoxy and the isomers thereof substituted by phenyl, C3-8 cycloalkyl or hetero ring.

[0216] In the formula (I), C1-4 alkoxy as a substituent of phenyl, C3-8 cycloalkyl or hetero ring in R1 group, C1-4 alkoxy as a substituent of carbocyclic ring or hetero ring in R3 or R4 group, or C1-4 alkoxy as a substituent of hetero ring represented by R4 and R16 taken together with the nitrogen atom to which they are attached means methoxy, ethoxy, propoxy, butoxy and the isomers thereof.

[0217] In the formula (I), C1-4 alkoxy as a substituent of phenyl in C1-4 alkyl substituted by one phenyl in R17 group means methoxy, ethoxy, propoxy, butoxy and the isomers thereof.

[0218] In the formula (I), C2-4 alkenyl substituted by phenyl, cycloalkyl or hetero ring group means ethenyl, propenyl, butenyl and the isomers thereof.

[0219] In the formula (I), C2-5 acyl as a substituent of phenyl, C3-8 cycloalkyl or hetero ring in R1 group, C2-5 acyl as a substituent of carbocyclic ring or hetero ring in R3 or R4 group, or C2-5 acyl as a substituent of hetero ring represented by R4 and R16 taken together with the nitrogen atom to which they are attached means acetyl, propionyl, butyryl, valeryl and the isomers thereof.

[0220] In the formula (I), halogen as a substituent of phenyl, C3-8 cycloalkyl or hetero ring in R1 group, or halogen as a substituent of carbocyclic ring or hetero ring in R3 or R4 group, or halogen as a substituent of hetero ring represented by R4 and R16 taken together with the nitrogen atom to which they are attached means fluoro, chloro, bromo and iodo.

[0221] In the formula (I), C1-4 alkoxycarbonyl represented by R6, R7, R14, R15, R21 or R22 means methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and the isomers thereof.

[0222] In the formula (i), C1-4 alkoxycarbonyl as a substituent of phenyl, C3-8 cycloalkyl or hetero ring in R1 group, or C1-4 alkoxycarbonyl as a substituent of carbocyclic ring or hetero ring in R3 or R4 group, or C1-4 alkoxycarbonyl as a substituent of hetero ring represented by R4 and R16 taken together with the nitrogen atom to which they are attached means methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and the isomers thereof.

[0223] In the formula (I), C1-4 alkylene represented by D group means methylene, ethylene, propylene, butylene and the isomers thereof.

[0224] In the formula (I), C2-4 alkenylene represented by D group means ethenylene, propenylene, butenylene and the isomers thereof.

[0225] In the formula (I), C1-8 alkyl represented by R4 group means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and the isomers thereof.

[0226] In the formula (I), C1-8 alkyl substituted by 1˜3 of substituent selected from (i)˜(v) represented by R4 group means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and the isomers thereof substituted by 1˜3 of substituent selected from (i)˜(v).

[0227] In the formula (I), 5˜7 memebered saturated hetero ring optionally containing another one nitrogen atom or one oxygen atom represented by R6 and R7 taken together with the nitrogen atom to which they are attached, by R14 and R15 taken together with the nitrogen atom to which they are attached or by R21 and 22 taken together with the nitrogen atom to which they are attached means pyrrolidine, piperidine, piperazine, morpholine, perhydroazepine etc.

[0228] In the formula (I), carbocyclic ring in R3 or R4 means C3-10 mono-, bi- and bridged carbocyclic ring. For example, C3-10 mono, bi and bridged carbocyclic ring includes cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopentene, cyclohexene, cyclopentadiene, cyclohexadiene, benzene, pentalene, indene, naphthalene, azulene, dihydronaphthalene, tetrahydronaphthalene, perhydronaphthalene, indan (dihydroindene), perhydroindene, bicyclopentane, bicyclohexane, bicycloheptane (bicyclo[2.2.1]heptane), bicycloheptene (bicyclo[2.2.1]hept-2-ene.), bicyclooctane, bicyclononane, bicyclodecane, adamantane etc.

[0229] In the formula (I), hetero ring in R1, R3 or R4 group means a 5˜15 memebered unsaturated, partial saturated or saturated mono-cyclic or bi-cyclic hetero ring containing 1˜2 nitrogen atom, 1˜2 oxygen atom and/or one sulfur atom. For example, a 5˜15 memebered unsaturated, partial saturated or saturated mono-cyclic or bi-cyclic hetero ring containing 1˜2 nitrogen atom; 1˜2 oxygen atom and/or one sulfur atom includes pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, tetrahydropyrimidine, hexahydropyrimidine, tetrahydropyridazine, hexahydropyridazine, hexahydroazepine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrrahydropyran, dihydrothiophene, tetrahydrothiophene, dihydrothiain (dihydrothiopyran), tetrahydrothiain (tetrahydrothiopyran), dihydroxazole, tetrahydroxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetraisothiazole, morpholine, thiomorpholine, indoline, isoindoline, dihydroindazole, perhydroindazole, dihydroquinoline, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzimidazole, perhydrobenzimidazole, dihydrobenzoxazine, dioxaindan, benzodioxane, quinuclidine, pyrrole, imidazole, pyrazole, pyridine, pyradine, pyrimidine, pyridazine, pyridazine, azepine, diazepine, furan, pyran, oxepin, oxazepine, thiophene, thiain (thiopyran), thiepin, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, oxazine, oxadiazine, oxazepin oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzimidazole, oxatetrahydrofuran, thiazolidinone, thiazolidinedione etc.

[0230] In the formula (I), hetero ring represented by R4 and R16 taken together with the nitrogen atom to which they are attached means a 5˜15 memebered unsaturated, partial saturated or saturated mono-cyclic or bi-cyclic hetero ring necessarily containing one nitrogen atom and further containing one nitrogen atom, one oxygen atom and/or one sulfur atom. For example, a 5˜15 memebered unsaturated, partial saturated or saturated mono-cyclic or bi-cyclic hetero ring necessarily containing one nitrogen atom and further containing one nitrogen atom, 1˜2 oxygen atom and/or one sulfur atom includes pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, tetrahydropyrimidine, hexahydropyrimidine, tetrahydropyridazine, hexahydropyridazine, hexahydroazepine, tetrahydroxazole, tetrahydroisoxazole, tetrahydrothiazole, tetrahydroisothiazole, morpholine, thiomorpholine, indoline, isoindoline, dihydroindazole, perhydroindazole, dihydroquinoine, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzimidazole, perhydrobenzimidazole, pyrrole, imidazole, pyrazole, indole, isoindole, indazole, benzimidazole etc.

[0231] Preferred R1 is C1-8 alkoxy, phenyl, C3-8 cycloalkyl, hetero ring, or C1-4 alkyl substituted by phenyl, C3-8 cycloalkyl or hetero ring. Particularly, preferred R1 is hetero ring.

[0232] Preferred A is bond or —CO—. Particularly, preferred A is —CO—.

[0233] Preferred E is —COO—, —O—, —S—, —SO— or —SO2—. Particularly, preferred E is —S—.

[0234] Preferred carbocyclic ring represented by R3 and carbocyclic ring as substituent of C1-4 alkyl in R3 is C3-10 cycloalkyl represented by cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane and cyclodecane. Particularly, preferred carbocyclic ring is cyclopentane or cyclohexane.

[0235] Preferred J is —NR16— (in which R16 is the same meaning as hereinbefore described.).

[0236] Preferred R4 is carbocyclic ring, hetero ring, or C1-8 alkyl substituted by carbocyclic ring or hetero ring. Particularly, preferred R4 is C1-8 alkyl substituted by carbocyclic ring.

[0237] [Salts]

[0238] In the present invention, non-toxic salts includes all such salts.

[0239] For example, the compounds of the present invention of the formula (I) maybe converted into the corresponding salts by known method. Non toxic and water-soluble salts are preferable. Suitable salts include the salts of alkalimetal (sodium, potassium etc.), alkaline-earth metal (calcium, magnesium etc.), ammonium salts, salts of organic amine which is pharmacologically permitted (tetramethyl ammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, dicyclohexylamine, benzylamine, phenetylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)amine, lysine, arginine, N-methyl-D-gulcamine etc.).

[0240] The compounds of the present invention of the formula (I) may be converted into the corresponding acid-addition salts by known method. Non toxic and water-soluble salts are preferable. Suitable acid-addition salts include the salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulphonic acid, phosphonic acid, nitric acid and the salts with organic acids such as acetic acid, trifluoroacetic acid, lactic acid, tartaric acid, oxalic acid, fumaric acid, maleic acid, citric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, isethionic acid, glucuronic acid and gluconic acid.

[0241] The compounds of the present invention of the formula (I) or salts thereof may be converted into a corresponding hydrate by known methods.

[0242] In the compounds of the formula (I), preferred compounds are as follows:

[0243] the compound of the formula (Ia) 7

[0244] (wherein all the symbols are the same meanings as hereinbefore described.), the compound of the formula (Ib) 8

[0245] (wherein all the symbols are the same meanings as hereinbefore described.), the compound of the formula (Ic) 9

[0246] (wherein all the symbols are the same meanings as hereinbefore described.), the compound of the formula (Id) 10

[0247] (wherein all the symbols are the same meanings as hereinbefore described.), the compound of the formula (Ie) 11

[0248] (wherein all the symbols are the same meanings as hereinbefore described.), the compound of the formula (If) 12

[0249] (wherein all the symbols are the same meanings as hereinbefore described.), the compound of the formula (Ig) 13

[0250] (wherein all the symbols are the same meanings as hereinbefore described.), the compound of the formula (Ih) 14

[0251] (wherein all the symbols are the same meanings as hereinbefore described.), non-toxic salts thereof or the hydrates thereof.

[0252] The concrete compounds are ones shown in the following Tables 1-40, non-toxic salts thereof and the hydrates thereof and ones described in Example. Also, the following concrete compounds include the isomers generated by asymmetric carbon atom(s), i.e., R, S and RS form. In the following each Table, Me is methyl, Boc is t-butoxycarbonyl, i-Bu is isobutyl, Ac is acetyl.

TABLE 1
(Ia-1)
15
No. R1
1   16
2   17
3   18
4   19
5   20
6   21
7   22
8   23
9   24
10  25
11  26
12  27
13  28
14  29
15  30
16  31
17  32
18  33
19  34
20  35
21  36
22  37
23  38
24  39

[0253]

TABLE 2
(Ia-2)
40
No. R1
1   41
2   42
3   43
4   44
5   45
6   46
7   47
8   48
9   49
10  50
11  51
12  52
13  53
14  54
15  55
16  56
17  57
18  58
19  59
20  60
21  61
22  62
23  63
24  64

[0254]

TABLE 3
(Ia-3)
65
No. R1
1   66
2   67
3   68
4   69
5   70
6   71
7   72
8   73
9   74
10  75
11  76
12  77
13  78
14  79
15  80
16  81
17  82
18  83
19  84
20  85
21  86
22  87
23  88
24  89

[0255]

TABLE 4
(Ia-4)
90
No. R1
1   91
2   92
3   93
4   94
5   95
6   96
7   97
8   98
9   99
10  100
11  101
12  102
13  103
14  104
15  105
16  106
17  107
18  108
19  109
20  110
21  111
22  112
23  113
24  114

[0256]

TABLE 5
(Ia-5)
115
No. R1
1   116
2   117
3   118
4   119
5   120
6   121
7   122
8   123
9   124
10  125
11  126
12  127
13  128
14  129
15  130
16  131
17  132
18  133
19  134
20  135
21  136
22  137
23  138
24  139

[0257]

TABLE 6
(Ib-1)
140
No. R1
1   141
2   142
3   143
4   144
5   145
6   146
7   147
8   148
9   149
10  150
11  151
12  152
13  153
14  154
15  155
16  156
17  157
18  158
19  159
20  160
21  161
22  162
23  163
24  164

[0258]

TABLE 7
(Ib-2)
165
No. R1
1   166
2   167
3   168
4   169
5   170
6   171
7   172
8   173
9   174
10  175
11  176
12  177
13  178
14  179
15  180
16  181
17  182
18  183
19  184
20  185
21  186
22  187
23  188
24  189

[0259]

TABLE 8
(Ib-3)
190
No. R1
1   191
2   192
3   193
4   194
5   195
6   196
7   197
8   198
9   199
10  200
11  201
12  202
13  203
14  204
15  205
16  206
17  207
18  208
19  209
20  210
21  211
22  212
23  213
24  214

[0260]

TABLE 9
(Ib-4)
215
No. R1
1   216
2   217
3   218
4   219
5   220
6   221
7   222
8   223
9   224
10  225
11  226
12  227
13  228
14  229
15  230
16  231
17  232
18  233
19  234
20  235
21  236
22  237
23  238
24  239

[0261]

TABLE 10
(Ib-5)
240
No. R1
1   241
2   242
3   243
4   244
5   245
6   246
7   247
8   248
9   249
10  250
11  251
12  252
13  253
14  254
15  255
16  256
17  257
18  258
19  259
20  260
21  261
22  262
23  263
24  264

[0262]

TABLE 11
(Ic-1)
265
No.	R1	No.	R1	No.	R1
1	266	9	267	17	268
2	269	10	270	18	271
3	272	11	273	19	274
4	275	12	276	20	277
5	278	13	279	21	280
6	281	14	282	22	283
7	284	15	285	23	286
8	287	16	288	24	289

[0263]

TABLE 12
(Ic-2)
290
No.	R1	No.	R1	No.	R1
1	291	9	292	17	293
2	294	10	295	18	296
3	297	11	298	19	299
4	300	12	301	20	302
5	303	13	304	21	305
6	306	14	307	22	308
7	309	15	310	23	311
8	312	16	313	24	314

[0264]

TABLE 13
(Ic-3)
315
No.	R1	No.	R1	No.	R1
1	316	9	317	17	318
2	319	10	320	18	321
3	322	11	323	19	324
4	325	12	326	20	327
5	328	13	329	21	330
6	331	14	332	22	333
7	334	15	335	23	336
8	337	16	338	24	339

[0265]

TABLE 14
(Ic-4)
340
No.	R1	No.	R1	No.	R1
1	341	9	342	17	343
2	344	10	345	18	346
3	347	11	348	19	349
4	350	12	351	20	352
5	353	13	354	21	355
6	356	14	357	22	358
7	359	15	360	23	361
8	362	16	363	24	364

[0266]

TABLE 15
(Ic-5)
365
No.	R1	No.	R1	No.	R1
1	366	9	367	17	368
2	369	10	370	18	371
3	372	11	373	19	374
4	375	12	376	20	377
5	378	13	379	21	380
6	381	14	382	22	383
7	384	15	385	23	386
8	387	16	388	24	389

[0267]

TABLE 16
(Id-1)
390
No.	R1	No.	R1	No.	R1
1	391	9	392	17	393
2	394	10	395	18	396
3	397	11	398	19	399
4	400	12	401	20	402
5	403	13	404	21	405
6	406	14	407	22	408
7	409	15	410	23	411
8	412	16	413	24	414

[0268]

TABLE 17
(Id-2)
415
No.	R1	No.	R1	No.	R1
1	416	9	417	17	418
2	419	10	420	18	421
3	422	11	423	19	424
4	425	12	426	20	427
5	428	13	429	21	430
6	431	14	432	22	433
7	434	15	435	23	436
8	437	16	438	24	439

[0269]

TABLE 18
(Id-3)
440
No.	R1	No.	R1	No.	R1
1	441	9	442	17	443
2	444	10	445	18	446
3	447	11	448	19	449
4	450	12	451	20	452
5	453	13	454	21	455
6	456	14	457	22	458
7	459	15	460	23	461
8	462	16	463	24	464

[0270]

TABLE 19
(Id-4)
465
No.	R1	No.	R1	No.	R1
1	466	9	467	17	468
2	469	10	470	18	471
3	472	11	473	19	474
4	475	12	476	20	477
5	478	13	479	21	480
6	481	14	482	22	483
7	484	15	485	23	486
8	487	16	488	24	489

[0271]

TABLE 20
(Id-5)
490
No.	R1	No.	R1	No.	R1
1	491	9	492	17	493
2	494	10	495	18	496
3	497	11	498	19	499
4	500	12	501	20	502
5	503	13	504	21	505
6	506	14	507	22	508
7	509	15	510	23	511
8	512	16	513	24	514

[0272]

TABLE 21
(Ie-1)
515
No.	R1	No.	R1	No.	R1
1	516	9	517	17	518
2	519	10	520	18	521
3	522	11	523	19	524
4	525	12	526	20	527
5	528	13	529	21	530
6	531	14	532	22	533
7	534	15	535	23	536
8	537	16	538	24	539

[0273]

TABLE 22
(Ie-2)
540
No.	R1	No.	R1	No.	R1
1	541	9	542	17	543
2	544	10	545	18	546
3	547	11	548	19	549
4	550	12	551	20	552
5	553	13	554	21	555
6	556	14	557	22	558
7	559	15	560	23	561
8	562	16	563	24	564

[0274]

TABLE 23
(Ie-3)
565
No.	R1	No.	R1	No.	R1
1	566	9	567	17	568
2	569	10	570	18	571
3	572	11	573	19	574
4	575	12	576	20	577
5	578	13	579	21	580
6	581	14	582	22	583
7	584	15	585	23	586
8	587	16	588	24	589

[0275]

TABLE 24
(Ie-4)
590
No.	R1	No.	R1	No.	R1
1	591	9	592	17	593
2	594	10	595	18	596
3	597	11	598	19	599
4	600	12	601	20	602
5	603	13	604	21	605
6	606	14	607	22	608
7	609	15	610	23	611
8	612	16	613	24	614

[0276]

TABLE 25
(Ie-5)
615
No.	R1	No.	R1	No.	R1
1	616	9	617	17	618
2	619	10	620	18	621
3	622	11	623	19	624
4	625	12	626	20	627
5	628	13	629	21	630
6	631	14	632	22	633
7	634	15	635	23	636
8	637	16	638	24	639

[0277]

TABLE 26
(If-1)
640
No.	R1	No.	R1	No.	R1
1	641	9	642	17	643
2	644	10	645	18	646
3	647	11	648	19	649
4	650	12	651	20	652
5	653	13	654	21	655
6	656	14	657	22	658
7	659	15	660	23	661
8	662	16	663	24	664

[0278]

TABLE 27
(If-2)
665
No.	R1	No.	R1	No.	R1
1	666	9	667	17	668
2	669	10	670	18	671
3	672	11	673	19	674
4	675	12	676	20	677
5	678	13	679	21	680
6	681	14	682	22	683
7	684	15	685	23	686
8	687	16	688	24	689

[0279]

TABLE 28
(If-3)
690
No.	R1	No.	R1	No.	R1
1	691	9	692	17	693
2	694	10	695	18	696
3	697	11	698	19	699
4	700	12	701	20	702
5	703	13	704	21	705
6	706	14	707	22	708
7	709	15	710	23	711
8	712	16	713	24	714

[0280]

TABLE 29
(If-4)
715
No.	R1	No.	R1	No.	R1
1	716	9	717	17	718
2	719	10	720	18	721
3	722	11	723	19	724
4	725	12	726	20	727
5	728	13	729	21	730
6	731	14	732	22	733
7	734	15	735	23	736
8	737	16	738	24	739

[0281]

TABLE 30
(If-5)
740
No.	R1	No.	R1	No.	R1
1	741	9	742	17	743
2	744	10	745	18	746
3	747	11	748	19	749
4	750	12	751	20	752
5	753	13	754	21	755
6	756	14	757	22	758
7	759	15	760	23	761
8	762	16	763	24	764

[0282]

TABLE 31
(Ig-1)
765
No. R1
1   766
2   767
3   768
4   769
5   770
6   771
7   772
8   773
9   774
10  775
11  776
12  777
13  778
14  779
15  780
16  781
17  782
18  783
19  784
20  785
21  786
22  787
23  788
24  789

[0283]

TABLE 32
(Ig-2)
790
No. R1
1   791
2   792
3   793
4   794
5   795
6   796
7   797
8   798
9   799
10  800
11  801
12  802
13  803
14  804
15  805
16  806
17  807
18  808
19  809
20  810
21  811
22  812
23  813
24  814

[0284]

TABLE 33
(Ig-3)
815
No. R1
1   816
2   817
3   818
4   819
5   820
6   821
7   822
8   823
9   824
10  825
11  826
12  827
13  828
14  829
15  830
16  831
17  832
18  833
19  834
20  835
21  836
22  837
23  838
24  839

[0285]

TABLE 34
(Ig-4)
840
No. R1
1   841
2   842
3   843
4   844
5   845
6   846
7   847
8   848
9   849
10  850
11  851
12  852
13  853
14  854
15  855
16  856
17  857
18  858
19  859
20  860
21  861
22  862
23  863
24  864

[0286]

TABLE 35
(Ig-5)
865
No. R1
1   866
2   867
3   868
4   869
5   870
6   871
7   872
8   873
9   874
10  875
11  876
12  877
13  878
14  879
15  880
16  881
17  882
18  883
19  884
20  885
21  886
22  887
23  888
24  889

[0287]

TABLE 36
(Ih-1)
890
No. R1
1   891
2   892
3   893
4   894
5   895
6   896
7   897
8   898
9   899
10  900
11  901
12  902
13  903
14  904
15  905
16  906
17  907
18  908
19  909
20  910
21  911
22  912
23  913
24  914

[0288]

TABLE 37
(Ih-2)
915
No. R1
1   916
2   917
3   918
4   919
5   920
6   921
7   922
8   923
9   924
10  925
11  926
12  927
13  928
14  929
15  930
16  931
17  932
18  933
19  934
20  935
21  936
22  937
23  938
24  939

[0289]

TABLE 38
(Ih-3)
940
No. R1
1   941
2   942
3   943
4   944
5   945
6   946
7   947
8   948
9   949
10  950
11  951
12  952
13  953
14  954
15  955
16  956
17  957
18  958
19  959
20  960
21  961
22  962
23  963
24  964

[0290]

TABLE 39
(Ih-4)
965
No. R1
1   966
2   967
3   968
4   969
5   970
6   971
7   972
8   973
9   974
10  975
11  976
12  977
13  978
14  979
15  980
16  981
17  982
18  983
19  984
20  985
21  986
22  987
23  988
24  989

[0291]

TABLE 40
(Ih-5)
990
No. R1
1   991
2   992
3   993
4   994
5   995
6   996
7   997
8   998
9   999
10  1000
11  1001
12  1002
13  1003
14  1004
15  1005
16  1006
17  1007
18  1008
19  1009
20  1010
21  1011
22  1012
23  1013
24  1014

[0292] [Processes for the Preparation Thereof]

[0293] (a) For the compounds of the formula (I), those in which E is —COO—, —OCO—, —CONR8—, —NR9CO—, —O—, —S—, or —CO—, i.e., the compounds of the formula (I-A) 1015

[0294] (wherein R1-1 is the same meaning as hereinbefore described for R1, provided that amino group which is comprised in the group represented by R1-1 may be protected, if necessary, and R3-1 is the same meaning as hereinbefore described for R3, provided that amino group which is comprised in the group represented by R3-1 may be protected, if necessary, and R4-1 is the same meaning as hereinbefore described for R4, provided that —COOH, hydroxy or amino group which is comprised in the group represented by R4-1 may be protected, if necessary, and E1 is —COO—, —OCO—, —CONR8—, —NR9CO—, —O—, —S— or —CO—, and the other symbols are the same meanings as hereinbefore described.) may be prepared by amidation or esterification of a compound of formula (II) 1016

[0295] (wherein all the symbols are the same meanings as hereinbefore described.) with a compound of formula (III)

J2—R4-1  (III)

[0296] (wherein J2 is —OH, —NHR16 or hetero ring containing NH group (this hetero ring is the same meaning as hereinbefore described for hetero ring represented by R4, R16 and nitrogen atom which R4 and R16 are bound to, together.), and the other symbol is the same meaning as hereinbefore described.), or by amidation or esterification of a compound of formula (IV) 1017

[0297] (wherein E2 is —COOH, —NHR9 or —OH, and the other symbols are the same meanings as hereinbefore described.)

[0298] with a compound of formula (V)

E3—R3-1  (V)

[0299] (wherein E3 is —OH, —NHR9 or —COOH, and the other symbol is the same meaning as hereinbefore described.).

[0300] The above amidation is known per se and can be carried out by, for example:

[0301] (1) using an acid haride,

[0302] (2) using a mixed acid anhydride,

[0303] (3) using a condensing agent etc.

[0304] Each of those methods can be carried out, for example, as follows:

[0305] (1) the method using an acid halide may be carried out, for example, by reacting a carboxylic acid with an acid halide (e.g., oxalyl chloride, thionyl chloride etc.) in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran, ethyl acetate etc.) or without a solvent at from −20° C. to the reflux temperature, and then by reacting the acid halide obtained with an amine in the presence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, N-methylmorpholine etc.) in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) at 0° C.˜40° C.,

[0306] (2) the method using a mixed acid anhydride may be carried out, for example, by reacting a carboxylic acid and an acid halide (e.g., pivaloyl chloride, tosyl chloride, mesyl chloride, ethyl chloroformate, isobutyl chloroformate etc.) in the presence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, N-methylmorpholine etc.) in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at −20° C.˜40° C., and then by reacting the mixture of acid anhydride obtained with a corresponding amine in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.), at 0° C.˜40° C.,

[0307] (3) the method using a condensing agent (e.g., 1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]cabodiimide (EDC), 2-chlorolmethylpyridinium iodide, 1,1′-carbonyldiimidazole (CDI) etc.) may be carried out, for example, by reacting a carboxylic acid with an amine using a condensing agent in the presence or absence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.), in the presence or absence of 1-hydroxybenzotriazole (HOBt) in an organic solvent (e.g., chloroform, methylene chloride, dimethyl formamide, diethyl ether, tetrahydrofuran etc.) or without a solvent at 0° C.˜40° C.

[0308] The reactions (1), (2) and (3) hereinbefore described may be preferably carried out in an atmosphere of inert gas (e.g., argon, nitrogen etc.) under anhydrous conditions.

[0309] The above esterification is known per se and can be carried out by, for example:

[0310] (1) using an acid haride,

[0311] (2) using a mixed acid anhydride,

[0312] (3) using a condensing agent etc.

[0313] Each of those methods can be carried out, for example, as follows:

[0314] (1) the method using an acid halide may be carried out, for example, by reacting a carboxylic acid with an acid halide (e.g., oxalyl chloride, thionyl chloride etc.) in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran ethyl acetate etc.) or without a solvent at from −20° C. to the reflux temperature, and then by reacting the acid halide obtained with an alcohol in the presence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, N-methylmorpholine etc.) in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) at 0° C.˜40° C.,

[0315] (2) the method using a mixed acid anhydride may be carried out, for example, by reacting a carboxylic acid and an acid halide (e.g., pivaloyl chloride, tosyl chloride, mesyl chloride, ethyl chloroformate, isobutyl chloroformate etc.) in the presence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, N-methylmorpholine etc.) in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at −20° C.˜40° C., and then by reacting the mixture of acid anhydride obtained with a corresponding alcohol in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.), at 0° C.˜40° C.,

[0316] (3) the method using a condensing agent (e.g., 1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]cabodiimide (EDC), 2-chloro-1-methylpyridinium iodide, 1,1′-carbonyldiimidazole (CDI) etc.) may be carried out, for example, by reacting a carboxylic acid with an alcohol using a condensing agent in the presence or absence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.), in the presence or absence of 1-hydroxybenzotriazole (HOBt) in an organic solvent (e.g., chloroform, methylene chloride, dimethyl formamide, diethyl ether, tetrahydrofuran etc.) or without a solvent at 0° C.˜40° C.

[0317] The reactions (1), (2) and (3) hereinbefore described may be preferably carried out in an atmosphere of inert gas (e.g., argon, nitrogen etc.) under anhydrous conditions.

[0318] Also, for the compounds of the formula (I-A), those in which E is —S—, i.e., the compounds of the formula (I-A-1) 1018

[0319] (wherein all the symbols are the same meanings as hereinbefore described.) may be prepared by the reaction of a compound of formula (VI) 1019

[0320] (wherein X is halogen, and the other symbols is the same meaning as hereinbefore described.).

[0321] The reaction of a compound of formula (VI) with a compound of formula (VII) is known per se and can be carried out, for example, in an organic solvent (e.g., dimethylformamide, acetone etc.), in the presence of base (e.g., potassium carbonate etc.), at 0° C.˜40° C.

[0322] (b) For the compounds of the formula (i), those in which E is —SO—, —SO2—, i.e., the compounds of formula (I-B) 1020

[0323] (wherein E4 is —SO— or —SO2— and the other symbols are the same meanings as hereinbefore described.) may be prepared by the oxidation of a compounds of formula (I-A) wherein E1 is —S—.

[0324] The above oxidation is known per se, and in case of the oxidation from sulfide group to sulfoxide group, for example, it can be carried out in an organic solvent (e.g., methylene chloride, chloroform, benzene, hexane, t-butyl alcohol etc.), in the presence of 1 equivalent of oxidizing agent (e.g., hydrogen peroxide, sodium periodate, acyl nitrite, sodium perborate, peracid (e.g., m-chloroperbenzoic acid, peracetic acid etc.) etc.), in a few minutes, at −78° C. to

[0325] Also, in the case of the oxidation from sulfide group to sulfone group, for example, it can be carried out in an organic solvent (e.g., methylene chloride, chloroform, benzene, hexane, t-butyl alcohol etc.), in the presence of an excess amount of oxidizing agent (e.g., hydrogen peroxide, sodium periodate, potassium pemanganate, sodium perborate, potassium hydrogen peroxosulfate, peracid (e.g., m-chloroperbenzoic acid, pracetic acid etc.) etc.), in a few hours, at −78° C.˜40° C.

[0326] (c) For the compounds of the formula (I), those in which E is —NR10—, i.e., the compounds of the formula (I-C) 1021

[0327] (wherein all the symbols are the same meanings as hereinbefore described.) may be prepared by the reaction of a compound of formula (VIII) 1022

[0328] (wherein all the symbols are the same meanings as hereinbefore described.) with a compound of formula (IX)

NHR10—R3-1  (IX)

[0329] (wherein all the symbols are the same meanings as hereinbefore described.).

[0330] The reaction of a compound of formula (VIII) with a compound of formula (IX) is known per se, and may be carried out, for example, in an organic solvent (e.g., methanol, ethanol etc.), using reducing agent (e.g., sodium cyanoborohydride, sodium borohydride etc.), in the presence or absence of pH modulator (e.g., acetic acid etc.), at 0° C.˜40° C.

[0331] (d) For the compounds of the formula (I), those in which E is —SO2NR11—, i.e., the compounds of the formula (I-D) 1023

[0332] (wherein all the symbols are the same meanings as hereinbefore described.) may be prepared by the reaction of a compound of formula (X) 1024

[0333] (wherein all the symbols are the same meanings hereinbefore described.) with a compound of formula (XI)

NHR11—R3-1  (XI)

[0334] (wherein all the symbols are the same meanings as hereinbefore described.).

[0335] The reaction of a compound of formula (X) with a compound of formula (XI) is known per se, and may be carried out, for example, by reacting a compound of formula (X) with an acid halide (e.g., oxalyl chloride, thionyl chloride, sulfulyl chloride etc.) in an organic solvent (chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) in the presence of base (e.g., triphenylphosphine etc.) at −20° C. to the reflux temperature, and then by reacting the compound thus obtained with a compound of formula (XI) in the presence of a tertiary amine (e.g., pyridine, triethylamine, diethylaniline, diethylaminopyridine etc.), in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.), at 0° C.˜40° C.

[0336] (e) For the compounds of the formula (I), those in which E is —NR12SO2—, i.e., the compounds of the formula (I-E) 1025

[0337] (wherein all the symbols are the same meanings as hereinbefore described.) may be prepared by the reaction of a compound of formula (XII) 1026

[0338] (wherein all the symbols are the same meanings as hereinbefore described.) with a compound of formula (XIII)

X—SO2—R3-1  (XIII)

[0339] (wherein X is halogen, and the other symbol is the same meaning as hereinbefore described.).

[0340] The reaction of a compound of formula (XII) with a compound of formula (XIII) may be carried out, for example, in organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.), in the presence of a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.), at 0° C.˜40° C.

[0341] (f) For the compounds of the formula (I), those in which A is —CO— or —SO2—, i.e., the compounds of the formula (I-F) 1027

[0342] (wherein A1 is —CO— or —SO2— and the other symbols are the same meanings as hereinbefore described.)

[0343] may be prepared by amidation or sulfonamidation of a compound of formula (XIV) 1028

[0344] (wherein all the symbols are the same meanings as hereinbefore described.) with a compound of formula (XV)

R1-1—A2  (2)

[0345] (wherein A2 is —COOH or —SO3H, and the other symbol is the same meaning as hereinbefore described.).

[0346] Sulfonamidation is known per se, and can be carried out, for example, by reacting a sulfonic acid with an acid halide (e.g., oxalyl chloride, thionyl chloride, phosphorus pentachloride, phosphorus trichloride etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) or without a solvent at −20° C. to the reflux temperature, and then by reacting the sulfonyl halide obtained with a tertiary amine (e.g., pyridine, triethylamine, dimethylaniline, dimethylaminopyridine etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran etc.) at 0° C.˜40° C.

[0347] Also, amidation may be carried out by the same method as hereinbefore described.

[0348] (g) For the compounds of the formula (I), those in which A is bond, R1 is C1-4 alkyl substituted by phenyl, C3-8 cycloalkyl, or hetero ring, i.e., the compounds of the formula (I-G) 1029

[0349] (wherein R12 is C1-4 alkyl substituted by phenyl, C3-8 cycloalkyl, or hetero ring (when amino group exists as a substituent of each ring, it may be protected, if necessary.), and the other symbols are the same meanings as hereinbefore described.)

[0350] may be prepared by the reaction of a compound of formula (XIV) 1030

[0351] (wherein all the symbols are the same meanings as hereinbefore described.) with a compound of formula (XVI)

R1-3—CHO  (XVI)

[0352] (wherein R1-3 is phenyl, C3-8 cycloalkyl, hetero ring, or C1-3 alkyl substituted by phenyl, C3-8 cycloalkyl or hetero ring (when amino group exists as a substituent of each ring, it may be protected, if necessary.)).

[0353] This reaction can be carried out by the same method in the reaction of a compound of formula (VIII) with a compound of formula (IX), as hereinbefore described.

[0354] (h) For the compounds of the formula (I), those in which R1 is hetero ring, or C1-4 alkyl substituted by hetero ring, and a substituent of such a hetero ring is C2-5 acyl or C1-4 alkoxycarbonyl, i.e., the compounds of the formula (I-H) 1031

[0355] (wherein R23 is bond or C1-4 alkylene, R24 is C1-4 alkoxycarbonyl or C2-5 acyl, R25 is C1-4 alkyl, C1-4 alkoxy, phenyl, phenoxy, benzyloxy, —SR5, halogen, nitro or —NR6R7, n is 0˜2, 1032

[0356] is the same meaning as hereinbefore described for hetero ring in R1, provided that it contains at least one nitrogen atom. Also, when amino group exists in a substituent represented by R25, it may be protected, if necessary, and the other symbols are the same meanings as hereinbefore described.) may be prepared by the amidation of a compound of formula (XVII) 1033

[0357] (wherein all the symbols are the same meanings as hereinbefore described.) with a compound of formula (XVIII)

R24—OH  (XVIII)

[0358] (wherein R24 is the same meaning as hereinbefore described.)

[0359] The amidation can be carried out by the same method as hereinbefore described.

[0360] (i) In the compounds of the formula (I), the compounds of formula (I-I) 1034

[0361] (wherein R1-4, R3-2 and R4-2 are the same meanings as hereinbefore described for R1, R3, R4, respectively, provided that at least one of R1-4, R3-2 and R1-2 is a group containing —COOH, hydroxy or amino group, and the other symbols are the same meanings as hereinbefore described.)

[0362] may be prepared by the deprotection under alkaline conditions, the deprotection under acidic conditions and/or hydrogenolysis of the above compound of formulae (I-A), (I-A-1), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G) or (I-H).

[0363] The deprotection under alkaline conditions is known per se, and may be carried out, for example, in an organic solvent (e.g., methanol, tetrahydrofuran, dioxane etc.), using an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide etc.), an alkaline earth metal hydroxide (e.g., calcium hydroxide etc.) or a carbonate (e.g., sodium carbonate, potassium carbonate etc.), an aqueous solution thereof or a mixture thereof at 0° C.˜40° C.

[0364] The deprotection under acidic conditions is known per se, and may be carried out, for example, in an organic solvent (e.g., methylene chloride, chloroform, dioxane, ethyl acetate, anisole etc.) or without a solvent, using an organic acid (e.g., trifluoroacetic acid, methanesulfonic acid, trimethylsilyl iodide etc.), or an inorganic acid (e.g., hydrogen chloride etc.) or a mixture thereof (e.g hydrobromoacetic acid etc.) at 0° C.˜90° C.

[0365] The hydrogenolysis is known per se, and may be carried out, for example, in an organic solvent (e.g., tetrahydrofuran, dioxane, diethyl ether, ethyl acetate, methanol, ethanol etc.), in the presence of a catalyst (e.g., palladium carbon, palladium, palladium hydroxide, palladium acetate, palladium black, platinum black, nickel, Raney-nickel etc.), at ordinary or elevated pressure under an atmosphere hydrogen gas, at 0° C.˜80° C.

[0366] It should be easily understood by those skilled in the art that the carboxy or hydroxy protecting group are not only t-butyl group or benzyl group but any group which can be easily and selectively eliminated can be used in the present invention. For example, a protecting group described in Protective Groups in Organic Synthesis (T. W. Greene, Wiley, New York (1991)) may be used. The amino protecting group are not only benzyloxycarbonyl group or t-butoxycarbonyl group but any group which can be easily and selectively eliminated can be used in the present invention. The proposed compounds of the present invention may be easily prepared using those protecting groups.

[0367] The compounds of formulae (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII) or (XVIII) are known per se or may be prepared by methods known per se or methods described in Example, but do not limit the present invention.

[0368] For example, the compounds of formula (X) may be prepared by the methods described in Liebigs Ann. Chem, 776-783, 1979.

[0369] For example, the compounds of formula (XII) may be prepared by the methods described in J. Org. Chem, Vol. 44, No. 10, 1979.

[0370] For example, for the compounds of formula (XIV), those in which E is —O—, —S—, —SO—, —SO2—, i.e., the compound of formula (XIV′), and for the compounds of formula (XVII), those in which E is —O—, —S—, —SO—, —SO2— i.e., the compounds of formula (XVII′) may be prepared by the method described in the following Scheme 1 and Scheme 2. 10351036

[0371] (in each Scheme, E5 is —O—, —S—, —SO—, or —SO2—, Boc is t-butoxycarbonyl, (Boc)2O is di-t-butyldicarbonate, R26 is bond or C1-3 alkylene, and the other symbols are the same meanings as hereinbefore described.)

[0372] The reactions described in the above-mentioned Schemes may be carried out by known methods. In the above-mentioned Schemes, compounds used for starting materials are may be known per se or may be easily prepared by known methods.

[0373] In the present invention, the other starting materials and each reagent are known per se or may be prepared by known methods.

[0374] In each reaction in the present specification, products may be purified by a conventional manner. For example, it may be carried out by distillation at atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization. Purification may be carried out after each reaction, or after a series of reactions.

[0375] [Pharmacological Activity]

[0376] It has been confirmed that the compounds of the present invention of the formula (I) possess an inhibitory action on N-type calcium channel according to the following experiment.

[0377] Determination of Inhibitory Activity on N-Type Calcium Channel:

[0378] Cell line was differentiated according to the method described in FEBS Letters, 235, 178-182, 1988. The cell was loaded with fluorescent reagent, Fura-2•AM (at the final concentration of 10 μM), at 37° C. for 30 minutes and suspended in Krebs-buffer containing HEPES (25 mM) to obtain the cell suspension. The obtained cell suspension was incubated in the presence or absence of the compounds of the present invention with nifedipine for 5 minutes. The cell was depolarized by adding potassium chloride solution (at the final concentration of 80 mM) thereto and then a fluorescence intensity at the emission wavelength of 500 nm excited by the UV of 340 nm and 380 nm alternately was measured using the intracellular calcium analyzer (Nippon Bunko Co., CAF-110). The inhibitory activity of the compound of the present invention (at the final concentration of 3 μM) on calcium influx into the cell was calculated from the difference in changing the fluorescence intensity at peak (ΔR) according to the following equation. 1$\begin{array}{c}\mathrm{Inhibitory}\mathrm{activity}\mathrm{of}\mathrm{the}\mathrm{compound}\\ \mathrm{of}\mathrm{the}\mathrm{present}\mathrm{invention}\left(3\mu M\right)\\ \mathrm{on}\mathrm{calcium}\mathrm{inlux}\left(\%\right)\end{array}=\left(1-\frac{\begin{array}{c}\mathrm{Mean}\mathrm{of}\Delta R\mathrm{in}\mathrm{case}\mathrm{of}\mathrm{solution}\\ \mathrm{in}\mathrm{the}\mathrm{presence}\mathrm{of}\mathrm{the}\mathrm{compound}\\ \mathrm{of}\mathrm{the}\mathrm{present}\mathrm{invention}\end{array}}{\begin{array}{c}\mathrm{Mean}\mathrm{of}\Delta R\mathrm{in}\mathrm{case}\mathrm{of}\mathrm{solution}\\ \mathrm{in}\mathrm{the}\mathrm{absence}\mathrm{of}\mathrm{the}\mathrm{compound}\\ \mathrm{of}\mathrm{the}\mathrm{present}\mathrm{invention}\end{array}}\right)\times 100$

[0379] The results were shown in Table 41.

TABLE 41
            Inhibitory activity
Example No. on Ca influx (%)
2           75
2 (29)      75
2 (80)      87
2 (86)      83
6 (22)      79
6 (27)      72
6 (44)      86
6 (68)      73
9 (13)      88

[0380] From the results of an experiment using the patch-clamp technique described in Pflüngers Archives, 391, 85-100, 1981, the compounds of the present invention at the concentration of 10 μM showed clearly an inhibitory action on flux of barium ion (calcium current) passed through an N-type calcium channel. The cells used in this experiment had been incubated according to the method described in FEBS Letters, 235, 178-182, 1988.

[0381] [Toxicity]

[0382] The toxicity of the compounds of the present invention are very low and therefore, it may be considered that the compounds of the present invention are safe for pharmaceutical use.

[0383] [Application for Pharmaceuticals]

[0384] The compounds of the formula (I) possess an inhibitory action on N-type calcium channel, so they are useful as agent for the prevention and/or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis or epilepsy etc. or agent for the treatment of pain (for example, acute pain, chronic pain, pain after operation, cancer pain, neuralgia, pain caused by infection etc.).

[0385] For the purpose above described, the compounds of the general formula (I), of the present invention, non-toxic salts thereof, acid addition salts thereof and hydrates thereof may be normally administered systematically or partially, usually by oral or parenteral administration.

[0386] The doses to be administered are determined depending upon age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment etc. In the human adult, the doses per person per dose are generally between 1 mg and 1000 mg, by oral administration, up to several times per day, and between 1 mg and 100 mg, by parenteral administration (preferred into vein) up to several times per day, or continuous administration between 1 and 24 hrs. per day into vein.

[0387] As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

[0388] When administration of the compounds of the present invention, it is used as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parenteral administration.

[0389] Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules.

[0390] Capsules contain hard capsules and soft capsules.

[0391] In such compositions, one or more of the active compound(s) is or are, admixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyinylpyrrolidone, magnesium metasilicate aluminate. The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents such as magnesium stearate, disintegrating agents such as cellulose calcium glycolate, and assisting agents for dissolving such as glutamic acid, asparaginic acid. The tablets or pills may, if desired, be coated with film of gastric or enteric material such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropyl cellulose phthalate etc., or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.

[0392] Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, syrups and elixirs etc. In such liquid compositions, one or more of the active compound(s) is or are comprised in inert diluent(s) commonly used in the art (for example, purified water, ethanol etc.). Besides inert diluents, such compositions may also comprise adjuvants such as wetting agents, suspending agents, sweetening agents, flavouring agents, perfuming agents and preserving agents.

[0393] Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents such as sodium hydrogen sulfate, stabilizing agents to give isotonicity, isotonic buffer such as sodium chloride, sodium citrate, citric acid. For preparation of such spray compositions, for example, the method described in the U.S. Pat. No. 2,868,691 or 3,095,355 may be used.

[0394] Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Aqueous solutions or suspensions include distilled water for injection and physiological salt solution. Non-aqueous solutions or suspensions include propylene glycol, polyethylene glycol, plant oil such as olive oil, alcohol such as ethanol, POLYSOLBATE80 (registered trade mark) etc. Such compositions may comprise additional diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent (for example, lactose), assisting agents such as assisting agents for dissolving (for example, glutamic acid, asparaginic acid). They may be sterilized for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They also may be manufactured in the form of sterile solid compositions and which can be dissolved in sterile water or some other sterile diluents for injection immediately before used.

[0395] Other compositions for parenteral administration include liquids for external use, and endemic liniments, ointment, suppositories and pessaries which comprise one or more of the active compound(s) and may be prepared by know methods.

REFERENCE EXAMPLE AND EXAMPLE

[0396] The following Reference Examples and Examples illustrate the present invention, but do not limit the present invention.

[0397] The solvents in the parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations and TLC.

[0398] NMR in the parentheses show measured solvents.

Reference Example 1

(2S)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanoic acid

[0399] 1037

[0400] Undercooling with ice, sodium hydride (60%, 3.95 g) was added to a solution of (2S)-3-hydroxy-2-t-butoxycarbonylaminopropanoic acid (10.11 g) in dimethylformamide (200 ml, hereinafter abbreviated as DMF). The mixture was stirred for 30 minutes at 0° C. Under cooling with ice, (bromomethyl)cyclohexane (9.0 ml) was added dropwise to the reaction mixture and tetrabutylammonium iodide (910 mg) was added thereto. The mixture was stirred for 23 hours at room temperature. Further, (bromomethyl)cyclohexane (2.1 ml) was added dropwise to the reaction mixture. The mixture was stirred for 4 hours. (Bromomethyl)cyclohexane (2.1 ml) was added dropwise to reaciton mixture again. The mixture was stirred for 25 hours at room temperature. The reaction mixture was concentrated and the residue was diluted with 1N hydrochloric acid and extracted with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (chloroform:methanol=97:3) to give the title compound (2.52 g) having the following physical data.

[0401] TLC: Rf 0.21 (chloroform:methanol=9:1);

[0402] NMR (CDCl3): δ 5.59-5.40 (1H, m), 4.46-4.27 (1H, m), 3.89-3.76 (1H, m), 3.64 (1H, dd, J=9.4, 4.6 Hz), 3.27 (2H, d, J=6.2 Hz), 1.79-0.79 (20H, m).

Reference Example 2

(2R)-3-cyclohexylmethylthio-2-t-butoxycarbonylaminopropanoic acid

[0403] 1038

[0404] To a solution of L-cysteine (133 mg) in ethanol (10 ml), 2N aqueous solution of sodium hydroxide (1.1 ml) and (bromomethyl)cyclohexane (0.17 ml) were added. The mixture was stirred for 2.5 hours at room temperature. Two normal aqueous solution of sodium hydroxide (0.6 ml) and di-tert-butyl dicarbonate (0.28 ml) were added to the reaction mixture. The mixture was stirred for 1 hour. Ethanol was removed by evaporation from the reaction mixture and it was acidified by adding 1 N hydrochloric acid and extraced with ethyl acetate. The extract was washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (chloroform:methanol=19:1) to give the title compound (135 mg) having the following physical data.

[0405] TLC: Rf 0.21 (ethyl acetate: acetic acid:water=9:1:1);

[0406] NMR (CDCl3): δ 4.42-4.28 (1H, m), 3.01 (1H, dd, J=14.2, 5.2 Hz), 2.92 (1H, dd, J=14.2, 3.4 Hz), 2.45 (2H, d, J=7.0 Hz), 1.91-0.81 (20H, m).

Example 1

(2S)-3-cycolpentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester

[0407] 1039

[0408] To a solution of (3S)-3-benzyloxycarbonyl-3-t-butoxycarbonylaminopropanoic acid (3.22 g), cyclopentanol (1.73 g) and dimethylaminopyridine (127 mg) in methylene chloride (20 ml), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloric acid salt (3.83 g, hereinafter abbreviated as EDC-HCl) was added. The mixture was stirred for 2 hours at room temperature. One normal hydrochloric acid was added to the reaction mixture. The mixture was extracted with methylene chloride. The extract was washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (hexane:ethyl acetate=9:1) to give the compound of the present invention (4.19 g) having thefollowing physical data.

[0409] TLC: Rf 0.42 (hexane:ethyl acetate=4:1);

[0410] NMR (CDCl3): δ 7.34 (5H, s), 5.50 (1H, d, J=8.3 Hz), 5.25-5.11 (3H, m), 4.64-4.56 (1H, m), 2.97 (1H, dd, J=5.1, 16.9 Hz), 2.77 (1H, dd, J=4.8, 16.9 Hz), 1.88-1.54 (8H, m), 1.43 (9H, s).

Example 1(1)˜Example 1(20)

[0411] By the reaction of the corresponding carboxylic acid derivatives with the corresponding alcohol derivatives or amine derivatives by the same desired procedure as Example 1, the following compounds of the present invention were obtained.

Example 1(1)

(2S)-3-benzyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester

[0412] 1040

[0413] TLC: Rf 0.45 (hexane:ethyl acetate=4:1);

[0414] 7.35 (5H, s), 5.50 (1H, d, J=7.5 Hz), 5.12 (2H, s), 4.86-4.73 (1H, m), 4.58-4.49 (1H, m), 3.04 (1H, dd, J=4.5, 16.8 Hz), 2.86 (1H, dd, J=4.8, 16.8 Hz), 1.86-1.58 (4H, m), 1.55-1.18 (15H, m).

Example 1(2)

(2S)-3-benzyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.cyclopentyl ester

[0415] 1041

[0416] TLC: Rf 0.42 (hexane:ethyl acetate=4:1);

[0417] NMR (CDCl3): δ 7.35 (5H, s), 5.97 (1H, d, J=7.8 Hz), 5.22-5.15 (1H, m), 5.12 (2H, s), 4.56-4.47 (1H, m), 3.02 (1H, dd, J=4.8, 16.9 Hz), 2.84 (1H, dd, J=4.8, 16.9 Hz), 1.88-1.49 (8H, m), 1.44 (9H, s).

Example 1(3)

(2R)-3-benxyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester

[0418] 1042

[0419] TLC: Rf 0.45 (hexane:ethyl acetate=4:1);

[0420] 7.35 (5H, s), 5.50 (1H, d, J=7.5 Hz), 5.12 (2H, s), 4.86-4.73 (1H, 4.58-4.49 (1H, m), 3.04 (1H, dd, J=4.5, 16.8 Hz), 2.86 (1H, dd, J=4.8, 16.8 Hz), 1.86-1.58 (4H, m), 1.55-1.18 (15H, m).

Example 1(4)

(2R)-3-benzyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.cyclopentyl ester

[0421] 1043

[0422] TLC: Rf 0.42 (hexane:ethyl acetate=4:1);

[0423] NMR (CDCl3): δ 7.34 (5H, s), 5.51 (1H, d, J=7.6 Hz), 5.22-5.15 (1H, m), 5.12 (2H, s), 4.57-4.47 (1H, m), 3.01 (1H, dd, J=4.8, 16.8 Hz), 2.84 (1H, dd, J=4.8, 16.8 Hz), 1.86-1.50 (8H, m), 1.44 (9H, s).

Example 1(5)

(2R)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester

[0424] 1044

[0425] TLC: Rf 0.30 (hexane:ethyl acetate=6:1);

[0426] NMR (CDCl3): δ 7.40-7.30 (5H, m), 5.50 (1H, bd, J=9.0 Hz), 5.20 (1H, d, J=12 Hz), 5.18 (1H, d, J=12 Hz), 5.20-5.07 (1H, m), 4.65-4.50 (1H, m), 2.93 (1H, dd, J=18, 5 Hz), 2.78 (1H, dd, J=18, 5 Hz), 1.80-1.48 (8H, m), 1.44 (9H, s).

Example 1(6)

(2S)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.benzyl ester

[0427] 1045

[0428] TLC: Rf 0.26 (hexane:ethyl acetate=5:1);

[0429] NMR (CDCl3): δ 7.40-7.30 (5H, m), 5.24-5.08 (4H, m), 4.43-4.25 (1H, m), 2.40-1.50 (12H, m), 1.43 (9H, s).

Example 1(7)

(2R)-4-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.benzyl Ester

[0430] 1046

[0431] TLC: Rf 0.46 (hexane:ethyl acetate=4:1);

[0432] NMR (CDCl3): δ 7.35 (5H, s), 5.20 (1H, d, J=2.4 Hz), 5.13 (1H, d, J=9.2 Hz), 4.79-4.67 (1H, m), 4.41-4.31 (1H, m), 2.44-2.30 (2H, m), 2.24-2.08 (1H, m), 2.04-1.66 (5H, m), 1.61-1.25 (15H, m).

Example 1(8)

(2R)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.benzyl ester

[0433] 1047

[0434] TLC: Rf 0.42 (hexane:ethyl acetate=4:1);

[0435] NMR (CDCl3): δ 7.35 (5H, s), 5.23-5.08 (4H, m), 4.40-4.29 (1H, m), 2.43-2.28 (2H, m), 2.23-2.03 (1H, m), 2.02-1.49 (9H, m), 1.42 (9H, s).

Example 1(9)

(2S)-4-benzyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester

[0436] 1048

[0437] TLC: Rf 0.51 (hexane:ethyl acetate=4:1);

[0438] NMR (CDCl3): δ 7.34 (5H, s), 5.18-5.04 (3H, m), 4.85-4.74 (1H, m), 4.37-4.24 (1H, m), 2.59-1.25 (23H, m).

Example 1 (10)

(2S)-4-benzyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.cyclopentyl ester

[0439] 1049

[0440] TLC: Rf 0.50 (hexane:ethyl acetate=4:1);

[0441] NMR (CDCl3): δ 7.36 (5H, s), 5.25-5.11 (4H, m), 4.37-4.15 (1H, m), 2.58-1.34 (21H, m).

Example 1(11)

(2R)-4-benzyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester

[0442] 1050

[0443] TLC: Rf 0.51 (hexane:ethyl acetate=4:1);

[0444] NMR (CDCl3): δ 7.36 (5H, s), 5.13 (2H, s), 5.14-5.04 (1H, m), 4.88-4.73 (1H, m), 4.39-4.22 (1H, m), 2.58-1.24 (23H, m).

Example 1(12)

(2R)-4-benzyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.cyclopentyl ester

[0445] 1051

[0446] NMR (CDCl3): δ 7.35 (5H, s), 5.25-5.03 (4H, m), 4.37-4.13 (1H, m), 2.59-1.37 (21H, m).

Example 11(13)

(2S)-3-cyclohexylcarbomoyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester

[0447] 1052

[0448] TLC: Rf 0.29 (hexane:ethyl acetate=2:1);

[0449] NMR (CDCl3): δ 7.43-7.25 (5H, m), 5.81 (1H, bd, J=9 Hz), 5.50 (1H, bd, J=9 Hz), 5.21 (1H, d, J=10 Hz), 5.16 (1H, d, J=10 Hz), 4.59-4.46 (1H, m), 3.81-3.60 (1H, m), 2.83 (1H, dd, J=16, 5 Hz), 2.68 (1H, dd, J=16, 5 Hz), 1.95-0.94 (10H, m), 1.42 (9H, s).

Example 1(14)

(2S)-3-cyclopentylcarbamoyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester

[0450] 1053

[0451] TLC: Rf 0.26 (hexane:ethyl acetate=2:1);

[0452] NMR (CDCl3): δ 7.43-7.25 (5H, m), 5.90-5.74 (1H, m), 5.73-5.55 (1H, m), 5.21 (1H, d, J=12 Hz), 5.16 (1H, d, J=12 Hz), 4.60-4.46 (1H, m), 4.24-4.05 (1H, m), 2.82 (1H, dd, J=16, 5 Hz), 2.68 (1H, dd, J=16, 5 Hz), 2.08-1.19 (8H, m), 1.42 (9H, s).

Example 1 (15)

(2S)-4-(pyrrolidin-1-ylcarbonyl)-2-t-butoxycarbonylaminobutanoic acid.benzyl ester

[0453] 1054

[0454] TLC: Rf 0.33 (hexane:ethyl acetate=1:1);

[0455] NMR (CDCl3): δ 7.40-7.30 (5H, m), 5.60-5.45 (1H, m), 5.21 (1H, d, J=12 Hz), 5.14 (1H, d, J=12 Hz), 4.40-4.23 (1H, m), 3.44 (2H, t, J=7 Hz), 3.27 (2H, t, J=7 Hz), 2.37-1.65 (8H, m), 1.44 (9H, s).

Example 1(16)

(2S)-3-cyclopentyloxycarbonyl-2-(N-t-butoxycarbonyl-N-methylamino)-propanoic acid.4-nitrobenzyl ester

[0456] 1055

[0457] TLC: Rf 0.49 (ethyl acetate:hexane=1:2);

[0458] NMR (CDCl3): δ 8.25-8.18 (2H, m), 7.51 (2H, d, J=8.8 Hz), 5.30-5.11 (3H, m), 4.82-4.60 (1H, m), 3.17-2.66 (5H, m), 1.98-1.33 (17H, m).

Example 1 (17)

(2S)-3-cyclohexyloxycarbonyl-2-(N-t-butoxycarbonyl-N-amino)propanoic acid.4-nitrobenzyl ester

[0459] 1056

[0460] TLC: Rf 0.38 (ethyl acetate:hexane=1:2);

[0461] NMR (CDCl3): δ 8.28-8.15 (2H, m), 7.51 (2H, d, J=8.8 Hz), 5.38-5.14 (2H, m), 4.85-4.62 (2H, m), 3.18-3.01 (1H, m), 2.98-2.69 (4H, m), 1.94-1.16 (19H, m).

Example 1(18)

(2S)-3-cuyclobutyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester

[0462] 1057

[0463] TLC: Rf 0.59 (hexane:ethyl acetate=2:1);

[0464] NMR (CDCl3): δ 7.36-7.31 (5H, m), 5.50 (1H, d, J=8.0 Hz), 5.22 (1H, d, J=12.4 Hz), 5.14 (1H, d, J=12.4 Hz), 5.01-4.86 (1H, m), 4.65-4.56 (1H, m), 2.99 (1H, dd, J=16.4, 6.0 Hz), 2.78 (1H, dd, J=16.4, 4.8 Hz), 2.39-2.21 (2H, m), 2.12-1.50 (4H, m), 1.43 (9H, s).

Example 1(19)

(2S)-3-(adamantan-2-yloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.benzyl ester

[0465] 1058

[0466] TLC: Rf 0.46 (hexane:ethyl acetate=4:1);

[0467] NMR (CDCl3): δ 7.34 (5H, s), 5.54 (1H, d, J=8.8 Hz), 5.22 (1H, d, J=12.2 Hz), 5.13 (1H, d, J=12.2 Hz), 4.93-4.87 (1H, br), 4.66-4.57 (1H, m), 3.04 (1H, dd, J=4.4, 16.8 Hz), 2.85 (1H, dd, J=4.6, 16.8 Hz), 2.01-1.65 (12H, m), 1.60-1.46 (2H, m), 1.43 (9H, s).

Example 1(20)

(2S)-3(adamantan-1-yloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.benzyl ester

[0468] 1059

[0469] TLC: Rf 0.46 (hexane:ethyl acetate=4:1)

[0470] NMR (CDCl3): δ 7.34 (5H, s), 5.50 (1H, d, J=8.6 Hz), 5.23 (1H, d, J=12.4 Hz), 5.13 (1H, d, J=12.4 Hz), 4.60-4.52 (1H, m), 2.93 (1H, dd, J=4.6, 16.8 Hz), 2.71 (1H, dd, J=4.8, 16.8 Hz), 2.19-2.08 (3H, br), 2.02 (6H, d, J=3.0 Hz), 1.63 (6H, s), 1.44 (9H, s).

Reference Example 3

(2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid

[0471] 1060

[0472] Under argon atmosphere, the compound prepared in Example 1 (4.19 g) was stirred in ethyl acetate (25 ml) and palladium carbon (5%, 500 mg) was added thereto. The mixture was stirred for 13 hours at room temperature under hydrogen atmosphere. The reaction mixture was filtered through Celite. The filtrate was concentrated to give the title compound (2.98 g) having the following physical data.

[0473] TLC: Rf 0.53 (chloroform:methanol=9:1);

[0474] NMR (CDCl3): δ 5.54 (1H, d, J=8.1 Hz), 5.24-5.17 (1H, m), 4.63-4.55 (1H, m), 2.97 (1H, dd, J=4.8, 17.1 Hz), 2.79 (1H, dd, J=4.8, 17.1 Hz), 1.87-1.55 (8H, m), 1.45 (9H, s).

Example 2

(2S0-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonylamino-propanamide

[0475] 1061

[0476] The compound prepared in Reference Example 1 (90 mg), dimethylaminopyridine (6 mg) and 4-methoxybenzylamine (43 mg) were dissolved in methylene chloride, and EDC-HCl (122 mg) was added thereto. The mixture was stirred for 12 hours at room temperature. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=3:1) to give the compound of the present invention (84 mg) having the following physical data.

[0477] TLC: Rf 0.20 (hexane:ethyl acetate=3:1);

[0478] NMR (CDCl3): δ 7.19 (2H, d, J=8.2 Hz), 6.85 (2H, d, J=8.2 Hz), 6.80-6.66 (1H, br), 5.52-5.26 (1H, br), 4.44 (1H, dd, J=5.2, 15.0 Hz), 4.36 (1H, dd, J=5.8, 15.0 Hz), 4.30-4.15 (1H, br), 3.89-3.79 (4H, m), 3.44 (1H, dd, J=7.0, 9.2 Hz), 3.27 (1H, dd, J=6.1, 9.3 Hz), 3.20 (1H, dd, J=6.1, 9.3 Hz), 1.94 (5H, m), 1.44 (9H, s), 1.34-1.04 (4H, m), 0.96-0.74 (2H, m).

Example 2(1)˜Example 2(119)

[0479] By the reaction of the compounds prepared in Reference Example 1, Reference Example 2, Reference Example 3, or the carboxylic acid derivatives (obtained by the same desired procedure as Reference Example 3, using the compounds prepared in Example 1(1)˜Example 1(20)) or the corresponding carboxylic acids derivatives thereof with the corresponding alcohol derivatives or amine derivatives by the same desired procedure as Example 2, the following compounds of the present invention were obtained.

Example 2(1)

(2S)-4-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-nitrobenzyl ester

[0480] 1062

[0481] TLC: Rf 0.37 (hexane:ethyl acetate=4:1);

[0482] NMR (CDCl3): δ 8.23 (2H, d, J=8.8 Hz), 7.53 (2H, d, J=8.8 Hz), 5.27 (2H, s), 5.12 (1H, d, J=8.6 Hz), 4.80-4.69 (1H, m), 4.44-4.33 (1H, m), 2.43-2.36 (2H, m), 2.31-1.20 (21H. m).

Example 2(2)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-fluorobenzyl ester

[0483] 1063

[0484] TLC: Rf 0.36 (hexane:ethyl acetate=4:1);

[0485] NMR (CDCl3): δ 7.36-7.29 (2H, m), 7.08-6.99 (2H, m), 5.48 (1H, d, J=2.3 Hz), 5.17 (1H, d, J=2.4 Hz), 5.09 (1H, d, J=12.4 Hz), 4.80-4.65 (1H, m), 4.65-4.52 (1H, m), 2.99 (1H, dd, J=4.5, 16.8 Hz), 2.78 (1H, dd, J=4.8, 16.8 Hz), 1.87-1.47 (6H, m), 1.43 (9H, s), 1.40-1.20 (4H, m).

Example 2(3)

(2R)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acic.4-fluorobenzyl ester

[0486] 1064

[0487] TLC: Rf 0.46 (ethyl acetate:hexane=1:4);

[0488] NMR (CDCl3): δ 7.36-7.29 (2H, m), 7.08-6.99 (2H, m), 5.49 (1H, d, J=8.5 Hz), 5.19 (1H, d, J=12.2 Hz), 5.09 (1H, d, J=12.2 Hz), 4.73-4.57 (2H, m), 2.98 (1H, dd, J=16.8, 4.8 Hz), 2.78 (1H, dd, J=16.8, 4.7 Hz), 1.80-1.24 (19H, m).

Example 2(4)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0489] 1065

[0490] TLC: Rf 0.39 (hexane:ethyl acetate=4:1);

[0491] NMR (CDCl3): δ 7.27 (2H, d, J=8.6 Hz), 6.87 (2H, d, J=8.6 Hz), 5.52-5.42 (1H, m), 5.15 (1H, d, J=12.0 Hz), 5.07 (1H, d, J=12.0 Hz), 4.75-4.64 (1H, m), 4.62-4.50 (1H, m), 3.81 (3H, s), 2.98 (1H, dd, J=4.4, 16.8 Hz), 2.76 (1H, dd, J=5.0, 16.8 Hz), 1.90-1.52 (6H, m), 1.43 (9H, s), 1.40-1.22 (4H, m).

Example 2(5)

(2R)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0492] 1066

[0493] TLC: Rf 0.31 (ethyl acetate:hexane=1:4);

[0494] NMR (CDCl3): δ 7.27 (2H, d, J=8.5 Hz), 6.87 (2H, d, J=8.5 Hz), 5.48 (1H, d, J=10.4 Hz), 5.15 (1H, d, J=12.0 Hz), 5.07 (1H, d, J=12.0 Hz), 4.73-4.55 (2H, m), 3.81 (3H, s), 2.98 (1H, dd, J=6.8, 4.8 Hz), 2.77 (1H, dd, J=6.8, 4.6 Hz), 1.82-1.09 (19H, m).

Example 2(6)

(2S)-3-cyclohexyloxycarbonyl-2-benzyloxycarbonylaminopropanoic acid.4-nitrobenzyl ester

[0495] 1067

[0496] TLC: Rf 0.17 (ethyl acetate:hexane=1:4).

[0497] NMR (CDCl3): δ 8.20 (2H, d, J=8.5 Hz), 7.48 (2H, d, J=8.5 Hz), 7.35 (5H, s), 5.78 (1H, d, J=8.8 Hz), 5.33-5.19 (2H, m), 5.13 (2H, s), 4.76-4.67 (2H, m), 3.06 (1H, dd, J=17.2, 4.4 Hz), 2.83 (1H, dd, J=17.2, 4.4 Hz), 1.75-1.22 (10H, m).

Example 2(7)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-nitrophenethyl ester

[0498] 1068

[0499] TLC: Rf 0.44 (hexane:ethyl acetate=3:1)

[0500] NMR (CDCl3): δ 8.18 (2H, d, J=8.2 Hz), 7.39 (2H, d, J=8.2 Hz), 5.43 (1H, d, J=9.6 Hz), 4.78-4.61 (1H, m), 4.60-4.46 (1H, m), 4.40 (2H, t, J=6.6 Hz), 3.07 (2H, t, J=6.6 Hz), 2.94 (1H, dd, J=4.8, 17.1 Hz), 2.76 (1H, dd, J=4.6, 17.1 Hz), 1.88-1.48 (6H, m), 1.44 (9H, s), 1.41-1.22 (4H, m).

Example 2(8)

(2S)-N-benzyl-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylamino-propanamide

[0501] 1069

[0502] TLC: Rf 0.37 (hexane:ethyl acetate=3:1);

[0503] NMR (CDCl3): δ 7.38-7.21 (5H, m), 6.88-6.72 (1H, br), 5.75-5.58 (1H, m), 4.82-4.68 (1H, m), 4.58-4.38 (3H, m), 3.02 (1H, dd, J=4.6, 17.0 Hz), 2.70 (1H, dd, J=6.4, 17.0 Hz), 1.91-1.47 (6H, m), 1.43 (9H, s), 1.40-1.23 (4H, m).

Example 2(9)

(2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0504] 1070

[0505] TLC: Rf 0.34 (hexane:ethyl acetate=4:1);

[0506] NMR (CDCl3): δ 7.27 (2H, d, J=8.6 Hz), 6.88 (2H, d, J=8.6 Hz), 5.48 (1H, d, J=8.8 Hz), 5.18-5.04 (3H, m), 4.60-4.51 (1H, m), 3.81 (3H, s), 2.96 (1H, dd, J=4.8, 17.0 Hz), 2.76 (1H, dd, J=4.8, 16.8 Hz), 1,83-1.54 (8H, m), 1.43 (9H, s).

Example 2(10)

(2S)-3-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester

[0507] 1071

[0508] TLC: Rf 0.39 (hexane:ethyl acetate=4:1);

[0509] NMR (CDCl3): δ 7.28 (2H, d, J=8.6 Hz), 6.88 (2H, d, J=8.6 Hz), 5.48 (1H, d, J=8.6 Hz), 5.05 (2H, s), 4.84-4.72 (1H, m), 4.57-4.47 (1H, m), 3.81 (3H, s), 3.02 (1H, dd, J=4.4, 16.8 Hz), 2.82 (1H, dd, J=4.8, 16.8 Hz), 1.85-1.60 (4H, m), 1.56-1.27 (15H, m).

Example 2(11)

(2S)-3-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid cyclohexyl ester

[0510] 1072

[0511] TLC: Rf 0.18 (hexane:ethyl acetate=4:1);

[0512] NMR (CDCl3): δ 8.23 (2H, d, J=8.8 Hz), 7.52 (2H, d, J=8.8 Hz), 5.48 (1H, d, J=8.0 Hz), 5.22 (2H, s), 4.86-4.74 (1H, m), 4.60-4.52 (1H, m), 3.07 (1H, dd, J=4.6, 16.8 Hz), 2.92 (1H, dd, J=5.0, 16.8 Hz), 1.88-1.58 (4H, m), 1.56-1.20 (15H, m).

Example 2(12)

(2S)-3-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid cyclopentyl ester

[0513] 1073

[0514] TLC: Rf 0.24 (hexane:ethyl acetate=4:1);

[0515] NMR (CDCl3): δ 7.28 (2H, d, J=8.8 Hz), 6.88 (2H, d, J=8.8 Hz), 5.47 (1H, d, J=8.4 Hz), 5.21-5.16 (1H, m), 5.05 (2H, s), 4.54-4.45 (1H, m), 3.81 (3H, s), 2.98 (1H, dd, J=4.8, 16.8 Hz), 2.76 (1H, dd, J=4.6, 16.8 Hz), 1.88-1.51 (8H, m), 1.44 (9H, s).

Example 2(13)

(2S)-3-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid cyclopentyl ester

[0516] 1074

[0517] TLC: Rf 0.15 (hexane:ethyl acetate=4:1);

[0518] NMR (CDCl3): δ 8.23 (2H, d, J=8.8 Hz), 7.51 (2H, d, J=8.8 Hz), 5.44 (1H, d, J=8.4 Hz), 5.22-5.17 (3H, m), 4.59-4.50 (1H, m), 3.04 (1H, dd, J=4.8, 16.8 Hz), 2.92 (1H, dd, J=5.0, 16.8 Hz), 1.94-1.52 (8H, m), 1.44 (9H, s).

Example 2(14)

(2R)-3-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester

[0519] 1075

[0520] TLC: Rf 0.39 (hexane:ethyl acetate=4:1);

[0521] NMR (CDCl3): δ 7.28 (2H, d, J=8.6 Hz), 6.88 (2H, d, J=8.6 Hz), 5.48 (1H, d, J=8.6 Hz), 5.05 (2H, s), 4.84-4.72 (1H, m), 4.57-4.47 (1H, m), 3.81 (3H, s), 3.02 (1H, dd, J=4.4, 16.8 Hz), 2.82 (1H, dd, J=4.8, 16.8 Hz), 1.85-1.60 (4H, m), 1.56-1.27 (15H, m).

Example 2(15)

(2R)-3-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester

[0522] 1076

[0523] TLC: Rf 0.18 (hexane:ethyl acetate=4:1);

[0524] NMR (CDCl3): δ 8.23 (2H, d, J=8.8 Hz), 7.52 (2H, d, J=8.8 Hz), 5.48 (1H, d, J=8.0 Hz), 5.22 (2H, s), 4.86-4.74 (1H, m), 4.60-4.52 (1H, m), 3.07 (1H, dd, J=4.6, 16.8 Hz), 2.92 (1H, dd, J=5.0, 16.8 Hz), 1.88-1.58 (4H, m), 1.56-1.20 (15H, m).

Example 2(16)

(2R)-3-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.cyclopentyl ester

[0525] 1077

[0526] TLC: Rf 0.24 (hexane:ethyl acetate=4:1)

[0527] NMR (CDCl3): δ 7.28 (2H, d, J=8.8 Hz), 6.88 (2H, d, J=8.8 Hz), 5.47 (1H, d, J=8.4 Hz), 5.21-5.16 (1H, m), 5.05 (2H, s), 4.54-4.45 (1H, m), 3.81 (3H, s), 2.98 (1H, dd, J=4.8, 16.8 Hz), 2.76 (1H, dd, J=4.6, 16.8 Hz), 1.88-1.51 (8H, m), 1.44 (9H, s).

Example 2(17)

(2R)-3-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.cyclopentyl ester

[0528] 1078

[0529] TLC: Rf 0.15(hexane:ethyl acetate=4:1)

[0530] NMR (CDCl3): δ 8.23 (2H, d, J=8.8 Hz), 7.51 (2H, d, J=8.8 Hz), 5.44 (1H, d, J=8.4 Hz), 5.22-5.17 (3H, m), 4.59-4.50 (1H, m), 3.04 (1H, dd, J=4.8, 16.8 Hz), 2.92 (1H, dd, J=5.0, 16.8 Hz), 1.94-1.52 (8H, m), 1.44 (9H, s).

Example 2(18)

(2R)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0531] 1079

[0532] TLC: Rf 0.20 (ethyl acetate:hexane=1:5);

[0533] NMR (CDCl3): δ 7.27 (2H, d, J=9 Hz), 6.88 (2H, d, J=9 Hz), 5.48 (1H, d, J=8 Hz), 5.20-5.03 (3H, m), 4.63-4.48 (1H, m), 3.81 (3H, s), 2.93 (1H, dd, J=18, 5 Hz), 2.77 (1H, dd, J=18, 5 Hz), 1.90-1.48 (8H, m), 1.43 (9H, s).

Example 2(19)

(2S)-4-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester

[0534] 1080

[0535] TLC: Rf 0.33 (ethyl acetate:hexane=1:4);

[0536] NMR (CDCl3): δ 7.22 (2H, d, J=9 Hz), 6.81 (2H, d, J=9 Hz), 5.12-4.95 (3H, m), 4.75-4.59 (1H, m), 4.33-4.15 (1H, m), 3.74 (3H, s), 2.40-1.05 (14H, m), 1.35 (9H, s).

Example 2(20)

(2S)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester

[0537] 1081

[0538] TLC: Rf 0.17 (ethyl acetate:hexane=1:5);

[0539] NMR (CDCl3): δ 7.29 (2H, d, J=9 Hz), 6.88 (2H, d, J=9 Hz), 5.20-5.03 (4H, m), 4.40-4.23 (1H, m), 3.81 (3H, s), 2.40-1.48 (12H, m), 1.42 (9H, s).

Example 2(21)

(2S)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-nitrobenzyl ester

[0540] 1082

[0541] TLC: Rf 0.16 (ethyl acetate:hexane=1:4);

[0542] NMR (CDCl3): δ 8.23 (2H, d, J=9 Hz) 7.53 (2H, d, J=9 Hz), 5.27 (2H, s), 5.21-5.05 (2H, m) 4.47-4.28 (1H, m) 2.46-1.49 (12H, m), 1.44 (9H, s).

Example 2(22)

(2R)-4-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester

[0543] 1083

[0544] TLC: Rf 0.33 (hexane:ethyl acetate=4:1);

[0545] NMR (CDCl3): δ 7.29 (2H, d, J=8.8 Hz), 6.88 (2H, d, J=8.8 Hz), 5.17-5.04 (3H, m), 4.79-4.69 (1H, m), 4.39-4.25 (1H, m), 3.81 (3H, s), 2.43-2.29 (2H, m), 2.24-2.05 (1H, m), 2.03-1.53 (7H, m), 1.51-1.27 (13H, m).

Example 2(23)

(2R)-4-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-nitrobenzyl ester

[0546] 1084

[0547] TLC: Rf 0.26 (hexane:ethyl acetate=4:1);

[0548] NMR (CDCl3): δ 8.23 (2H, d, J=8.8 Hz), 7.53 (2H, d, J=8.8 Hz), 5.29 (2H, s), 5.12 (1H, d, J=9.0 Hz), 4.81-4.69 (1H, m), 4.45-4.34 (1H, m), 2.48-2.35 (2H, m), 2.30-2.11 (1H, m), 2.07-1.53 (7H, m), 1.51-1.28 (13H, m).

Example 2(24)

(2R)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester

[0549] 1085

[0550] TLC: Rf 0.34 (hexane:ethyl acetate=4:1);

[0551] NMR (CDCl3): δ 7.29 (2H, d, J=8.8 Hz), 6.88 (2H, d, J=8.8 Hz), 5.19-5.04 (4H, m), 4.37-4.26 (1H, m), 3.81 (3H, S), 2.44-2.27 (2H, m), 2.23-2.04 (1H, m), 2.00-1.57 (9H, m), 1.43 (9H, s).

Example 2(25)

(2R)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-nitrobenzyl ester

[0552] 1086

[0553] TLC: Rf 0.21 (hexane:ethyl acetate=4:1);

[0554] NMR (CDCl3): δ 8.23 (2H, d, J=8.8 Hz), 7.53 (2H, d, J=8.8 Hz), 5.27 (2H, s), 5.20-5.09 (2H, m), 4.43-4.33 (1H, m), 2.50-2.33 (2H, m), 2.28-2.10 (1H, m), 2.06-1.52 (9H, m), 1.43 (9H, s).

Example 2(26)

(2S)-4-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester

[0555] 1087

[0556] TLC: Rf 0.29 (ethyl acetate:hexane=1:4);

[0557] NMR (CDCl3): δ 7.34-7.20 (2H, m), 6.94-6.81 (2H, m), 5.12-5.00 (1H, m), 5.05 (2H, s), 4.84-4.74 (1H, m), 4.36-4.20 (1H, m), 3.81 (3H, s), 2.47-1.22 (23H, m).

Example 2(27)

(2S)-4-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester

[0558] 1088

[0559] TLC: Rf 0.27 (ethyl acetate:hexane=1:4);

[0560] NMR (CDCl3): δ 8.29-8.18 (2H, m), 7.56-7.46 (2H m), 7.52 (2H, d, J=8.8 Hz), 5.30-5.05 (3H, m), 4.86-4.75 (1H, m), 4.37-4.25 (1H, m), 2.64-2.38 (2H, m), 2.33-2.13 (1H, m), 2.06-1.17 (20H, m).

Example 2(28)

(2S)-4-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclopentyl ester

[0561] 1089

[0562] TLC: Rf 0.29 (ethyl acetate:hexane=1:4);

[0563] NMR (CDCl3): δ 7.28 (2H, d, J=11.2 Hz), 6.89 (2H, d, J=11.2 Hz), 5.24-5.20 (1H, m), 5.13-5.01 (1H, m), 5.05 (2H, s), 4.31-4.21 (1H, m), 3.81 (3H, s), 2.47-1.59 (12H, m), 1.43 (9H, s).

Example 2(29)

(2S)-4-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclopentyl ester

[0564] 1090

[0565] TLC: Rf 0.20 (ethyl acetate:hexane=1:4);

[0566] NMR (CDCl3): δ 8.28-8.18 (2H, m), 7.76-7.46 (2H, m), 5.25-5.06 (2H, m), 5.22 (2H, s), 4.35-4.24 (1H, m), 2.55-2.47 (2H, m), 2.40-1.53 (10H, m), 1.44 (9H, s).

Example 2(30)

(2R)-4-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester

[0567] 1091

[0568] TLC: Rf 0.42 (ethyl acetate:hexane=1:4);

[0569] NMR (CDCl3): δ 7.33-7.23 (2H, m), 6.93-6.84 (2H, m), 5.12-5.00 (1H, m), 5.05 (2H, s), 4.84-4.74 (1H, m), 4.36-4.20 (1H, m), 3.81 (3H, s), 2.47-1.22 (23H, m).

Example 2(31)

(2R)-4-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester

[0570] 1092

[0571] TLC: Rf 0.27 (ethyl acetate:hexane=1; 4);

[0572] NMR (CDCl3): δ 8.26-8.18 (2H, m), 7.56-7.46 (2H, m), 5.22 (2H, s), 5.15-5.06 (1H, m), 4.86-4.75 (1H, m), 4.37-4.25 (1H, m), 2.56-1.20 (23H, m).

Example 2(32)

(2R)-4-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclopentyl ester

[0573] 1093

[0574] TLC: Rf 0.29 (ethyl acetate:hexane=1:4);

[0575] NMR (CDCl3): δ 7.33-7.24 (2H, m), 7.28 (2H, d, J=11.2 Hz), 6.93-6.84 (2H, m), 6.89 (2H, d, J=11.2 Hz), 5.24-5.03 (2H, m), 5.05 (2H, S), 4.31-4.21 (1H, m), 3.81 (3H, s), 2.47-1.59 (12H, m), 1.43 (9H, s).

Example 2(33)

(2R)-4-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclopentyl ester

[0576] 1094

[0577] TLC: Rf 0.24 (ethyl acetate:hexane=1:4);

[0578] NMR (CDCl3): δ 8.25-8.18 (2H, m), 7.55-7.47 (2H, m), 5.25-5.06 (2H, m), 5.22 (2H, s), 4.35-4.24 (1H, m), 2.55-2.47 (2H, m), 2.31-1.53 (10H, m), 1.44 (9H, s).

Example 2(34)

(2S)-N-(4-methoxybenzyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylamino-propanamide

[0579] 1095

[0580] TLC: Rf 0.18 (ethyl acetate:hexane=1:3);

[0581] NMR (CDCl3): δ 7.18 (2H, d, J=9 Hz), 6.85 (2H, d, J=9 Hz), 6.85-6.67 (1H, m), 5.80-5.58 (1H, m), 4.83-4.67 (1H, m), 4.60-4.40 (1H, m), 4.43-4.25 (2H, m), 3.79 (3H, s), 2.98 (1H, dd, J=18, 5 Hz), 2.68 (1H, dd, J=18, 5 Hz), 1.95-1.60 (5H, m), 1.60-1.10 (5H, m), 1.42 (9H, s).

Example 2(35)

(2S)-3-cyclohexylcarbomoyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0582] 1096

[0583] TLC: Rf 0.31 (ethyl acetate:hexane=1:3);

[0584] NMR (CDCl3): δ 7.28 (2H, d, J=9 Hz), 6.87 (2H, d, J=9 Hz), 5.85-5.70 (1H, m), 5.53-5.35 (1H, m), 5.14 (1H, d, J=12 Hz), 5.10 (1H, d, J=12 Hz), 4.55-4.43 (1H, m), 3.80 (3H, s), 3.78-3.58 (1H, m), 2.81 (1H, dd, J=15, 5 Hz), 2.66 (1H, dd, J=15, 5 Hz), 1.95-1.48 (5H, m), 1.48-0.94 (5H, m), 1.42 (9H, s).

Example 2(36)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylcarbamoyl-2-t-butoxycarbonylamino-propanamide

[0585] 1097

[0586] TLC: Rf 0.19 (ethyl acetate:hexane=1:3);

[0587] NMR (CDCl3): δ 7.25-7.10 (1H, m), 7.17 (2H, d, J=9 Hz), 6.84 (2H, d, J=9 Hz), 6.33-6.15 (1H, m), 5.87-5.70 (1H, m), 4.53-4.40 (1H, m), 4.36 (2H, d, J=6 Hz), 3.79 (3H, s), 3.78-3.58 (1H, m), 2.84 (1H, dd, J=15, 5 Hz), 2.51 (1H, dd, J=15, 5 Hz), 1.94-1.50 (5H, m), 1.50-0.97 (5H, m), 1.42 (9H, s).

Example 2(37)

(2S)-N-(4-methoxybenzyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylamino-propanamide

[0588] 1098

[0589] TLC: Rf 0.21 (ethyl acetate:hexane=1:3);

[0590] NMR (CDCl3): δ 7.18 (2H, d, J=9 Hz), 6.85 (2H, d, J=9 Hz), 6.80-6.70 (1H, m), 5.78-5.62 (1H, m), 5.23-5.08 (1H, m), 4.59-4.23 (3H, m), 3.80 (3H, s), 2.96 (1H, dd, J=18, 5 Hz), 2.65 (1H, dd, J=18, 8 Hz), 1.93-1.48 (8H, m), 1.42 (9H, s).

Example 2(38)

(2S)-3-cyclopentylcarbamoyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0591] 1099

[0592] TLC: Rf 0.46 (ethyl acetate:hexane=1:);

[0593] NMR (CDCl3): δ 7.28 (2H, d, J=9 Hz), 6.87 (2H, d, J=9 Hz), 5.83-5.73 (1H, m), 5.64-5.47 (1H, m), 5.14 (1H, d, J=12 Hz), 5.09 (1H, d, J=12 Hz), 4.56-4.40 (1H, m), 4.21-4.04 (1H, m), 3.81 (3H, s), 2.79 (1H, dd, J=15, 5 Hz), 2.65 (1H, dd, J=15, 5 Hz), 2.05-1.84 (2H, m), 1.75-1.48 (4H, m), 1.46-1.17 (2H, m), 1.42 (9H, s).

Example 2(39)

(2S)-N-(4-methoxybenzyl)-3-cyclopentylcarbamoyl-2-t-butoxycarbonylamino-propanamide

[0594] 1100

[0595] TLC: Rf 0.33 (methanol:methylene chloride=1:19);

[0596] NMR (CDCl3): δ 7.23-7.10 (1H, m), 7.17 (2H, d, J=9 Hz), 6.84 (2H, d, J=9 Hz), 6.32-6.15 (1H, m), 6.00-5.82 (1H, m), 4.51-4.31 (3H, m), 4.20-4.03 (1H, m), 3.79 (3H, s), 2.83 (1H, dd, J=15, 5 Hz), 2.50 (1H, dd, J=15, 8 Hz), 2.05-1.80 (2H, m), 1.75-1.46 (4H, m), 1.46-1.23 (2H, m), 1.42 (9H, s).

Example 2(40)

(2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.2-pyridylmethyl ester

[0597] 1101

[0598] TLC: Rf 0.41 (hexane:ethyl acetate=2:1);

[0599] NMR (CDCl3): δ 8.58 (1H, d, J=4.6 Hz), 7.74-7.66 (1H, m), 7.37 (1H, d, J=7.8 Hz), 7.23 (1H, dd, J=4.6, 7.8 Hz), 5.55 (1H, d, J=8.8 Hz), 5.31 (2H, s), 5.20-5.12 (1H, m), 4.72-4.62 (1H, m), 3.02 (1H, dd, J=4.8, 16.8 Hz), 2.81 (1H, dd, J=4.8, 16.8 Hz), 1.84-1.56 (8H, m), 1.44 (9H, s).

Example 2(41)

(2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-t-butylbenzyl ester

[0600] 1102

[0601] TLC: Rf 0.45 (hexane:ethyl acetate=6:1);

[0602] NMR (CDCl3): δ 7.38 (2H, d, J=8.6 Hz), 7.27 (2H, d, J=8.6 Hz), 5.49 (1H, d, J=8.6 Hz), 5.21-5.08 (3H, m), 4.62-4.53 (1H, m), 2.96 (1H, dd, J=4.8, 16.8 Hz), 2.77 (1H, dd, J=4.8, 16.8 Hz), 1.76-1.52 (8H, m), 1.43 (9H, s), 1.32 (9H, s).

Example 2(42)

(2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.2-methoxybenzyl ester

[0603] 1103

[0604] TLC: Rf 0.32 (hexane:ethyl acetate=4:1);

[0605] NMR (CDCl3): δ 7.34-7.26 (2H, m), 6.95 (1H, d, J=6.6 Hz), 6.86 (1H, d, J=8.4 Hz), 5.50 (1H, d, J=8.8 Hz), 5.23 (2H, s), 5.18-5.10 (1H, m), 4.65-4.56 (1H, m), 3.83 (3H, s), 2.96 (1H, dd, J=4.8, 16.8 Hz), 2.87 (1H, dd, J=4.8, 16.8 Hz), 1.84-1.45 (8H, m), 1.44 (9H, s).

Example 2(43)

(2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.3-methoxybenzyl ester

[0606] 1104

[0607] TLC: Rf 0.32 (hexane:ethyl acetate=4:1);

[0608] NMR (CDCl3): δ 7.31-7.23 (1H, m), 6.93-6.84 (3H, m), 5.50 (1H, d, J=8.8 Hz), 5.22-5.08 (3H, m), 4.64-4.54 (1H, m), 3.81 (3H, s), 2.97 (1H, dd, J=4.8, 16.8 Hz), 2.77 (1H, dd, J=4.8, 16.8 Hz), 1.86-1.50 (8H, m), 1.44 (9H, s).

Example 2(44)

(2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.3-pyridylmethyl ester

[0609] 1105

[0610] TLC: Rf 0.36 (hexane:ethyl acetate=1:1);

[0611] NMR (CDCl3): δ 8.60-8.57 (2H, m), 7.69 (1H, d, J=7.6 Hz), 7.33-7.27 (1H, m), 5.50 (1H, d, J=9.4 Hz), 5.28-5.10 (3H, m), 4.64-4.54 (1H, m), 2.97 (1H, dd, J=4.8, 17.0 Hz), 2.77 (1H, dd, J=4.8, 17.0 Hz), 1.86-1.49 (8H, m), 1.43 (9H, s).

Example 2(45)

(2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-pyridylmethyl ester

[0612] 1106

[0613] TLC: Rf 0.29 (hexane:ethyl acetate=1:1);

[0614] NMR (CDCl3): δ 8.60 (2H, d, J=6.0 Hz), 7.25 (2H, d, J=6.0 Hz), 5.54 (1H, d, J=8.8 Hz), 5.28-5.12 (3H, m), 4.70-4.61 (1H, m), 3.02 (1H, dd, J=4.8, 16.8 Hz), 2.80 (1H, dd, J=4.8, 16.8 Hz), 1.87-1.52 (8H, m), 1.45 (9H, s).

Example 2(46)

(2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-chlorobenzyl ester

[0615] 1107

[0616] TLC: Rf 0.26 (hexane:ethyl acetate=6:1);

[0617] NMR (CDCl3): δ 7.33 (2H, d, J=8.8 Hz), 7.27 (2H, d, J=8.8 Hz), 5.49 (1H, d, J=8.0 Hz), 5.22-5.06 (3H, m), 4.63-4.54 (1H, m), 2.96 (1H, dd, J=4.6, 16.8 Hz), 2.76 (1H, dd, J=4.6, 16.8 Hz), 1.83-1.53 (8H, m), 1.44 (9H, s).

Example 2(47)

(2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-bromobenzyl ester

[0618] 1108

[0619] TLC: Rf 0.25 (hexane:ethyl acetate=6:1);

[0620] NMR (CDCl3): δ 7.48 (2H, d, J=8.6 Hz), 7.21 (2H, d, J=8.6 Hz), 5.49 (1H, d, J=8.4 Hz), 5.20-5.04 (3H, m), 4.63-4.54 (1H, m), 2.96 (1H, dd, J=4.6, 17.0 Hz), 2.76 (1H, dd, J=4.6, 17.0 Hz), 1.83-1.52 (8H, m), 1.43 (9H, s).

Example 2(48)

(2S)-4-(pyrrolidin-1-ylcarbonyl)-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester

[0621] 1109

[0622] TLC: Rf 0.33 (methylene chloride:methanol=19:1);

[0623] NMR (CDCl3): δ 7.30 (2H, d, J=9 Hz), 6.87 (2H, d, J=9 Hz), 5.58-5.40 (1H, m), 5.15 (1H, d, J=13 Hz), 5.06 (1H, d, J=13 Hz), 4.38-4.20 (1H, m), 3.81 (3H, s), 3.48-3.38 (2H, m), 3.32-3.20 (2H, m), 2.16-1.78 (8H, m), 1.42 (9H, s).

Example 2(49)

(2S)-3-cyclohexylcarbonyloxy-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0624] 1110

[0625] TLC: Rf 0.25 (ethyl acetate:hexane=1:5),

[0626] NMR (CDCl3): δ 7.29 (2H, d, J=9 Hz), 6.88 (2H, d, J=9 Hz), 5.28 (1H, d, J=8 Hz), 5.14 (1H, d, J=12 Hz), 5.09 (1H, d, J=12 Hz), 4.64-4.52 (1H, m), 4.45 (1H, dd, J=11, 4 Hz), 4.26 (1H, dd, J=11, 4 Hz), 3.81 (3H, s), 2.27-2.10 (1H, m), 1.89-1.53 (5H, m), 1.53-1.05 (5H, m), 1.44 (9H, s).

Example 2(50)

(2S)-3-cyclopentyloxycarbonyl-2-(N-methyl-N-t-butoxycarbonylamino)-propanoic acid.4-methoxybenzyl ester

[0627] 1111

[0628] TLC: Rf 0.65 (ethyl acetate:hexane=1:2);

[0629] NMR (CDCl3): δ 7.31-7.25 (2H, m), 6.91-6.83 (2H, m), 5.23-5.01 (3H, m), 4.86-4.55 (1H, m), 3.81 (3H, s), 3.03 (1H, dd, J=16.2, 6.4 Hz), 2.91-2.83 (2H, m), 2.71 (1H, dd, J=16.2, 7.8 Hz), 1.96-1.52 (8H, m), 1.43-1.38 (9H, m).

Example 2(51)

(2S)-3-cyclohexyloxycarbonyl-2-(N-methyl-N-t-butoxycarbonylamino)-propanoic acid.4-methoxybenzyl ester

[0630] 1112

[0631] TLC: Rf 0.75 (ethyl acetate:hexane=1:2);

[0632] NMR (CDCl3): δ 7.27(2H, d, J=8.6 Hz), 6.87 (2H, d, J=8.6 Hz), 5.18-5.01 (2H, m), 4.88-4.55 (2H, m), 3.81 (3H, s), 3.05 (1H, dd, J=16.4, 6.4 Hz), 2.91-2.83 (3H, m), 2.74 (1H, dd, J=16.4, 8.4 Hz), 1.89-1.16 (19H, m).

Example 2(52)

(2R)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0633] 1113

[0634] TLC: Rf 0.18 (ethyl acetate:hexane=1:8);.

[0635] NMR (CDCl3): δ 7.32-7.25 (2H, m), 6.92-6.85 (2H, m), 5.36 (1H, br. d, J=8.8 Hz), 5.18 (1H, d, J=12.0 Hz), 5.06 (1H, d, J=12.0 Hz), 4.48-4.34 (1H, m), 3.81-3.76 (4H, m), 3.60 (1H, dd, J=9.8, 3.2 Hz), 3.19 (1H, dd, J=9.4, 6.6 Hz), 3.09 (1H, dd, J=9.4, 6.4 Hz), 1.74-1.13 (19H, m).

Example 2(53)

(2S)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0636] 1114

[0637] TLC: Rf 0.18 (ethyl acetate:hexane=1:8);

[0638] NMR (CDCl3): δ 7.32-7.25 (2H, m), 6.92-6.85 (2H, m), 5.36 (1H, br. d, J=8.8 Hz), 5.18 (1H, d, J=12.0 Hz), 5.06 (1H, d, J=12.0 Hz), 4.48-4.34 (1H, m), 3.81-3.76 (4H, m), 3.60 (1H, dd, J=9.8, 3.2 Hz), 3.19 (1H, dd, J=9.4, 6.6 Hz), 3.09 (1H, dd; J=9.4, 6.4 Hz), 1.74-1.13 (19H, m).

Example 2(54)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxyphenethyl ester

[0639] 1115

[0640] TLC: Rf 0.60 (ethyl acetate:hexane=1:2);

[0641] NMR (CDCl3): δ 7.17-7.09 (2H, m), 6.88-6.80 (2H, m), 5.45 (1H. br. d, J=8.8 Hz), X 4.78-4.65 (1H, m), 4.59-4.49 (1H, m), 4.40-4.22 (2H, m), 3.79 (3H, s), 2.99-2.85 (3H, m), 2.76 (1H, dd, J=17.0, 4.6 Hz), 1.86-1.24 (19H, m)

Example 2(55)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.3-(4-methoxyphenyl)propyl ester

[0642] 1116

[0643] TLC: Rf 0.67 (ethyl acetate:hexane=1:2),

[0644] NMR (CDCl3): δ 7.13-7.05 (2H, m), 6.86-6.79 (2H, m), 5.49 (1H, br. d, J=8.6 Hz), 4.81-4.70 (1H, m), 4.60-4.51 (1H, m), 4.24-4.04 (2H, m), 3.79 (3H, s), 2.98 (1H, dd, J=16.6, 4.6 Hz), 2.79 (1H, dd, J=16.6, 4.8 Hz), 2.62 (2H, t, J=7.4 Hz), 2.00-1.16 (21H, m).

Example 2(56)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.furan-2-ylmethyl ester

[0645] 1117

[0646] TLC: Rf 0.63 (ethyl acetate:hexane=1:2);

[0647] NMR (CDCl3): δ 7.42-7.40 (1H, m), 6.41 (1H, d, J=3.2 Hz), 6.35 (1H, dd, J=3.2, 2.0 Hz), 5.46 (1H, d, J=8.6 Hz), 5.12 (2H, s), 4.81-4.67 (1H, m), 4.62-4.53 (1H, m), 2.96 (1H, dd, J=16.8, 4.8 Hz), 2.77 (1H, dd, J=16.8, 5.0 Hz), 1.86-1.16 (19H, m).

Example 2(57)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.thiophen-2-ylmethyl ester

[0648] 1118

[0649] TLC: Rf 0.62 (ethyl acetate:hexane=1:2);

[0650] NMR (CDCl3): δ 7.32 (1H, dd, J=5.0, 1.4 Hz), 7.10-7.08 (1H, m), 6.98 (1H, dd, J=5.0, 3.2), 5.48 (1H, d, J=8.4 Hz), 5.37 (1H, d, J=12.8 Hz), 5.28 (1H, d, J=12.8 Hz), 4.76-4.66 (1H, m), 4.62-4.53 (1H, m), 2.97 (1H, dd, J=17.2, 4.8 Hz), 2.78 (1H, dd, J=17.2, 4.6 Hz), 1.86-1.22 (19H, m).

Example 2(58)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanioc acid.4-(4-methoxyphenyl)butyl ester

[0651] 1119

[0652] TLC: Rf 0.63 (ethyl acetate:hexane=1:2);

[0653] NMR (CDCl3): δ 7.12-7.05 (2H, m), 6.86-6.79 (2H, m), 5.47 (1H, d, J=8.8 Hz), 4.79-4.68 (1H, m), 4.58-4.49 (1H, m), 4.18-4.12 (2H, m), 2.96 (1H, dd, J=17.2, 4.0 Hz), 2.78 (1H, dd, J=17.2, 4.8 Hz), 2.61-2.54 (2H, m), 1.89-1.16 (23H, m).

Example 2(59)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester

[0654] 1120

[0655] TLC: Rf 0.82 (ethyl acetate:hexane=1:2);

[0656] NMR (CDCl3): δ 5.48 (1H, d, J=8.4 Hz), 4.88-4.70 (2H, m), 4.56-4.47 (1H, m), 2.97 (1H, dd, J=16.6, 4.0 Hz), 2.78 (1H, dd, J=16.6, 4.8 Hz), 1.90-1.18 (29H, m).

Example 2(60)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.methyl ester

[0657] 1121

[0658] TLC: Rf 0.55 (ethyl acetate:hexane=1:2);

[0659] NMR (CDCl3): δ 5.47 (1H, d, J=8.0 Hz), 4.82-4.71 (1H, m), 4.62-4.53 (1H, m), 3.76 (3H, s), 2.97 (1H, dd, J=16.8, 4.6 Hz), 2.78 (1H, dd, J=16.8, 5.0 Hz), 1.90-1.18 (19H, m).

Example 2(61)

(2S)-N-(4-methoxyphenyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylamino-propanamide

[0660] 1122

[0661] TLC: Rf 0.51 (ethyl acetate:hexane=1:2);

[0662] NMR (CDCl3): δ 8.41 (1H, br. s), 7.45-7.37 (2H, m), 6.89-6.81 (2H, m), 5.80 (1H, d, J=7.0 Hz), 4.84-4.73 (1H, m), 4.66-4.57 (1H, m), 3.79 (3H, s), 3.01 (1H, dd, J=16.8, 4.4 Hz), 2.73 (1H, dd, J=16.8, 7.0 Hz), 1.86-1.16 (19H, m).

Example 2(62)

(2S)-3-cyclobutyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0663] 1123

[0664] TLC: Rf 0.57 (ethyl acetate:hexane=1:2);

[0665] NMR (CDCl3): δ 7.31-7.24 (2H, m), 6.92-6.85 (2H, m), 5.48 (1H, d, J=9.0 Hz), 5.15 (1H, d, J=11.8 Hz), 5.07 (1H, d, J=11.8 Hz), 5.01-4.86 (1H, m), 4.62-4.52 (1H, m), 3.81 (3H, s), 2.96 (1H, dd, J=17.2, 5.2 Hz), 2.76 (1H, dd, J=17.2, 4.8 Hz), 2.37-2.22 (2H, m), 2.12-1.43 (13H, m).

Example 2(63)

(2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.diphenylmethyl ester

[0666] 1124

[0667] TLC: Rf 0.33 (ethyl acetate:hexane=1:5);

[0668] NMR (CDCl3): δ 7.45-7.18 (10H, m), 6.90 (1H, s), 5.56 (1H, d, J=8 Hz), 4.75-4.58 (2H, m), 3.03 (1H, dd, J=18, 5 Hz), 2.83 (1H, dd, J=18, 5 Hz), 1.80-1.08 (10H, m), 1.43 (9H, s).

Example 2(64)

(2S)-N-((1S)-2-phenyl-1-benzyloxycarbonylethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide

[0669] 1125

[0670] TLC: Rf 0.53 (ethyl acetate:hexane=1:2);

[0671] NMR (CDCl3): δ 7.39-7.19 (8H, m), 7.08-7.03 (2H, m), 6.97 (1H, d, J=8.4 Hz), 5.61 (1H, d, J=8.4 Hz), 5.14 (1H, d, J=12.4 Hz), 5.08 (1H, d, J=12.4 Hz), 4.90-4.69 (2H, m), 4.56-4.42 (1H, m), 3.10 (2H, d, J=6.0 Hz), 2.93 (1H, dd, J=17.2, 4.6 Hz), 2.62 (1H, dd, J=17.2, 6.2 Hz), 1.89-1.18 (19H, m).

Example 2(65)

(2S)-N-((1S)-1-benzyloxycarbonylethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide

[0672] 1126

[0673] TLC: Rf 0.47 (ethyl acetate:hexane=1:2);

[0674] NMR (CDCl3): δ 7.41-7.31 (5H, m), 7.09 (1H, d, J=6.4 Hz), 5.67 (1H, d, J=7.8 Hz), 5.20 (1H, d, J=12.0 Hz), 5.13 (1H, d, J=12.0 Hz), 4.81-4.46 (3H, m), 2.96 (1H, dd, J=16.8, 4.4 Hz), 2.64 (1H, dd, J=16.8, 6.6), 1.92-1.18 (19H, m).

Example 2(66)

(2S)-3-benzyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0675] 1127

[0676] TLC: Rf 0.33 (ethyl acetate:hexane=1:3);

[0677] NMR (CDCl3): δ 7.40-7.27 (5H, m), 7.23 (2H, d, J=9 Hz), 6.85 (2H, d, J=9 Hz), 5.56-5.40 (1H, m), 5.07 (4H, s), 4.65-4.50 (1H, m), 3.80 (3H, s), 3.03 (1H, dd, J=18, 5 Hz), 2.85 (1H, dd, J=18, 5 Hz), 1.42 (9H, s).

Example 2(67)

(2S)-3-cycloheptyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0678] 1128

[0679] TLC: Rf 0.36 (hexane:ethyl acetate=4:1);

[0680] NMR (CDCl3): δ 7.27 (2H, d, J=8.4 Hz), 6.88 (2H, d, J=8.4 Hz), 5.48 (1H, d, J=8.4 Hz), 5.15 (1H, d, J=12.2 Hz), 5.07 (1H, d, J=12.2 Hz), 4.94-4.82 (1H, m), 4.61-4.52 (1H, m), 3.81 (3H, s), 2.95 (1H, dd, J=4.4, 16.8 Hz), 2.76 (1H, dd, J=4.8, 16.8 Hz), 1.90-1.75 (2H, m), 1.68-1.34 (19H, m).

Example 2(68)

(2S)-3-cyclooctyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0681] 1129

[0682] TLC: Rf 0.38 (hexane:ethyl acetate=4:1);

[0683] NMR (CDCl3): δ 7.27 (2H, d, J=8.4 Hz), 6.88 (2H, d, J=8.4 Hz), 5.49 (1H, d, J=8.4 Hz), 5.16 (1H, d, J=12.0 Hz), 5.07 (1H, d, J=12.0 Hz), 4.96-4.84 (1H, m), 4.61-4.52 (1H, m), 3.81 (3H, s), 2.94 (1H, dd, J=4.4, 16.8 Hz), 2.75 (1H, dd, J=4.8, 16.8 Hz), 1.75-1.46 (14H, m), 1.43 (9H, s).

Example 2(69)

(2S)-3-(adamantan-2-yloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0684] 1130

[0685] TLC: Rf 0.43 (hexane:ethyl acetate=4:1);

[0686] NMR (CDCl3): δ 7.27 (2H, d, J=8.6 Hz), 6.87 (2H, d, J=8.6 Hz), 5.51 (1H, d, J=8.4 Hz), 5.16 (1H, d, J=12.0 Hz), 5.06 (1H, d, J=12.0 Hz), 4.92-4.87 (1H, br), 4.63-4.54 (1H, m), 3.81 (3H, s), 3.01 (1H, dd, J=4.6, 16.8 Hz), 2.83 (1H, dd, J=4.8, 16.8 Hz), 2.01-1.67 (12H, m), 1.58-1.45 (2H, m), 1.43 (9H, s).

Example 2(70)

(2S)-3-(adamantan-1-yloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0687] 1131

[0688] TLC: Rf 0.42 (hexane:ethyl acetate=4:1);

[0689] NMR (CDCl3): δ 7.29 (2H, d, J=8.6 Hz), 6.87 (2H, d, J=8.6 Hz), 5.49 (1H, d, J=8.4 Hz), 5.17 (1H, d, J=11.9 Hz), 5.05 (1H, d, J=11.9 Hz), 4.57-4.48 (1H, m), 3.80 (3H, s), 2.90 (1H, dd, J=4.4, 16.8 Hz), 2.69 (1H, dd, J=4.8, 16.8 Hz), 2.18-2.07 (3H, br), 2.01 (6H, d, J=3.0 Hz), 1.63 (6H, t, J=3.0 Hz), 1.44 (9H, s).

Example 2(71)

(2S, 3R)-3-cyclohexylcarbonyloxy-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester

[0690] 1132

[0691] TLC: Rf 0.35 (ethyl acetate:hexane=1:5);

[0692] NMR (CDCl3): δ 7.29 (2H, d, J=9 Hz), 6.88 (2H, d, J=9 Hz), 5.46-5.30 (1H, m), 5.17 (1H, d, J=10 Hz), 5.06 (1H, d, J=13 Hz), 5.04 (1H, d, J=13 Hz), 4.44 (1H, dd, J=10, 2 Hz), 3.81 (3H, s), 2.20-2.00 (1H, m), 1.85-1.50 (5H, m), 1.46 (9H, s), 1.40-1.00 (5H, m), 1.25 (3H, d, J=6 Hz).

Example 2(72)

(2S)-N-((1S)-1-(4-methoxybenzyloxycarbonyl)ethyl)-3-cyclohexyloxycarbonyl-2-benzyloxycarbonylaminopropanamide

[0693] 1133

[0694] TLC: Rf 0.31 (ethyl acetate:hexane=1:2);

[0695] NMR (CDCl3): δ 7.39-7.24 (7H, m), 7.03 (1H, d, J=7.2 Hz), 6.92-6.85 (2H, m), 5.91 (1H, d, J=7.8 Hz), 5.16-5.03 (4H, m), 4.82-4.69 (1H, m), 4.64-4.47 (2H, m), 3.81 (3H, s), 2.99 (1H, dd, J=17.2, 4.0 Hz), 2.65 (1H, dd, J=17.2, 6.4 Hz), 1.84-1.18 (13H, m).

Example 2(73)

(2S)-N-((1S)-2-phenyl-1-(4-methoxybenzyloxycarbonyl)ethyl)-3-cyclohexyl-oxycarbonyl-2-benzyloxycarbonylaminopropanamide

[0696] 1134

[0697] TLC: Rf 0.36 (ethyl acetate:hexane=1:2);

[0698] NMR (CDCl3): δ 7.38-7.33 (5H, m), 7.25-7.16 (5H, m), 7.05-6.84 (5H, m), 5.87 (1H, d, J=8.2 Hz), 5.15-4.98 (4H, m), 4.86-4.67 (2H, m), 4.59-4.50 (1H, m), 3.82 (3H, s), 3.06 (2H, d, J=6.0 Hz), 2.94 (1H, dd, J=17.2, 4.4 Hz), 2.62 (1H, dd, J=17.2, 6.6 Hz), 1.84-1.18 (10H, m).

Example 2(74)

(3S)-3-t-butoxycarbonylamino-3-(1, 2, 3, 4-tetrahydroquinolin-1-ylcarbonyl)-propanoic acid.cyclohexyl ester

[0699] 1135

[0700] TLC: Rf 0.48 (ethyl acetate:hexane=1:2);

[0701] NMR (DMSO-d6): 7.50-7.05 (5H, m), 4.97 (1H, dd, J=15.4, 7.0 Hz), 4.67-4.52 (1H, m), 3.83-3.50 (2H, m), 2.70-2.38 (4H, m), 1.94-1.80 (2H, m), 1.75-1.18 (19H, m).

Example 2(75)

(3S)-3t-butoxycarbonylamino-3-(1, 2, 3, 4-tetrahydroisoquinolin-2-yl-carbonyl)propanoic acid.cyclohexyl ester

[0702] 1136

[0703] TLC: Rf 0.42 (ethyl acetate:hexane=1:2);

[0704] NMR (CDCl3): δ 7.23-7.11 (4H, m), 5.42 (1H, d, J=9.2 Hz), 5.14-5.03 (1H, m), 4.88-4.58 (3H, m), 4.02-3.71 (2H, m), 2.97-2.55 (4H, m), 1.92-1.08 (19H, m).

Example 2(76)

(2S)-N-methyl-N-(1, 1-dimethyl-2-phenylethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide

[0705] 1137

[0706] TLC: Rf 0.56 (ethyl acetate:hexane=1:2);

[0707] NMR (CDCl3): δ 7.31-7.09 (5H, m), 5.39 (1H, d, J=9.2 Hz), 4.99-4.88 (1H, m>, 4.81-4.71 (1H, m), 3.35 (1H, d, J=13.2 Hz), 3.00 (1H, d, J=13.2 Hz), 2.73 (1H, dd, J=15.4, 6.6 Hz), 2.65 (3H, s), 2.54 (1H, dd, J=15.4, 6.6 Hz), 1.93-1.19 (25H, m).

Example 2(77)

(2S)-6-cyclohexylcarbonylamino-2-t-butoxycarbonylaminohexanoid acid.4-methoxybenzyl ester

[0708] 1138

[0709] TLC: Rf 0.37 (ethyl acetate:hexane=1:1);

[0710] NMR (CDCl3): δ 7.32-7.25 (2H, m), 6.93-6.85 (2H, m), 5.55-5.44 (1H, m), 5.17-5.03 (3H, m), 4.35-4.21 (1H, m), 3.81 (3H, s), 3.23-3.14 (2H, m), 2.08-1.96 (1H, m), 1.88-1.18 (25H, m).

Example 2(78)

(2R)-3-(4-methoxybenzylthio)-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester

[0711] 1139

[0712] TLC: Rf 0.70 (ethyl acetate:hexane=1:2);

[0713] NMR (CDCl3): δ 7.28-7.19 (2H, m), 6.88-6.81 (2H, m), 5.29 (1H, d, J=7.4 Hz), 4.90-4.77 (1H, m), 4.54-4.44 (1H, m), 3.79 (3H, s), 3.70 (2H, s), 2.89 (1H, dd, J=14.0, 4.4 Hz), 2.79 (1H, dd, J=14.0, 6.0 Hz), 1.92-1.18 (19H, m).

Example 2(79)

(2R)-N-(4-methoxybenzyl)-3-(4-methoxybenzylthio)-2-t-butoxycarbonyl-aminopropanamide

[0714] 1140

[0715] TLC: Rf 0.28 (ethyl acetate:hexane=1:2);

[0716] NMR (CDCl3): δ 7.26-7.16 (4H, m), 6.89-6.78 (4H, m), 6.53-6.41 (1H, m), 5.26 (1H, d, J=7.4 Hz), 4.38 (2H, d, J=5.4 Hz), 4.27-4.18 (1H, m), 3.79 (3H, s), 3.78 (3H, s), 3.68 (2H, s), 2.91 (1H, dd, J=14.0, 5.4 Hz), 2.74 (1H, dd, J=14.0, 6.8 Hz), 1.43 (9H, s).

Example 2(80)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylamino-propanamide

[0717] 1141

[0718] TLC: Rf 0.48 (ethyl acetate:hexane=1:2);

[0719] NMR (CDCl3): δ 7.25-7.18 (2H, m), 6.89-6.84 (2H, m), 6.68-6.60 (1H, m), 5.36 (1H, d, J=7.0 Hz), 4.39 (2H, d, J=5.6 Hz), 4.28-4.18 (1H, m), 3.80 (3H, s), 2.98 (1H, dd, J=14.0, 5.8 Hz), 2.82 (1H, dd, J=14.0, 7.0 Hz), 2.46 (1H, dd, J=12.8, 7.0 Hz), 2.39 (1H, dd, J=12.8, 6.6 Hz), 1.83-0.82 (20H, m).

Example 2(81)

(2S)-N-(4-methoxybenzyl)-3-benzyloxy-2-t-butoxycarbonylaminopropanamide

[0720] 1142

[0721] TLC: Rf 0.26 (ethyl acetate:hexane=1:2);

[0722] NMR (CDCl3): δ 7.38-7.12 (7H, m), 6.84-6.77 (2H, m), 6.69-6.61 (1H, m), 5.44-5.34 (1H, m), 4.56 (1H, d, J=11.4 Hz), 4.47 (1H, d, J=11.4 Hz), 4.39 (2H, d, J=5.8 Hz), 4.34-4.24 (1H, m), 3.95 (1H, dd, J=9.2, 3.8 Hz), 3.78 (3H, s), 3.59 (1H, dd, J=9.2, 6.6 Hz), 1.43 (9H, s).

Example 2(82)

(2S)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonyl-aminopropanamide

[0723] 1143

[0724] TLC: Rf 0.42 (ethyl acetate:hexane=1:2);

[0725] NMR (CDCl3): δ 7.18-7.11 (2H, m), 6.72-6.56 (3H, m), 5.46-5.30 (1H, m), 4.41 (1H, dd, J=14.2, 5.4 Hz), 4.30 (1H, dd, J=14.2, 5.2 Hz), 4.29-4.15 (1H, m), 3.82 (1H, dd, J=9.2, 3.6 Hz), 3.47 (1H, dd, J=9.2, 6.8), 3.31-3.16 (2H, m), 2.93 (6H, s), 1.75-0.74 (20H, m).

Example 2(83)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonylamino-propanamide

[0726] 1144

[0727] TLC: Rf 0.18 (ethyl acetate:hexane=1:2);

[0728] NMR (CDCl3): δ 7.23-7.16 (2H, m), 6.89-6.82 (2H, m), 6.78-6.68 (1H, m), 5.46-5.28 (1H, m), 4.45 (1H, dd, J=14.2, 5.4 Hz), 4.35 (1H, dd, J=14.2, 5.6 Hz), 4.28-4.16 (1H, m), 3.86-3.79 (4H, m), 3.47 (1H, dd, J=9.2, 7.0 Hz), 3.27 (1H, dd, J=8.8, 6.4 Hz), 3.20 (1H, dd, J=8.8, 6.2 Hz), 1.75-0.74 (20H, m).

Example 2(84)

(2S)-N-methyl-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonyl-aminopropanamide

[0729] 1145

[0730] TLC: Rf 0.56 (ethyl acetate:hexane=1:2);

[0731] NMR (CDCl3): δ 7.21-7.13 (2H, m), 6.89-6.80 (2H, m), 5.47-5.38 (1H, m), 5.00-4.70 (2H, m), 4.45 (0.3H, d, J=16.6 Hz), 4.30 (0.7H, d, J=14.4 Hz), 3.79 (3H, s), 3.66-3.47 (2H, m), 3.22-3.14 (2H, m), 3.01 (2.1H, s), 2.89 (0.9H, s), 1.74-0.74 (20H, m).

Example 2(85)

(2RS)-N-(4-methoxybenzyl)-4-cyclohexylmethoxy-2-t-butoxycarbonylamino-butanamide

[0732] 1146

[0733] TLC: Rf 0.24 (ethyl acetate:hexane=1:2);

[0734] NMR (CDCl3): δ 7.20 (2H, d, J=9 Hz), 6.86 (2H, d, J=9 Hz), 6.83-6.68 (1H, m), 6.00-5.85 (1H, m), 4.39 (2H, d, J=6 Hz), 4.37-4.17 (1H, m), 3.80 (3H, s), 3.62-3.43 (2H, m), 3.13 (2H, d, J=6 Hz), 2.16-1.97 (2H, m), 1.80-1.00 (9H, m), 1.42 (9H, s), 1.00-0.70 (2H, m).

Example 2(86)

(2S)-N-(4-nitrobenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonylamino-propanamide

[0735] 1147

[0736] TLC: Rf 0.28 (ethyl acetate:hexane=1:2)

[0737] NMR (CDCl3): δ 8.22-8.14 (2H, m), 7.48-7.41 (2H, m), 7.02-6.94 (1H, m), 5.37 (1H, d, J=6.4 Hz), 4.64 (1H, dd, J=13.2, 5.8 Hz), 4.53 (1H, dd, J=13.2, 6.2 Hz), 4.34-4.22 (1H, m), 3.87 (1H, dd, J=9.2, 3.6 Hz), 3.52 (1H , dd, J=9.2, 6.6 Hz), 3.30 (1H, dd, J=9.2, 6.2 Hz), 3.24 (1H, dd, J=9.2, 6.0 Hz), 1.77-0.78 (20H, m).

Example 2(87)

(2S)-N-(4-methoxybenzyl)-3-(2-cyclohexenyloxy)-2-t-butoxycarbonylamino-propanamide

[0738] 1148

[0739] TLC: Rf 0.26 (ethyl acetate:hexane=1:2);

[0740] NMR (CDCl3): δ 7.20 (2H, d, J=9 Hz), 6.84 (2H, d, J=9 Hz), 6.84-6.59 (1H, m), 5.90-5.78 (1H, m), 5.74-5.60 (1H, m), 5.52-5.34 (1H, m), 4.41 (2H, d, J=6 Hz), 4.30-4.15 (1H, m), 4.00-3.83 (2H, m), 3.79 (3H, s), 3.64-3.48 (1H, m), 2.05-1.90 (2H, m), 1.90-1.35 (4H, m), 1.43 (9H, S).

Example 2(88)

(2S)-N-(4-methoxybenzyl)-3-cyclohexyloxy-2-t-butoxycarbonylamino-propanamide

[0741] 1149

[0742] TLC: Rf 0.28 (ethyl acetate:hexane=1:2);

[0743] NMR (CDCl3): δ 7.20 (2H, d, J=9 Hz), 6.85 (2H, d, J=9 Hz), 6.85-6.70 (1H, m), 5.50-5.30 (1H, m), 4.41 (2H, d, J=6 Hz), 4.26-4.14 (1H, m), 3.88 (1H, dd, J=9, 14 Hz), 3.80 (3H, s), 3.50 (1H, dd, J=9, 7 Hz), 3.36-3.20 (1H, m), 1.90-1.05 (10H, m), 1.44 (9H, s).

Example 2(89)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylamino-propanamide

[0744] 1150

[0745] TLC: Rf 0.43 (ethyl acetate:hexane=1:2);

[0746] NMR (CDCl3): δ 7.25-7.18 (2H, m), 6.90-6.82 (2H, m), 6.68-6.58 (1H, m), 5.35 (1H, d, J=7.4 Hz), 4.40 (2H, d, J=6.0 Hz), 4.28-4.18 (1H, m), 3.80 (3H, s), 2.99 (1H, dd, J=13.6, 5.6 Hz), 2.82 (1H, dd, J=13.6, 7.0 Hz), 2.48 (1H, dd, J=12.8, 7.0), 2.39 (1H, dd, J=12.8, 6.6 Hz), 1.86-0.80 (20H, m).

Example 2(90)

(2R)-N-(4-methoxybenzyl)-3-cyclopentylmethylthio-2-t-butoxycarbonylamino-propanamide

[0747] 1151

[0748] TLC: Rf 0.36 (ethyl acetate:hexane=1:2);

[0749] NMR (CDCl3): δ 7.25-7.18 (2H, m), 6.89-6.82 (2H, m), 6.68-6.59 (1H, m), 5.36 (1H, d, J=7.4 Hz), 4.39 (2H, d, J=5.6 Hz), 4.29-4.19 (1H, m), 3.80 (3H, s), 3.00 (1H, dd, J=13.6, 5.4 Hz), 2.84 (1H, dd, J=13.6, 6.6 Hz), 2.54 (2H, d, J=7.4 Hz), 2.10-1.95 (1H, m), 1.91-1.08 (17H, m).

Example 2(91)

(2S)-N-(4-methoxybenzyl)-3-cyclopentylmethoxy-2-t-butoxycarbonylamino-propanamide

[0750] 1152

[0751] TLC: Rf 0.33 (ethyl acetate:hexane=1:2);

[0752] NMR (CDCl3): δ 7.25-7.16 (2H, m), 7.01-6.82 (2H, m), 6.81-6.69 (1H, m), 5.42 (1H, d, J=5.8 Hz), 4.44 (1H, dd, J=15.4, 6.0 Hz), 4.37 (1H, dd, J=15.4, 5.8 Hz), 4.29-4.18 (1H, m), 3.84 (1H, dd, J=9.2, 3.8 Hz), 3.80 (3H , s), 3.50 (1H, dd, J=9.2, 7.0 Hz), 3.37 (1H, dd, J=16.8, 7.4 Hz), 3.28 (1H, dd, J=16.8, 6.8 Hz), 2.14-1.99 (1H, m), 1.75-0.83 (17H, m).

Example 2(92)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylcarbonylamino-2-t-butoxycarbonyl-aminopropanamide

[0753] 1153

[0754] TLC: Rf 0.20 (ethyl acetate:hexane=1:1);

[0755] NMR (CDCl3+CD3OD): δ 7.22-7.14 (2H, m), 6.87-6.80 (2H, m), 4.40 (1H, d, J=14.8 Hz), 4.29 (1H, d, J=14.8 Hz), 4.25-4.20 (1H m), 3.78 (3H, s), 3.72-3.48 (2H, m), 2.09-1.97 (1H, m), 1.86-1.16 (19H, m).

Example 2(93)

(2S)-N-(4-methoxybenzyl)-4-(2-cyclohexenyloxy)-2-t-butoxycarbonylamino-butanamide

[0756] 1154

[0757] TLC: Rf 0.19 (ethyl acetate:hexane=1; 2);

[0758] NMR (CDCl3): δ 7.24-7.15 (2H, m), 6.94-6.78 (3H, m), 5.94-5.74 (2H, m), 5.72-5.60 (1H, m), 4.50-4.15 (3H, m), 3.82-3.52 (3H, m), 3.80 (3H, s), 2.13-1.90 (4H, m), 1.80-1.35 (4H, m), 1.42 (9H, s).

Example 2(94)

(2S)-N-(4-methoxybenzyl)-4-cyclohexyloxy-2-t-butoxycarbonylamino-butanamide

[0759] 1155

[0760] TLC: Rf 0.21 (ethyl acetate:hexane=1:2);

[0761] NMR (CDCl3): δ 7.25-7.15 (2H, m), 7.00-6.80 (3H, m), 6.03-5.88 (1H, m), 4.52-4.15 (3H, m), 3.80 (3H, s), 3.71-3.42 (2H, m), 3.26-3.08 (1H, m), 2.10-1.95 (2H, m), 1.85-1.05 (10H, m), 1.42 (9H, s).

Example 2(95)

(2S)-N-(4-methoxybenzyl)-3-cyclopentylmethylthio-2-t-butoxycarbonylamino-propanamide

[0762] 1156

[0763] TLC: Rf 0.53 (ethyl acetate:chloroform=15:100);

[0764] NMR (CDCl3): δ 7.25-7.18 (2H, m), 6.90-6.82 (2H, m), 6.64 (1H, t, J=6.0 Hz), 5.36 (1H, d, J=7.2 Hz), 4.39 (2H, d, J=6.0 Hz), 4.29-4.19 (1H, m), 3.80 (3H, s), 3.00 (1H, dd, J=14.0, 5.4 Hz), 2.84 (1H, dd, J=14.0, 7.0 Hz), 2.54 (2H, d, J=7.0 Hz), 2.13-1.91 (1H, m), 1.90-1.08 (17H, m).

Example 2(96)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonylamino-propanamide

[0765] 1157

[0766] TLC: Rf 0.21 (ethyl acetate:hexane=1:2);

[0767] NMR (CDCl3): δ 8.21-8.14 (2H, m), 7.48-7.41 (2H, m), 7.03 (1H, t, J=5.8 Hz), 5.39 (1H, d, J=6.2 Hz), 4.63 (1H, dd, J=16.2, 5.8 Hz), 4.53 (1H, dd, J=16.2, 6.2 Hz), 4.36-4.22 (1H, m), 3.87 (1H, dd, J=9.0, 3.6 Hz), 3.53 (1H, dd, J=9.2, 6.6 Hz), 3.30 (1H, dd, J=9.2, 6.2 Hz), 3.24 (1H, dd, J=9.2, 6.2 Hz), 1.79-0.76 (20H, m).

Example 2(97)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylamino-propanamide

[0768] 1158

[0769] TLC: Rf 0.40 (ethyl acetate:hexane=1:2);

[0770] NMR (CDCl3): δ 8.19-8.14 (2H, m), 7.48-7.43 (2H, m), 7.12 (1H, t, J=6.0 Hz), 5.44 (1H, d, J=7.2 Hz), 4.66-4.47 (2H, m), 4.36-4.25 (1H, m), 2.98 (1H, dd, J=13.8, 5.8 Hz), 2.86 (1H, dd, J=13.8, 6.6 Hz), 2.56-2.33 (2H, m), 1.95-0.71 (20H, m).

Example 2(98)

(2R)-N-(furan-2-ylmethyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylamino-propanamide

[0771] 1159

[0772] TLC: Rf 0.60 (ethyl acetate:hexane=1:2);

[0773] NMR (CDCl3): δ 7.37-7.34 (1H, m), 6.76-6.71 (1H, m), 6.33 (1H, dd, J=5.0, 1.8 Hz), 6.26-6.23 (1H, m), 5.35 (1H, d, J=7.2 Hz), 4.51 (1H, dd, J=15.4, 5.4 Hz), 4.40 (1H, dd, J=5.4, 5.4 Hz), 4.28-4.18 (1H, m), 2.98 (1H, dd, J=13.8, 5.4 Hz), 2.81 (1H, dd, J=13.8, 7.0 Hz), 2.45 (1H, dd, J=12.6, 7.0 Hz), 2.39 (1H, dd, J=12.6, 6.6 Hz), 1.88-0.78 (20H, m).

Example 2(99)

(2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonyl-aminopropanamide

[0774] 1160

[0775] TLC: Rf 0.43 (ethyl acetate:hexane=1:2);

[0776] NMR (CDCl3): δ 7.20-7.12 (2H, m), 6.73-6.67 (2H, m), 6.55-6.51 (1H, m), 5.35 (1H, d, J=7.4 Hz), 4.44-4.17 (3H, m), 2.98 (1H, dd, J=13.8, 5.4 Hz), 2.94 (6H, s), 2.82 (1H, dd, J=13.8, 7.0 Hz), 2.51-2.34 (2H, m), 1.88-0.79 (20H, m).

Example 2(100)

(2R)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanoic acid.4-methoxybenzyl ester

[0777] 1161

[0778] TLC: Rf 0.68 (ethyl acetate:hexane=1:2);

[0779] NMR (CDCl3): δ 7.34-7.25 (2H, m), 6.92-6.85 (2H, m), 5.36 (1H, d, J=8.0 Hz), 5.16 (1H, d, J=11.6 Hz), 5.08 (1H, d, J=11.6 Hz), 4.57-4.48 (1H, m), 3.81 (3H, s), 2.93 (2H, d, J=4.8 Hz), 2.35 (2H, d, J=7.0 Hz), 1.85-0.75 (20H, m).

Example 2(101)

(2R)-N-(4-methoxycyclohexylmethyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0780] 1162

[0781] (The relative configuration of cyclohexyl ring substituted by methoxy group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 2(102).)

[0782] TLC: Rf 0.40 (ethyl acetate:hexane=1:2);

[0783] NMR (CDCl3): δ 6.47 (1H, t, J=6.0 Hz), 5.37 (1H, d, J=7.4 Hz), 4.22-4.12 (1H, m), 3.46-3.36 (1H, m), 3.29 (3K, s), 3.17-3.09 (2H, m), 2.95 (1H, dd, J=13.6, 5.6 Hz), 2.78 (1H, dd, J=13.6, 6.8 Hz), 2.54-2.38 (2H, m), 2.00-0.81 (29H, m).

Example 2(102)

(2R)-N-(4-methoxycyclohexylmethyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0784] 1163

[0785] (The relative configuration of cyclohexyl ring substituted by methoxy group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 2(101).)

[0786] TLC: Rf 0.30 (ethyl acetate:hexane=1:2),

[0787] NMR (CDCl3): δ 6.46 (1H, t, J=5.6 Hz), 5.36 (1H, d, J=7.0 Hz), 4.22-4.12 (1H, m), 3.34 (3H, s), 3.17-2.91 (4H, m), 2.79 (1H, dd, J=13.8, 7.0 Hz), 2.54-2.38 (2H, m), 2.15-2.01 (2H, m), 1.89-0.82 (27H, m).

Example 2(103)

(2R)-N-(4-phenoxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexylmethyl-thiopropanamide

[0788] 1164

[0789] NMR (CDCl3): δ 7.39-7.22 (m, 4H), 7.15-7.06 (m, 1H), 7.03-6.93 (m, 4H), 6.70 (t, J=5.3 Hz, 1H), 5.35 (d, J=6.8 Hz, 1H), 4.44 (d, J=6.0 Hz, 2H), 4.30-4.20 (m, 1H), 2.99 (dd, J=14.0, 5.6 Hz, 1H), 2.83 (dd, J=14.0, 7.0 Hz, 1H), 2.52-2.36 (m, 2H), 1.88-0.79 (m, 20H).

Example 2(104)

(2R)-N-((1S)-1-(4-nitrophenyl)ethyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0790] 1165

[0791] TLC: Rf 0.46 (ethyl acetate:hexane=1:2)

[0792] NMR (CDCl3): δ 8.25-8.15 (2H, m), 7.54-7.45 (2H, m), 6.84 (1H, d, J=7 Hz), 5.36 (1H, d, J=7 Hz), 5.15 (1H, quintet, J=7 Hz), 4.21 (1H, td, J=7, 5 Hz), 2.93 (1H, dd, J=14, 5 Hz), 2.79 (1H, dd, J=14, 7 Hz), 2.44 (2H, d, J=7 Hz), 1.88-0.78 (11H, m), 1.52 (3H, d, J=7 Hz), 1.46 (9H, s).

Example 2(105)

(2R)-N-((1R)-1-(4-nitrophenyl)ethyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0793] 1166

[0794] TLC: Rf 0.47 (ethyl acetate:hexane=1:2);

[0795] NMR (CDCl3): δ 8.22-8.15 (2H, m), 7.51-7.44 (2H, m), 6.89 (1H, d, J=7.8 Hz), 5.32 (1H, d, J=7.0 Hz), 5.21-5.06 (1H, m), 4.27-4.17 (1H, m), 2.95 (1H, dd, J=14.0, 5.8 Hz), 2.80 (1H, dd, J=14.0, 7.0 Hz), 2.44 (1H, dd, J=12.4, 6.8 Hz), 2.38 (1H, dd, J=12.4, 6.6 Hz), 1.88-0.80 (23H, m).

Example 2(106)

(2R)-N-methyl-N-(4-nitrobenzyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0796] 1167

[0797] TLC: Rf 0.37 (ethyl acetate:hexane=1:2);

[0798] NMR (CDCl3): δ 8.25-8.16 (2H, m), 7.48-7.41 (2H, m), 5.38-5.25 (1H, m), 4.95-4.60 (3H, m), 3.14 (2.33H, s), 2.98 (0.67H, s), 2.96-2.66 (2H, m), 2.46 (1.56H, d, J=6.6 Hz), 2.33 (0.44H, d, J=6.6 Hz), 1.88-0.81 (20H, m).

Example 2(107)

(2R)-N-(1-(4-methoxyphenyl)-1-methylethyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide

[0799] 1168

[0800] TLC: Rf 0.21 (ethyl acetate:hexane=1:5);

[0801] NMR (CDCl3): δ 7.37-7.26 (2H, m), 6.89-6.79 (2H, m), 6.70 (1H, bs), 5.36 (1H, d, J=8 Hz), 4.11 (1H, td, J=7, 5 Hz), 3.80 (3H, s), 2.91 (1H, dd, J=14, 5 Hz), 2.75 (1H, dd, J=14, 7 Hz), 2.47 (2H, d, J=7 Hz), 1.90-0.80 (11H, m), 1.70 (3H, s), 1.69 (3H, s), 1.47 (9H, s).

Example 2(108)

(2R)-N-(1-methyl-1-(4-nitrophenyl)ethyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide

[0802] 1169

[0803] TLC: Rf 0.34 (ethyl acetate:hexane=1:3);

[0804] NMR (CDCl3): δ 8.22-8.12 (2H, m), 7.60-7.49 (2H, m), 6.89 (1H, bs), 5.31 (1H, d, J=8 Hz), 4.14 (1H, td, J=7, 5 Hz), 2.90 (1H, dd, J=14, 5 Hz), 2.75 (1H, dd, J=14, 7 Hz), 2.47 (2H, d, J=7 Hz), 1.90-0.80 (11H, m), 1.71 (3H, s), 1.70 (3H, s), 1.50 (9H, s).

Example 2(109)

(2S)-N-((1R)-1-(4-nitrophenyl)ethyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0805] 1170

[0806] TLC: Rf 0.37 (ethyl acetate:hexane=1:2);

[0807] NMR (CDCl3): δ 8.23-8.16 (2H, m), 7.53-7.46 (2H, m), 6.83 (1H, d, J=7.4 Hz), 5.36 (1H, d, J=7.4 Hz), 5.22-5.08 (1H, m), 4.25-4.16 (1H, m), 2.94 (1H, dd, J=13.6, 5.6 Hz) 2.78 (1H, dd, J=13.6, 7.0 Hz), 2.44 (2H, d, J=6.8 Hz), 1.88-0.80 (23H, m).

Example 2(110)

(2R)-N-methyl-N-(4-methoxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0808] 1171

[0809] TLC: Rf 0.44 (ethyl acetate:hexane=1:2).

Example 2(111)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(N′-methyl-N′-(t-butoxy-carbonyl)amino)propanamide

[0810] 1172

[0811] TLC: Rf 0.71 (hexane:ethyl acetate=1:1).

Example 2(112)

(2R)-N-(4-benzyloxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0812] 1173

[0813] TLC: Rf 0.54 (ethyl acetate:hexane=1:2);

[0814] NMR (CDCl3): δ 7.46-7.15 (m, 7H), 6.98-6.88 (m, 2H), 6.64 (t, J=6.0 Hz, 1H), 5.35 (d, J=6.6 Hz, 1H), 5.05 (s, 2H), 4.39 (d, J=5.4 Hz, 2H), 4.28-4.18 (m, 1H), 2.98 (dd, J=3.8, 5.8 Hz, 1H), 2.82 (dd, J=13.8, 7.0 Hz, 1H), 2.42 (d, J=7.8 Hz, 2H), 1.88-0.76 (m, 20H).

Example 2(113)

(2R)-N-(3-benzyloxy-4-methoxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide

[0815] 1174

[0816] TLC: Rf 0.33 (hexane:ethyl acetate=2:1);

[0817] NMR (CDCl3): δ 7.47-7.30 (m, 5H), 6.86-6.84 (m, 3H), 6.60 (t, J=6.0 Hz, 1H) 5.31 (d, J=6.8 Hz, 1H), 5.14 (s, 2H), 4.35 (d, J=6.0 Hz, 2H), 4.26-4.16 (m, 1H), 3.87 (s, 3H), 2.96 (dd, J=13.6, 5.6 Hz, 1H), 2.80 (dd, J=13.6, 6.6 Hz, 1H), 2.50-2.34 (m, 2H), 1.85-1.57 (m, 5H), 1.53-1.35 (m, 10H), 1.33-0.78 (m, 5H).

Example 2(114)

N-((1R)-2-cyclohexylmethylthio-1-(4-phenylpiperazin-1-ylcarbonyl)ethyl)-carbamide acid.t-butyl ester

[0818] 1175

[0819] TLC: Rf 0.49 (ethyl acetate:hexane=1:2);

[0820] NMR (CDCl3): δ 7.33-7.25 (m, 2H), 6.95-6.89 (m, 3H), 5.41 (d, J=8.7 Hz, 1H), 4.86-4.78 (m, 1H), 3.82-3.76 (m, 4H), 3.26-3.17 (m, 4H), 2.87 (dd, J=13.5, 7.5 Hz, 1H), 2.76 (dd, J=13.5, 6.0 Hz, 1H), 2.44 (d, J=6.9 Hz, 2H), 1.84-0.86 (m, 20H).

Example 2(115)

(2R)-N-(2-phenoxypyridin-5-yl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0821] 1176

[0822] TLC: Rf 0.56 (ethyl acetate:hexane=1:2);

[0823] NMR (CDCl3): δ 8.53 (br. s, 1H), 8.20 (d, J=3.0 Hz, 1H), 8.07 (dd, J=9.0, 2.8 Hz, 1H), 7.44-7.34 (m, 2H), 7.22-7.09 (m, 3H), 6.89 (d, J=9.2 Hz, 1H), 5.47 (d, J=7.2 Hz, 1H), 4.42-4.32 (m, 1H), 3.04 (dd, J=13.8, 6.2 Hz, 1H), 2.88 (dd, J=13.8, 7.0 Hz, 1H), 2.48 (d, J=6.6 Hz, 2H), 1.90-0.79 (m, 20H).

Example 2(116)

(2R)-N-(2-phenoxypyridin-5-ylmethyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0824] 1177

[0825] TLC: Rf 0.59 (ethyl acetate:hexane=1:1);

[0826] NMR (CDCl3): δ 8.11-8.07 (m, 1H), 7.66 (dd, J=8.4, 2.2 Hz, 1H), 7.46-7.35 (m, 2H), 7.25-7.08 (m, 4H), 6.87 (d, J=8.4 Hz, 1H), 6.82-6.74 (m, 1H), 5.34 (d, J=7.2 Hz, 1H), 4.42 (d, J=6.4 Hz, 2H), 4.29-4.19 (m, 1H), 2.97 (dd, J=13.6, 5.6 Hz, 1H), 2.82 (dd, J=13.6, 6.6 Hz, 1H), 2.42 (d, J=6.6 Hz, 2H), 1.88-0.78 (m, 20H).

Example 2(117)

(2R)-N-(4-(morpholin-4-yl)benzyl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0827] 1178

[0828] TLC: Rf 0.41 (ethyl acetate:hexane=1:1);

[0829] NMR (CDCl3): δ 7.23-7.18 (m, 2H), 6.89-6.84 (m, 2H), 6.60 (t, J=5.1 Hz, 1H), 5.35 (d, J=7.8 Hz, 1H), 4.38 (d, J=5.7 Hz, 2H), 4.26-4.20 (m, 1H), 3.88-3.84 (m, 4H), 3.16-3.12 (m, 4H), 2.98 (dd, J=13.8, 5.7 Hz, 1H), 2.82 (dd, J=13.8, 6.9 Hz, 1H), 2.45 (dd, J=12.6, 6.6 Hz, 1H), 2.40 (dd, J=12.6, 6.9 Hz, 1H), 1.85-0.82 (m, 20H).

Example 2(118)

(2R)-N-(1-phenylpiperidin-4-yl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0830] 1179

[0831] TLC: Rf 0.42 (hexane:ethyl acetate=2:1);

[0832] NMR (CDCl3): δ 7.29-7.22 (m, 2K), 6.95-6.92 (m, 2H), 6.88-6.82 (m, 1H), 6.37 (d, J=7.5 Hz, 1H), 5.36 (d, J=6.6 Hz, 1H), 4.20-4.13 (m, 1H), 4.01-3.88 (m, 1H), 3.63-3.56 (m, 2K), 2.99-2.86 (m, 3H), 2.78 (dd, J=13.5, 6.9 Hz, 1H), 2.48 (dd, J=12.6, 6.9 Hz, 1H), 2.45 (dd, J=12.6, 6.6 Hz, 1H), 2.08-1.98 (m, 2H), 1.87-1.78 (br, 2H), 1.76-1.54 (m, 5K), 1.52-1.38 (m, 100H), 1.31-1.06 (m, 3K), 1.00-0.86 (m, 2K).

Example 2(119)

(2R)-N-(1-methylpiperidin-4-yl)-2-t-butoxycarbonylamino-3-cyclohexyl-methylthiopropanamide

[0833] 1180

[0834] TLC: Rf 0.41 (chloroform:methanol=9:1);

[0835] NMR (CDCl3): δ 6.41 (d, J=6.9 Hz, 1H), 5.36 (d, J=6.6 Hz, 1H), 4.19-4.12 (m, 1H), 3.88-3.75 (m, 1H), 2.97-2.75 (m, 4H), 2.51-2.40 (m, 2H), 2.36 (s, 3H), 2.31-2.21 (m, 2H), 1.99-1.88 (m, 2H), 1.86-1.56 (m, 7H), 1.53-1.59 (m, 10H), 1.30-0.86 (m, 5H).

Example 3˜Example 3(1)

[0836] By the same desired procedure as Reference Example 3, using the compounds prepared in Example 2(64) and Example 2(65), the following compounds of the present invention were obtained.

Example 3

(2S)-N-((1S)-1-carboxy-2-phenylethyl)-3-cyclohexyloxycarbonyl-2-t-butoxy-carbonylaminopropanamide

[0837] 1181

[0838] TLC: Rf 0.51 (chloroform:methanol=9:1);

[0839] NMR (CDCl3): δ 7.35-7.17 (5H, m), 7.04 (1H, d, J=7.8 Hz), 6.90-6.10 (1H, br. s), 5.64 (1H, d, J=8.0 Hz), 4.86-4.69 (2H, m), 4.61-4.42 (1H, m), 3.18 (1H, dd, J=13.8, 5.4 Hz), 3.07 (1H, dd, J=13.8, 6.2 Hz), 2.86 (1H, dd, J=17.0, 5.0 Hz), 2.64 (1H, dd, J=17.0, 6.2 Hz), 1.88-1.18 (19H, m).

Example 3(1)

(2S)-N-((1S)-1-carboxyethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonyl-aminopropanamide

[0840] 1182

[0841] TLC: Rf 0.46 (chloroform:methanol=9:1);

[0842] NMR (CDCl3): δ 7.20 (1H, d, J=6.0 Hz), 6.50-6.00 (1H, br. s), 5.74 (1H, d, J=8.4 Hz), 4.85-4.69 (1H, m), 4.66-4.47 (2H, m), 2.93 (1H, dd, J=17.0, 5.2 Hz), 2.69 (1H, dd, J=17.0, 6.0 Hz), 1.92-1.20 (22H, m).

Example 4˜Example 4(1)

[0843] By the reaction of the compounds prepared in Example 3 and Example 3(1) with alcohol derivatives by the same desired procedure as Example 2, the following compounds of the present invention were obtained.

Example 4

(2S)-N-((1S)-1-(4-methoxybenzyloxycarbonyl)ethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide

[0844] 1183

[0845] TLC:Rf 0.34 (ethyl acetate:hexane=1:2)

[0846] NMR (CDCl3): δ 7.31-7.24 (2H, m), 7.07 (1H, d, J=7.0 Hz), 6.92-6.85 (2H, m), 5.66 (1H, d, J=8.2 Hz), 5.13 (1H, d, J=12.2 Hz), 5.06 (11H, d, J=12.2 Hz), 4.84-4.70 (1H, m), 4.62-4.46 (2H, m), 3.81 (3H, s), 2.96 (1H, dd, J=16.8, 4.4 Hz), 2.64 (1H, dd, J=16.8, 6.4 Hz), 1.92-1.24 (22H, m).

Example 4(l)

(2S)-N-((1S)-2-phenyl-1-(4-methoxybenzyloxycarbonyl)ethyl)-3-cyclohexyl-oxycarbonyl-2-t-butoxycarbonylaminopropanamide

[0847] 1184

[0848] TLC: Rf 0.42 (ethyl acetate:hexane=1:2);

[0849] NMR (CDCl3): δ 7.26-7.19 (5H, m), 7.06-7.01 (2H, m), 6.97 (1H, d, J=8. OHz), 6.91-6.84 (2H, m), 5.61 (1H, d, J=7.8 Hz), 5.09 (1H, d, J=12.0 Hz), 5.01 (1H, d, J=12.0 Hz), 4.86-4.69 (2H, m), 4.56-4.40 (1H, m), 3.82 (3H, s), 3.08 (1H, d, J=5.8 Hz), 2.93 (1H, dd, J=17.0, 4.4 Hz), 2.62 (1H, dd, J=17.0, 6.2 Hz), 1.90-1.18 (19H, m).

Reference Example 4

(2l S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-aminopropanamide.hydrochloride

[0850] 1185

[0851] Under cooling with ice, a solution of 4N solution of hydrogen chloride in dioxane (12 ml) was added dropwise to the compound prepared in Example 2 (1180 mg). The solution was warmed to room temperature and stirred for 1 hour. The reaction mixture was concentrated to give the title compound (920 mg) having the following physical data.

[0852] TLC: Rf 0.78 (chloroform:methanol=9:1);

[0853] NMR (CD3OD): δ 7.26-7.19 (2H, m), 6.91-6.83 (2H, m), 4.43 (1H, d, J=14.6 Hz), 4.28 (1H, d, J=14.6 Hz), 4.03 (1H, dd, J=5.8, 4.0 Hz), 3.83-3.66 (5H, m), 3.35-3.20 (2H, m), 1.75-0.81 (11H, m).

Example 5

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-benzoylaminoprpanamide

[0854] 1186

[0855] Benzoyl chloride (0.04 ml) was added dropwise to a solution of the compound prepared in Reference Example 4 (95 mg) and pyridine (0.07 ml) in methylene chloride (2 ml). The mixture was stirred for 1 hour at room temperature. The reaction mixture was diluted with methylene chloride and washed with 1N hydrochloric acid, water and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:1) to give the compound of the present invention (90 mg) having the following physical data.

[0856] TLC: Rf 0.21 (ethyl acetate:hexane=1:2);

[0857] NMR (CDCl3): δ 7.86-7.80 (2H, m), 7.56-7.39 (3H, m), 7.27-7.18 (3H, m), 6.93-6.83 (3H, m), 4.70 (1H, ddd, J=8.8, 6.4, 4.2 Hz), 4.47 (1H, dd, J=14.8, 5.6 Hz), 4.39 (1H, dd, J=14.8, 5.6 Hz), 3.95 (1H, dd, J=9.0, 4.2 Hz), 3.80 (3H, s), 3.50 (1H, t, J=8.4 Hz), 3.36 (1H, dd, J=9.0, 6.2 Hz), 3.24 (1H, dd, J=9.0, 6.2 Hz), 1.77-0.71 (11H, m).

Example 6˜Example 6(86)

[0858] By the same desired procedure as Reference Example 4→Example 5, using the compounds prepared in Example 2, Example 2(4), Example 2(9), Example 2(80), Example 2(83), Example 2(100)˜Example 2(119), Example 3 and Example 3(1), the following compounds of the present invention were obtained.

[0859] Also, (−)-3-t-butoxycarbonylthiazolidin-2-ylcarboxylic acid was used for the preparation of the compound of Example 6(60).

[0860] (+)-3-t-butoxycarbonylthiazolidin-2-ylcarboxylic acid was used for the preparation of the compound of Example 6(61).

[0861] (+)-3-t-butoxycarbonylthiazolidin-2-ylcarboxylic acid was used for the preparation of the compound of Example 6(63).

Example 6

(2S)-3-cyclopentyloxycarbonyl-2-methylcarbonylaminopropanoic acid.4-methoxybenzyl ester

[0862] 1187

[0863] TLC: Rf 0.27 (ethyl acetate:hexane=1:1)

[0864] NMR (CDCl3): δ 7.29-7.23 (2H, m), 6.92-6.84 (2H, m), 6.50 (1H, br. d, J=7.0 Hz), 5.19-5.05 (3H, m), 4.88-4.80 (1H, m), 3.81 (3H, s), 2.97 (1H, dd, J=17.2, 4.4 Hz), 2.78 (1H, dd, J=17.2, 4.4 Hz), 2.02 (3H, s), 1.92-1.46 (8H, m).

Example 6(1)

(2S)-3-cyclopentyloxycarbonyl-2-benzoylaminopropanoic acid.4-methoxybenzyl ester

[0865] 1188

[0866] TLC: Rf 0.54 (ethyl acetate:hexane=1:1);

[0867] NMR (CDCl3): δ 7.82-7.77 (2H, m), 7.56-7.38 (3H, m), 7.32-7.21 (3H, m), 6.91-6.84 (2H, m), 5.18-5.01 (4H, m), 3.81 (3H, s), 3.08 (1H, dd, J=17.0, 4.2 Hz), 2.91 (1H, dd, J=17.0, 4.6 Hz), 1.92-1.49 (8H, m).

Example 6(2)

(2S)-3-cyclopentyloxycarbonyl-2-pivalocyaminopropanoic acid.4-methoxybenzyl ester

[0868] 1189

[0869] TLC: Rf 0.53 (ethyl acetate:hexane=1:1);

[0870] NMR (CDCl3): δ 7.29-7.23 (2H, m), 6.91-6.85 (2H, m), 6.71 (1H, br. d, J=8.2 Hz), 5.18-5.04 (3H, m), 4.86-4.77 (1H, m), 3.81 (3H, s), 2.98 (1H, dd, J=17.2, 4.4 Hz), 2.77 (1H, dd, J=17.2, 4.4 Hz), 1.94-1.45 (8H, m), 1.19(9H, s).

Example 6(3)

(2S)-3-cyclopentyloxycarbonyl-2-cinnamoylaminopropanoic acid.4-methoxybenzyl ester

[0871] 1190

[0872] TLC: Rf 0.56 (ethyl acetate:hexane=1:1);

[0873] NMR (CDCl3). 7.63 (1H, d, J=15.6 Hz), 7.53-7.46 (2H, m), 7.40-7.33 (3H, m), 7.32-7.25 (2H, m), 6.92-6.84 (2H, m), 6.68 (1H, br. d, J=8.0 Hz), 6.44 (1H, d, J=15.6 Hz), 5.22-5.08 (3H, m), 5.03-4.94 (1H, m), 3.80 (3H, s), 3.05 (1H, dd, J=17.4, 4.4 Hz), 2.87 (1H, dd, J=17.4, 4.4 Hz), 1.93-1.44 (8H, m).

Example 6(4)

(2S)-3-cyclopentyloxycarbonyl-2-valerylaminopropanoic acid.4-methoxybenzyl ester

[0874] 1191

[0875] TLC: Rf 0.50 (ethyl acetate:hexane=1:1);

[0876] NMR (CDCl3): δ 7.30-7.23 (2H, m), 6.92-6.84 (2H, m), 6.47 (1H, d, J=8.3 Hz), 5.16 (1H, d, J=12.0 Hz), 5.08 (1H, d, J=12.0 Hz), 4.90-4.81 (1H, m), 3.81 (3H, s), 2.98 (1H, dd, J=17.0, 4.3 Hz), 2.77 (1H, dd, J=17.0, 4.5 Hz), 2.22 (2H, t, J=7.4 Hz), 1.92-1.46 (10H, m), 1.42-1.24 (2H, m), 0.98 (3H, t, J=8.0 Hz).

Example 6(5)

(2S)-3-cyclopentyloxycarbonyl-2-(octylcarbonylamino)propanoic acid.4-methoxybenzyl ester

[0877] 1192

[0878] TLC: Rf 0.62 (ethyl acetate:hexane=11);

[0879] NMR (CDCl3): δ 7.30-7.23 (2H, m), 6.91-6.84 (2H, m), 6.46 (1H, d, J=7.6 Hz), 5.18-5.04 (3H, m), 4.89-4.81 (1H, m), 3.81 (3H, s), 2.98 (1H, dd, J=17.2, 4.2 Hz), 2.77 (1H, dd, J=17.2, 4.4 Hz), 2.21 (2H, t, J=7.0 Hz), 1.92-1.46 (8H, m), 1.38-1.15 (12H, m), 0.88 (3H, t, J=7.2 Hz).

Example 6(6)

(2S)-3-cyclopentyloxycarbonyl-2-mesylaminopropanoic acid.4-methoxybenzyl ester

[0880] 1193

[0881] TLC: Rf 0.54 (ethyl acetate:hexane=1:1);

[0882] NMR (CDCl3): δ 7.31-7.24 (2H, m), 6.92-6.85 (2H, m), 5.48 (1H, d, J=9.2 Hz), 5.22-5.05 (3H, m), 4.41-4.32 (1H, m), 3.81 (3H, s), 3.00 (1H, dd, J=17.4, 4.6 Hz), 2.99 (3H, s), 2.80 (1H, dd, J=17.4, 4.4 Hz), 1.94-1.46 (8H, m).

Example 6(7)

(2S)-3-cyclopentyloxycarbonyl-2-phenylsulfonylaminopropanoic acid.4-methoxybenzyl ester

[0883] 1194

[0884] TLC: Rf 0.69 (ethyl acetate:hexane=1:1);

[0885] NMR (CDCl3): δ 7.87-7.82 (2H, m), 7.60-7.41 (3H, m), 7.16-7.10 (2H, m), 6.89-6.81 (2H, m), 5.69 (1H, d, J=8.3 Hz), 5.13-5.03 (1H, m), 4.94 (3H, s), 4.21-4.12 (1H, m), 3.81 (3H, s), 2.92 (1H, dd, J=17.0, 4.3 Hz), 2.77 (1H, dd, J=17.0, 4.8 Hz), 1.93-1.44 (8H, m).

Example 6(8)

(2S)-3-cyclopentyloxycarbonyl-2-(butylsulfonylamino)propanoic acid.4-methoxybenzyl ester

[0886] 1195

[0887] TLC: Rf 0.60 (ethyl acetate:hexane=1:2);

[0888] NMR (CDCl3): δ 7.31-7.22 (2H, m), 6.92-6.83 (2H, m), 5.36 (1H, d, J=9.0 Hz), 5.21-5.05 (3H, m), 4.39-4.30 (1H, m), 3.79 (3H, s), 3.06-2.93 (3H, m), 2.79 (1H, dd, J=17.2, 4.4 Hz), 1.92-1.24 (12H, m), 0.91 (3H, t, J=7.2 Hz).

Example 6(9)

(2S)-3-cyclopentyloxycarbonyl-2-(octylsulfonylamino)propanoic acid.4-methoxybenzyl ester

[0889] 1196

[0890] TLC: Rf 0.55 (ethyl acetate:hexane=1:2);

[0891] NMR (CDCl3): δ 7.31-7.23 (2H, m), 6.92-6.73 (2H, m), 6.88 (2H, d, J=8.8 Hz), 5.35 (1H, d, J=10.0 Hz), 5.21-5.05 (3H, m), 4.39-4.30 (1H, m), 3.81 (3H, s), 3.03-2.93 (3H, m), 2.79 (1H, dd, J=17.2, 4.4 Hz), 1.87-1.27 (20H, m), 0.89 (3H, t, J=6.8 Hz).

Example 6(10)

(2S)-3-cyclopentyloxycarbonyl-2-((E)-styrylsulfonylamino)propanoic acid.4-methoxybenzyl ester

[0892] 1197

[0893] TLC: Rf 0.38 (ethyl acetate:hexane=1:2);

[0894] NMR (CDCl3): δ 7.49-7.41 (6H, m), 7.17 (2H, d, J=8.8 Hz), 6.82-6.71 (3H, m), 5.55 (1H, d, J=8.6 Hz), 5.15-5.00 (3H, m), 4.26-4.17 (1H, m), 3.78 (3H, s), 3.01 (1H, dd, J=17.2, 4.4 Hz), 2.84 (1H, dd, J=17.2, 4.4 Hz), 1.89-1.44 (8H, m).

Example 6(11)

(2S)-3-cyclopentyloxycarbonyl-2-benzyloxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[0895] 1198

[0896] TLC: Rf 0.67 (ethyl acetate:hexane=1:2);

[0897] NMR (CDCl3): δ 7.39-7.23 (7H, m), 6.91-6.82 (2H, m), 5.74 (1H, d, J=9.2 Hz), 5.17-5.04 (5H, m), 4.67-4.58 (1H, m), 3.80 (3H, s), 2.97 (1H, dd, J=17.0, 4.6 Hz), 2.78 (1H, dd, J=17.0, 4.8 Hz), 1.88-1.46 (8H, m).

Example 6(12)

(2S)-3-cyclohexyloxycarbonyl-2-benzoylaminopropanoic acid.4-methoxybenzyl ester

[0898] 1199

[0899] TLC: Rf 0.42 (ethyl acetate:hexane=1; 2);

[0900] NMR (CDCl3): δ 7.83-7.76 (2H, m), 7.52-7.39 (3H, m), 7.32-7.21 (3H, m), 6.91-6.83 (2H, m), 5.21 (1H, d, J=12.0 Hz), 5.11 (1H, d, J=12.0 Hz), 5.10-5.02 (1H, m), 4.77-4.64 (1H, m), 3.81 (3H, s), 3.11 (1H, dd, J=17.0, 4.2 Hz), 2.93 (1H, dd, J=17.0, 4.6 Hz), 1.84-1.16 (10H, m).

Example 6(13)

(2S)-3-cyclohexyloxycarbonyl-2-(4-fluorobenzoylamino)propanoic acid.4-methoxybenzyl ester

[0901] 1200

[0902] TLC: Rf 0.37 (ethyl acetate:hexane=1:2);

[0903] NMR (CDCl3): δ 7.86-7.76 (2H, m), 7.32-7.06 (5H, m), 6.91-6.84 (2H, m), 5.20 (1H, d, J=1.8 Hz), 5.11 (1H, d, J=11.8 Hz), 5.08-4.99 (1H, m), 4.77-4.63 (1H, m), 3.81 (3H, m), 3.10 (1H, dd, J=17.2, 5.0 Hz), 2.91 (1H, dd, J=17.2, 5.0 Hz), 1.84-1.13 (10H, m).

Example 6(14)

(2S)-3-cyclohexyloxycarbonyl-2-(4-methoxybenzoyl)propanoic acid.4-methoxybenzyl ester

[0904] 1201

[0905] TLC: Rf 0.32 (ethyl acetate:hexane=1:2);

[0906] NMR (CDCl3): δ 7.80-7.73 (2H, m), 7.31-7.15 (2H, m), 7.13 (1H, d, J=7.8 Hz), 6.96-6.85 (4H, m), 5.20 (1H, d, J=12.0 Hz), 5.13 (1H, d, J=12.0 Hz), 5.08-5.00 (1H, m), 4.77-4.63 (1H, m), 3.85 (3H, s), 3.81 (3H, s), 3.09 (1H, dd, J=17.2, 4.4 Hz), 2.91 (1H, dd, J=17.2, 4.4 Hz), 1.84-1.09 (10H, m).

Example 6(15)

(2S)-3-cyclohexyloxycarbonyl-2-(4-phenylbenzoylamino)propanoic acid.4-methoxybenzyl ester

[0907] 1202

[0908] TLC: Rf 0.42 (ethyl acetate:hexane=1:2);

[0909] NMR (CDCl3): δ 7.91-7.84 (2H, m), 7.69-7.58 (4H, m), 7.52-7.25 (6H, m), 6.92-6.85 (2H, m), 5.22 (1H, d, J=12.0 Hz), 5.11 (1H, d, J=12.0 Hz), 5.13-5.04 (1H, m), 4.80-4.64 (1H, m), 3.81 (3H, s), 3.12 (1H, dd, J=17.2, 4.2 Hz), 2.94 (1H, dd, J=17.2, 4.6 Hz), 1.84-1.14 (10H, m).

Example 6(16)

(2S)-3-cyclohexyloxycarbonyl-2-(4-nitrobenzoylamino)propanoic acid.4-methoxybenzyl ester

[0910] 1203

[0911] TLC: Rf 0.36 (ethyl acetate:hexane=1:2);

[0912] NMR (CDCl3): δ 8.32-8.26 (2H, m), 7.99-7.92 (2H, m), 7.36 (1H, br. d, J=7.8 Hz), 7.32-7.25 (2H, m), 6.92-6.85 (2H, m), 5.22 (1H, d, J=12.0 Hz), 5.12 (1H, d, J=12.0 Hz), 5.08-5.00 (1H, m), 4.78-4.63 (1H, m), 3.81 (3H, s), 3.13 (1H, dd, J=17.2, 4.2 Hz), 2.93 (1H, dd, J=17.2, 4.4 Hz), 1.84-1.14 (10H, m).

Example 6(17)

(2S)-3-cyclohexyloxycarbonyl-2-(4-acetylbenzoylamino)propanoic acid.4-methoxybenzyl ester

[0913] 1204

[0914] TLC: Rf 0.24 (ethyl acetate:hexane=1:2);

[0915] NMR (CDCl3): δ 8.05-7.98 (2H, m), 7.90-7.85 (2H, m), 7.33-7.25 (3H, m), 6.92-6.84 (2H, m), 5.21 (1H, d, J=11.8 Hz), 5.12 (1H, d, J=11.8 Hz), 5.09-5.01 (1H, m), 4.78-4.64 (1H, m), 3.81 (3H, s), 3.12 (1H, dd, J=17.0, 4.2 Hz), 2.93 (1H, dd, J=17.0, 4.6 Hz), 2.64 (3H, s), 1.84-1.18 (10H, m).

Example 6(18)

(2S)-3-cyclohexyloxycarbonyl-2-(4-methylthiobenzoylamino)propanoic acid.4-methoxybenzyl ester

[0916] 1205

[0917] TLC: Rf 0.37 (ethyl acetate:hexane=1:2);

[0918] NMR (CDCl3): δ 7.75-7.68 (2H, m), 7.30-7.22 (4H, m), 7.18 (1H, br. d, J=7.8 Hz), 6.91-6.84 (2H, m), 5.20 (1H, d, J=11.8 Hz), 5.11 (1H, d, J=11.8 Hz), 5.08-5.00 (1H, m), 4.78-4.62 (1H, m), 3.81 (3H, s), 3.10 (1H, dd, J=17.2, 4.4 Hz), 2.91 (1H, dd, J=17.2, 4.6 Hz), 2.51 (3H, s), 1.84-1.12 (10H, m).

Example 6(19)

(2S)-3-cyclohexyloxycarbonyl-2-(4-dimethylaminobenzoylamino)propanoic acid.4-methoxybenzyl ester

[0919] 1206

[0920] TLC: Rf 0.24 (ethyl acetate:hexane=1:2);

[0921] NMR (CDCl3): δ 7.74-7.66 (2H, m), 7.32-7.25 (2H, m), 7.04 (1H, br. d, J=7.4 Hz), 6.91-6.83 (2H, m), 6.69-6.63 (2H, m), 5.19 (1H, d, J=12.2 Hz), 5.11 (1H, d, J=12.2 Hz), 5.10-5.02 (1H, m), 4.78-4.64 (1H, m), 3.81 (3H, s), 3.09 (1H, dd, J=17.0, 4.4 Hz), 3.02 (6H, s) 2.91 (1H, dd, J=17.0, 4.6 Hz), 1.84-1.16 (10H, m).

Example 6(20)

(2S)-N-((1S)-1-carboxyethyl)-3-cyclohexyloxycarbonyl-2-benzyloxycarbonyl-aminopopanamide

[0922] 1207

[0923] TLC: Rf 0.48 (chloroform:methanol=8:2);

[0924] NMR (CDCl3+CD3OD): δ 7.52 (1H, d, J=6.2 Hz), 7.37-7.28 (5H, m), 6.36 (1H, d, J=9.2 Hz), 5.15 (1H, d, J=12.2 Hz), 5.07 (1H, d, J=112.2 Hz), 4.79-4.52 (2H, m), 4.42-4.29 (1H, m), 2.87 (1H, dd, J=16.8, 6.2 Hz), 2.74 (1H, dd, J=16.8, 5.8 Hz), 1.82-1.08 (13H, m).

Example 6(21)

(2S)-N-((1S)-2-phenyl-1-carboxyethyl)-3-cyclohexyloxycarbonyl-2-benzyloxycarbonylaminopropanamide.dicyclohexylamine salt

[0925] 1208

[0926] TLC: Rf 0.46 (chloroform:methanol=8:2)

[0927] NMR (CDCl3+CD3OD): δ 7.37-7.28 (5H, m), 7.19-7.12 (5H, m), 5.13 (1H, d, J=12.0 Hz), 5.01 (1H, d, J=12.0 Hz), 4.79-4.64 (1H, m), 4.61-4.40 (2H, m), 3.26-2.66 (6H, m), 2.06-1.08 (30H, m).

Example 6(22)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-phenylsulfonylamino-propanamide

[0928] 1209

[0929] TLC: Rf 0.31 (ethyl acetate:hexane=1:2);

[0930] NMR (CDCl3): δ 7.91-7.85 (2H, m), 7.66-7.48 (3H, m), 7.16-7.09 (2H, m), 7.00-6.95 (1H, m), 6.88-6.80 (2H, m), 5.67-5.64 (1H, m), 4.36 (1H, dd, J=14.6, 5.6 Hz), 4.27 (1H, dd, J=14.6, 5.4 Hz), 3.82-3.70 (5H, m), 3.29-3.21 (1H, m), 3.16 (1H, dd, J=9.0, 6.2 Hz), 3.04 (1H, dd, J=9.0, 6.6 Hz), 1.72-0.64 (11H, m).

Example 6(23)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-pivaloylaminopropanamide

[0931] 1210

[0932] TLC: Rf 0.24 (ethyl acetate:hexane=1:2);

[0933] NMR (CDCl3): δ 7.23-7.15 (2H, m), 6.89-6.77 (3H, m), 6.67 (1H, d, J=6.0 Hz), 4.50-4.29 (3H, m), 3.83-3.76 (4H, m), 3.43-3.16 (3H, m), 1.72-0.71 (20H, m).

Example 6(24)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-(4-methoxybenzoylamino)-propanamide

[0934] 1211

[0935] TLC: Rf 0.11 (ethyl acetate:hexane=1:2);

[0936] NMR (CDCl3): δ 7.83-7.75 (2H, m), 7.25-7.17 (2H, m), 7.10 (1H, d, J=5.8 Hz), 6.97-6.82 (5H, m), 4.68 (1H, ddd, J=10.0, 5.8, 3.8 Hz), 4.42 (2H, d, J=5.4 Hz), 3.95 (1H, dd, J=9.2, 4.0 Hz), 3.86 (3H, s), 3.80 (3H, s), 3.49 (1H, t, J=9.2 Hz), 3.36 (1H, dd, J=9.2, 6.2 Hz), 3.24 (1H, dd, J=9.2, 6.6 Hz), 1.76-0.74 (11H, m).

Example 6(25)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-(4-nitrobenzoylamino)-propanamide

[0937] 1212

[0938] TLC: Rf 0.26 (ethyl acetate:hexane=1:2);

[0939] NMR (CDCl3): δ 8.33-8.26 (2H, m), 8.01-7.94 (2H, m), 7.38 (1H, d, J=5.8 Hz), 7.25-7.18 (2H, m), 6.95-6.83 (3H, m), 4.67 (1H, ddd, J=9.6, 5.8, 4.0 Hz), 4.48 (1H, dd, J-=14.6, 5.8 Hz), 4.38 (1H, dd, J=14.6, 5.4 Hz), 3.92 (1H, dd, J=9.2, 4.4 Hz), 3.80 (3H, s), 3.49 (1H, t, J=9.2 Hz), 3.37 (1H, dd, J=9.6, 6.2 Hz), 3.24 (1H, dd, J=9.6, 6.6 Hz), 1.74-0.70 (11H, m).

Example 6(26)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-(12-methyltridecylcarbonyl-amino)propanamide

[0940] 1213

[0941] TLC: Rf 0.60 (ethyl acetate:hexane=1:1);

[0942] NMR (CDCl3): δ 7.23-7.15 (2H, m), 6.89-6.82 (2H, m), 6.81-6.70 (1H, m), 6.41 (1H, d, J=6.2 Hz), 4.50 (1H, ddd, J=8.4, 6.6, 4.4 Hz), 4.39 (2H, d, J=6.2 Hz), 3.86-3.73 (4H, m), 3.39 (1H, t, J=8.8 Hz), 3.30 (1H, dd, J=9.4, 6.0 Hz), 3.19 (1H, dd, J=9.4, 6.2 Hz), 2.22 (1H, t, J=7.0 Hz), 1.74-0.70 (38H, m).

Example 6(27)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-cyclohexylcarbonylamino-propanamide

[0943] 1214

[0944] TLC: Rf 0.48 (ethyl acetate:hexane=1:1);

[0945] NMR (CDCl3): δ 7.22-7.15 (2H, m), 6.89-6.73 (3H, m), 6.43 (1H, d, J=6.4 Hz), 4.48 (1H, ddd, J=8.2, 6.4, 4.2 Hz), 4.46-4.29 (2H, m), 3.82-3.73 (4H, m), 3.38 (1H, t, J=8.4 Hz), 3.31 (1H, dd, J=9.2, 6.4 Hz), 3.20 (1H, dd, J=9.2, 6.2 Hz), 2.14 (1H, tt, J=11.6, 4.0 Hz), 1.94-0.71 (21H, m).

Example 6(28)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-(4-methoxyphenylsulfonyl-amino)propanamide

[0946] 1215

[0947] TLC: Rf 0.21 (ethyl acetate:hexane=1:2);

[0948] NMR (CDCl3): δ 7.83-7.76 (2H, m), 7.16-7.09 (2H, m), 7.05-6.94 (3H, m), 6.88-6.80 (2H, m), 5.55 (1H, d, J=5.4 Hz), 4.38 (1H, dd, J=14.6, 5.8 Hz), 4.28 (1H, dd, J=14.6, 5.6 Hz), 3.88 (3H, s), 3.82-3.67 (5H, m), 3.26 (1H, dd, J=8.8, 6.4 Hz), 3.17 (1H, dd, J=9.2, 6.2 Hz), 3.05 (1H, dd, J=9.2, 6.2 Hz), 1.74-0.79 (11H, m).

Example 6(29)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-cyclohexylsulfonylamino-propanamide

[0949] 1216

[0950] TLC: Rf 0.24 (ethyl acetate:hexane=1:2);

[0951] NMR (CDCl3): δ 7.23-7.16 (2H, m), 7.01 (1H, t, J=4.8 Hz), 6.90-6.82 (2H, m), 5.23 (1H, d, J=6.6 Hz), 4.40 (2H, d, J=5.8 Hz), 4.06-3.97 (1H, m), 3.85 (1H, dd, J=9.2, 4.0 Hz), 3.80 (3H, s), 3.55 (1H, dd, J=9.2, 7.2 Hz), 3.28 (1H, dd, J=9.2, 6.6 Hz), 3.20 (1H, dd, J=9.2, 6.2 Hz), 2.90 (1H, tt, J=11.8, 3.2 Hz), 2.28-2.08 (2H, m), 1.93-1.82 (2H, m), 1.76-1.04 (15H, m), 0.94-0.70 (2H, m).

Example 6(30)

(2R)-N-(4-methoxybenzyl)3-cyclohexylmethylthio-2-cyclopentylcarbonyl-aminopropanamide

[0952] 1217

[0953] TLC: Rf 0.19 (ethyl acetate:hexane=1:2);

[0954] NMR (CDCl3): δ 7.24-7.05 (3H, m), 6.87-6.80 (2H, m), 6.59 (1H, d, J=7.0 Hz), 4.62-4.52 (1H, m), 4.39 (1H, dd, J=15.0, 5.8 Hz), 4.31 (1H, dd, J=15.0, 5.4 Hz), 3.78 (3H, s), 2.93 (1H, dd, J=13.4, 5.4 Hz), 2.79 (1H, dd, J=13.4, 7.4 Hz), 2.66-2.50 (1H, m), 2.45 (2H, d, J=7.0 Hz), 1.95-0.78 (19H, m).

Example 6(31)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-cyclohexylcarbonyl-aminopropanamide

[0955] 1218

[0956] TLC: Rf 0.27 (ethyl acetate:hexane=1:2);

[0957] NMR (CDCl3): δ 7.24-7.16 (2H, m), 6.89-6.78 (3H, m), 6.46 (1H, d, J=6.8 Hz), 4.52-4.42 (1H, m), 4.38 (2H, d, J=5.8 Hz), 3.79 (3H, S), 2.95 (1H, dd, J=13.6, 5.0 Hz), 2.74 (1H, dd, J=13.6, 8.0 Hz), 2.47 (2H, d, J=7.0 Hz), 2.20-2.05 (1H, m), 1.92-0.82 (21H, m).

Example 6(32)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-cyclobutylcarbonylamino-propanamide

[0958] 1219

[0959] TLC: Rf 0.15 (hexane:ethyl acetate=2:1)

[0960] NMR (CDCl3): δ 7.20 (2H, d, J=8.6 Hz), 6.86 (2H, d, J=8.6 Hz), 6.80-6.72 (1H, br), 6.35 (1H, d, J=7.0 Hz), 4.52-4.38 (3H, m), 3.80 (3H, s), 3.09-2.91 (2H, m), 2.73 (1H, dd, J=8.0, 14.0 Hz), 2.48 (2H, d, J=6.6 Hz), 2.38-2.07 (4H, m), 2.06-1.32 (8H, m), 1.27-1.08 (3H, m), 1.03-0.89 (2H, m).

Example 6(33)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-cycloheptylcarbonyl-aminopropanamide

[0961] 1220

[0962] TLC: Rf 0.30 (hexane:ethyl acetate=2:1);

[0963] NMR (CDCl3): δ 7.20 (2H, d, J-8.6 Hz), 6.86 (2H, d, J=8.6 Hz), 6.80-6.74 (1H, br), 6.37 (1H, d, J=7.0 Hz), 4.50-4.37 (3H, m), 3.80 (3H, s), 2.95 (1H, dd, J=5.6, 14.0 Hz), 2.74 (1H, dd, J-8.0,14.0 Hz), 2.47 (2H, d, J=6.6 Hz), 2.35-2.20 (11H, m), 1.95-1.33 (18H, m), 1.30-1.08 (3H, m), 1.03-0.90 (2H, m).

Example 6(34)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(4-methoxycyclohexyl-carbonylamino)propanamide

[0964] 1221

[0965] (The relative configuration of cyclohexyl ring substituted by methoxy group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 6(35).) less polar

[0966] TLC: Rf 0.46 (hexane:ethyl acetate=1:1);

[0967] NMR (CDCl3): δ 7.20 (2H, d, J=8.8 Hz), 6.86 (2H, d, J=8.8 Hz), 6.82-6.79 (1H, br), 6.49 (1H, d, J=7.0 Hz), 4.51-4.37 (3H, m), 3.80 (3H, s), 3.46-3.39 (1H, m), 3.29 (3H, s), 2.95 (1H, dd, J=5.6, 14.0 Hz), 2.73 (1H, dd, J=8.0, 14.0 Hz), 2.47 (2H, d, J=6.6 Hz), 2.28-2.13 (1H, m), 2.00-1.59 (12H, m), 1.51-0.93 (7H, m).

Example 6(35)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(4-methoxycyclohexyl-carbonylamino)propanamide

[0968] 1222

[0969] (The relative configuration of cyclohexyl ring substituted by methoxy group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 6(34).) more polar

[0970] TLC: Rf 0.33 (hexane:ethyl acetate=1:1);

[0971] NMR (CDCl3): δ 7.20 (2H, d, J=8.8 Hz), 6.86 (2H, d, J=8.8 Hz), 6.77 (1H, t, J=5.8 Hz), 6.48 (1H, d, J=7.0 Hz), 4.50-4.37 (3H, m), 3.80 (3H, s), 3.35 (3H, s), 3.12 (1H, tt, J=4.2, 10.6 Hz), 2.94 (1H, dd, J=5.1, 13.9 Hz), 2.72 (1H, dd, J=8.1, 13.9 Hz), 2.47 (2H, d, J=6.6 Hz), 2.17-2.03 (3H, m), 2.00-1.57 (8H, m), 1.51-0.93 (9H, m).

Example 6(36)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-3-t-butoxy-carbonylthiazolidin-2-ylcarbonylamino)propanamide

[0972] 1223

[0973] TLC: Rf 0.29 (ethyl acetate:hexane=2:3);

[0974] NMR (CD3OD): δ 7.23 (2H, d, J=9 Hz), 6.85 (2H, d, J=9 Hz), 5.23 (1H, bs), 4.56-4.44 (1H, m), 4.44-4.22 (2H, m), 4.00-3.84 (1H, m), 3.81-3.63 (1H, m), 3.77 (3H, s), 3.40-2.65 (4H, m), 2.42 (2H, d, J=7 Hz), 1.91-1.58 (6H, m), 1.58-1.10 (3H, m), 1.45 and 1.40 (9H, s), 1.05-0.80 (2H, m).

Example 6(37)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(2-methylpropylcarbonyl-amino)propanamide

[0975] 1224

[0976] TLC: Rf 0.36 (ethyl acetate:hexane=2:3)

[0977] NMR (CD3OD): δ 7.26-7.16 (2H, m), 6.91-6.76 (3H, m), 6.43 (1H, d, J=8 Hz), 4.50 (1H, td, J=8, 5 Hz), 4.38 (2H, d, J=6 Hz), 3.80 (3H, s), 2.95 (1H, dd, J=14, 6 Hz), 2.76 (1H, dd, J=14, 8 Hz), 2.47 (2H, d, J=7 Hz), 2.20-1.95 (3H, m), 1.89-1.56 (6H, m), 1.56-1.05 (3H, m), 1.05-0.78 (2H, m), 0.94 (3H, d, J=7 Hz), 0.93 (3H, d, J=7 Hz).

Example 6(38)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(2-methylpropyloxy-carbonylamino)propanamide

[0978] 1225

[0979] TLC: Rf 0.53 (ethyl acetate:hexane=2:3);

[0980] NMR (CDCl3): δ 7.26-7.15 (2H, m), 6.92-6.80 (2H, m), 6.75-6.58 (1H, m), 5.58 (1H, d, J=8 Hz), 4.40 (2H, d, J=6 Hz), 4.27 (1H, td, J=8, 5 Hz), 3.85 (2H, d, J=7 Hz), 3.80 (3H, s), 2.99 (1H, dd, J=14, 5 Hz), 2.82 (1H, dd, J=14, 8 Hz), 2.44 (2H, d, J=7 Hz), 2.02-1.55 (6H, m), 1.55-1.03 (4H, m), 1.03-0.77 (2H, m), 0.92 (6H, d, J=7 Hz).

Example 6(39)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(1-(t-butoxycarbonyl)-piperidin-4-ylcarbonylamino)propanamide

[0981] 1226

[0982] TLC: Rf 0.17 (hexane:ethyl acetate=2:1);

[0983] NMR (CDCl3): δ 7.20 (2H, d, J=8.2 Hz), 6.87 (2H, d, J=8.2 Hz), 6.79-6.73 (1H, br), 6.54 (1H, d, J=7.2 Hz), 4.50-4.38 (3H, m), 4.16-4.10 (2H, br), 3.80 (3H, s), 2.93 (1H, dd, J=4.9, 13.7 Hz), 2.81-2.67 (3H, m), 2.48 (2H, d, J=7.0 Hz), 2.29 (1H, tt, J=4.0, 11.8 Hz), 1.83-1.57 (9H, m), 1.46 (9H, s), 1.36-0.84 (6H, m).

Example 6(40)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(4-(t-butoxycarbonyl-amino)cyclohexylcarbonylamino)propanamide

[0984] 1227

[0985] (The relative configuration of cyclohexyl ring substituted by t-butoxycarbonylamino group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 6(41).)

[0986] TLC: Rf 0.27 (hexane:ethyl acetate=1:1);

[0987] NMR (CDCl3): δ 7.20 (2H, d, J=8.8 Hz), 6.94-6.82 (3H, m), 6.61 (1H, d, J=6.8 Hz), 4.71 (1H, d, J=8.0 Hz), 4.54-4.44 (1H, m), 4.38 (2H, d, J=5.4 Hz), 3.79-3.65 (4H, m), 2.92 (1H, dd, J=5.4, 13.8 Hz), 2.75 (1H, dd, J=8.0, 13.8 Hz), 2.47 (2H, d, J=6.6 Hz), 2.30-2.15 (1H, br), 1.92-1.53 (13H, m), 1.44 (9H, s), 1.26-1.08 (4H, m), 1.00-0.83 (2H, m).

Example 6(41)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(4-(t-butoxycarbonyl-amino)cyclohexylcarbonylamino)propanamide

[0988] 1228

[0989] (The relative configuration of cyclohexyl ring substituted by t-butoxycarbonylamino group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 6(40).)

[0990] TLC: Rf 0.27 (hexane:ethyl acetate=1:1);

[0991] NMR (CDCl3): δ 7.20 (2H, d, J=8.8 Hz), 6.86 (2H, d, J=8.8 Hz), 6.78-6.73 (1H, br), 6.48 (1H, d, J=6.6 Hz), 4.49-4.37 (4H, m), 3.80 (3H, s), 3.51-3.30 (1H, br), 2.93 (1H, dd, J=5.1, 13.9 Hz), 2.72 (1H, dd, J=8.1, 13.9 Hz), 2.48 (2H, d, J=6.6 Hz), 2.14-1.53 (14H, m), 1.44 (9H, s), 1.27-1.07 (4H, m), 1.00-0.83 (2H, m).

Example 6(42)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(tetrahydrofuran-2-ylcarbonylamino)propanamide

[0992] 1229

[0993] TLC: Rf 0.27 (hexane:ethyl acetate=2:1);

[0994] NMR (DMSO-d6): δ 7.43 (1H, t, J=10.6 Hz), 7.20 (2H, d, J=8.8 Hz), 6.85 (2H, d, J=8.8 Hz), 6.80-6.71 (1H, br), 4.55-4.31 (4H, m), 4.05-3.83 (2H, m), 3.79 (3H, s), 3.00-2.74 (2H, m), 2.45 (2H, t, J=6.6 Hz), 2.36-1.62 (9H, m), 1.51-1.07 (4H, m), 1.03-0.90 (2H, m).

Example 6(43)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-cyclohexylcarbonyl-aminopropanamide

[0995] 1230

[0996] TLC: Rf 0.31 (ethyl acetate:hexane=2:3);

[0997] NMR (CDCl3): δ 7.25-7.14 (2H, m), 6.93-6.72 (3H, m), 6.43 (1H, d, J=6 Hz), 4.49 (1H, ddd, J=8, 6, 4 Hz), 4.43-4.28 (2H, m), 3.84-3.73 (1H, m), 3.80 (3H, s), 3.45-3.33 (1H, m), 3.29 (1H, dd, J=9, 5 Hz), 3.21 (1H, dd, J=9, 6 Hz), 2.24-2.06 (1H, m), 1.95-0.70 (21H, m).

Example 6(44)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonyl-thiazolidin-4-ylcarbonylamino)propanamide

[0998] 1231

[0999] TLC: Rf 0.29 (ethyl acetate:hexane=2:3);

[1000] NMR (CD3OD): δ 7.27-7.17 (2H, m), 6.90-6.80 (2H, m), 4.67-4.43 (4H, m), 4.32 (1H, d, J=15 Hz), 4.30 (1H, d, J=15 Hz), 3.76 (3H, s), 3.42-3.30 (1H, m), 3.12 (1H, dd, J=12, 5 Hz), 3.00-2.70 (2H, m), 2.41 (2H, d, J=6 Hz), 1.90-0.78 (11H, m), 1.45 (9H, s).

Example 6(45)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2S)-1-t-butoxycarbonyl-pyrrolidin-2-ylcarbonylamino)propanamide

[1001] 1232

[1002] TLC: Rf 0.38 (ethyl acetate:chloroform=1:4);

[1003] NMR (DMSO-d6): δ 8.03-7.97 (1H, m), 7.57 (1H, d, J=8.8 Hz), 7.18 (2H, d, J=8.8 Hz), 6.85 (2H, d, J=8.8 Hz), 4.45-4.40 (1H, m), 4.21 (2H, d, J=7.5 Hz), 4.15-4.12 (1H, m), 3.73 (3H, s), 3.40-3.30 (2H, m), 2.85 (1H, dd, J=15.0, 8.7 Hz), 2.76 (1H, dd, J=15.0, 6.3 Hz), 2.42 (2H, d, J=3.0 Hz), 2.11-2.03 (1H, m), 1.88-1.72 (4H, m), 1.69-1.58 (3H, m), 1.45-1.33 (2H, m), 1.26-1.10 (3H, m), 0.98-0.92 (2H, m).

Example 6(46)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(thiazol-4-ylcarbonyl-amino)propanamide

[1004] 1233

[1005] TLC: Rf 0.38 (ethyl acetate:hexane=1:1);

[1006] NMR (CDCl3): δ 8.77 (1H, d, J=1.8 Hz), 8.18 (1H, d, J=7.8 Hz), 8.12 (1H, d, J=1.8 Hz), 7.25-7.18 (2H, m), 6.88-6.81 (3H, m), 4.78-4.68 (1H, m), 4.51-4.33 (2H, m), 3.79 (3H, s), 3.16 (1H, dd, J=14.0, 5.6 Hz), 2.92 (1H, dd, J=14.0, 7.4 Hz), 2.57-2.41 (2H, m), 1.88-0.80 (11H, m).

Example 6(47)

(2R)-N-((1R)-1-(4-nitrophenyl)ethyl)-3-cyclohexylmethylthio-2-((4R)-+ b3-t--butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide

[1007] 1234

[1008] TLC: Rf 0.67 (ethyl acetate:hexane=1:1);

[1009] NMR (CDCl3): δ 8.19-8.12 (2H, m), 7.58-7.32 (3H, m), 7.12 (1H, d, J=8.0 Hz), 5.20-5.06 (1H, m), 4.67-4.46 (4H, m), 3.40-3.15 (3H, m), 2.75 (1H, dd, J=13.6, 5.8 Hz) 2.38-2.14 (2H, m), 1.80-0.64 (23H, m).

Example 6(48)

(2S)-N-((1R)-1-(4-nitrophenyl)ethyl)-3-cyclohexylmethylthio-2-((4R)-+ b3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide

[1010] 1235

[1011] TLC: Rf 0.61 (ethyl acetate:hexane=1:1);

[1012] NMR (CDCl3): δ 8.21-8.14 (2H, m), 7.58-7.30 (3H, m), 7.05 (1H, d, J=7.4 Hz), 5.19-5.05 (1H, m), 4.65-4.47 (4H, m), 3.37-3.06 (3H, m), 2.79(1H, dd, J=13.8, 6.2 Hz) 2.50 (1H, dd, J=12.4, 6.6 Hz), 2.40 (1H, dd, J=12.4, 7.0 Hz), 1.90-0.78 ((23H, m).

Example 6(49)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(2-t-butoxycarbonyl-aminothiazol-4-ylcarbonylamino)propanamide

[1013] 1236

[1014] TLC: Rf 0.28 (ethyl acetate:hexane=2:3);

[1015] NMR (CDCl3): δ 8.09 (1H, bs), 7.91 (1H, bd, J=8 Hz), 7.66 (1H, s), 7.25-7.15 (2H, m), 6.89-6.78 (3H, m), 4.66 (1H, td, J=8, 6), 4.50-4.28 (2H, m), 3.80 (3H, s), 3.07 (1H, dd, J=14, 6 Hz), 2.91 (1H, dd, J=14, 8 Hz), 2.48 (2H, d, J=7 Hz), 1.90-0.78 (11H, m), 1.56 (9H, s).

Example 6(50)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4S)-3-t-butoxycarbonyl-thiazolidin-4-ylcarbonylamino)propanamide

[1016] 1237

[1017] TLC: Rf 0.34 (ethyl acetate:hexane=2:3);

[1018] NMR (CD3OD) δ 7.27-7.17 (2H, m), 6.90-6.80 (2H, m), 4.66-4.43 (4H, m), 4.40-4.23 (2H, m), 3.78 (3H, s), 3.43-3.30 (1H, m), 3.16 (1H, dd, J=12, 6 Hz), 3.08-2.75 (1H, m), 2.78 (1H, dd, J=14, 7 Hz), 2.41 (2H, d, J=7 Hz), 1.90-0.80 (11H, m), 1.43 (9H, s).

Example 6(51)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonyl-thiazolidin-4-ylcarbonylamino)propanamide

[1019] 1238

[1020] TLC: Rf 0.36 (ethyl acetate:hexane=1:1);

[1021] NMR (CD3OD) δ 8.25-8.15 (2H, m), 7.61-7.51 (2H, m), 4.70-4.41 (6H, m), 3.45-3.32 (1H, m), 3.22-3.08 (1H, m), 3.04-2.72 (2H, m), 2.45 (2H, d, J=7 Hz), 1.91-0.80 (11H, m), 1.45 (9H, s).

Example 6(52)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((2RS)-3-t-butoxycarbonyl-thiazolidin-2-ylcarbonylamino)propanamide

[1022] 1239

[1023] TLC: Rf 0.38 (ethyl acetate:hexane=1:1);

[1024] NMR (CD3OD): δ 8.23-8.14 (2H, m), 7.61-7.49 (2H, m), 5.22 (1H, bs), 4.62-4.42 (3H, m), 4.00-3.87 (1H, m), 3.80-3.64 (1H, m), 3.33-2.70 (4H, m), 2.45 (2H, d, J=7 Hz), 1.91-0.80 (11H, m), 1.45 and 1.40 (9H, s).

Example 6(53)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((4R)-3-methylthiazolidin-4-ylcarbonylamino)propanamide

[1025] 1240

[1026] TLC: Rf 0.32 (ethyl acetate:hexane=1:1);

[1027] NMR (CDCl3): δ 8.23-8.16 (2H, m), 7.89 (1H, d, J=7.4 Hz), 7.49-7.42 (2H, m), 7.20-7.09 (1H, m), 4.61 (1H, dd, J=15.6, 6.2 Hz), 4.50 (1H, dd, J=15.6, 5.8 Hz), 4.51-4.40 (1H, m) 4.18 (1H, d, J=9.8 Hz), 3.89 (1H, dd, J=9.8, 1.0 Hz), 3.79 (1H, dd, J=7.4, 2.6 Hz), 3.52 (1H, dd, J=1.0, 2.6 Hz), 3.13 (1H, dd, J=11.0, 7.4 Hz), 2.98-2.80 (2H, m), 2.47 (3H, s), 2.45 (2H, d, J=7.4 Hz), 1.88-0.80 (11H, m).

Example 6(54)

(2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxy-carbonylthiazolidin-4-ylcarbonylamino)propanamide

[1028] 1241

[1029] TLC: Rf 0.35 (ethyl acetate:hexane=2:3);

[1030] NMR (CD3OD): δ 7.20-7.10 (2H, m), 6.77-6.67 (2H, m), 4.67-4.43 (4H, m), 4.29 (1H, d, J=6 Hz), 4.28 (1H, d, J=6 Hz), 3.41-3.30 (1H, m), 3.12 (1H, dd, J=12, 5 Hz), 3.00-2.65 (8H, m), 2.41 (2H, d, J=7 Hz), 1.88-0.80 (11H, m), 1.45 (9H, s).

Example 6(55)

(2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-((2RS)-3-t-butoxy-carbonylthiazolidin-2-ylcarbonylamino)propanamide

[1031] 1242

[1032] TLC: Rf 0.29 (ethyl acetate:hexane=2:3);

[1033] NMR (CD3OD): δ 7.20-7.10 (2H, m), 6.77-6.67 (2H, m), 5.23 (1H, bs), 4.55-4.43 (1H, m), 4.40-4.16 (2H, m), 4.00-3.84 (1H, m), 3.79-3.63 (1H, m), 3.30-2.66 (10H, m), 2.42 (2H, d, J=7 Hz), 1.90-0.80 (11H, m), 1.45 and 1.42 (9H, s).

Example 6(56)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-(1-t-butoxycarbonylimidazol-4-ylcarbonylamino)propanamide

[1034] 1243

[1035] TLC: Rf 0.48 (methylene chloride:ethyl acetate=4:1);

[1036] NMR (CDCl3): δ 8.17 (2H, d, J=8.8 Hz), 8.03 (1H, d, J=1.4 Hz), 7.98 (1H, d, J=1.4 Hz), 7.85 (1H, d, J=7.4 Hz), 7.45 (2H, d, J=8.8 Hz), 7.10 (1H, t, J=6.2 Hz), 4.78-4.68 (1H, m), 4.57 (2H, d, J=6.2 Hz), 3.12 (1H, dd, J=5.8, 13.6 Hz), 2.96 (1H, dd, J=7.0, 13.6 Hz), 2.50 (2H, d, J=6.6 Hz), 1.88-1.36 (15H, m), 1.30-0.90 (5H, m).

Example 6(57)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((4R)-2,2-dimethylthiazolidin-4-ylcarbonylamino)propanamide

[1037] 1244

[1038] TLC: Rf 0.47 (ethyl acetate:hexane=2:1);

[1039] NMR (CDCl3): δ 8.24-8.17 (2H, m), 7.81 (1H, bd, J=8 Hz), 7.50-7.42 (2H, m), 7.09 (1H, bt, J=6 Hz), 4.68-4.45 (3H, m), 4.16 (1H, t, J=7 Hz), 3.45 (1H, dd, J=11, 8 Hz), 3.37 (1H, dd, J=11, 7 Hz), 2.97 (1H, dd, J=14, 5 Hz), 2.82 (1H, dd, J=14, 8 Hz), 2.62-2.35 (1H, b), 2.49 (2H, d, J=7 Hz), 1.88-0.78 (11H, m), 1.65 (3H, s), 1.57 (3H, s).

Example 6(58)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-(thiophen-2-ylcarbonyl-amino)propanamide

[1040] 1245

[1041] TLC: Rf 0.20 (hexane:ethyl acetate=2:1)

[1042] NMR (CDCl3): δ 8.18 (2H, d, J=8.8 Hz), 7.58-7.52 (2H, m), 7.47 (2H, d, J=8.8 Hz), 7.31-7.25 (1H, br), 7.11 (1H, dd, J=3.6, 5.2 Hz), 7.04, (1H, d, J=6.6 Hz), 4.77-4.49 (3H, m), 3.13 (1H, dd, J=5.2, 14.0 Hz), 2.87 (1H, dd, J=8.2, 14.0 Hz), 2.54 (2H, d, J=7.0 Hz), 1.88-1.37 (6H, m), 1.33-0.82 (5H, m).

Example 6(59)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-(5-methyloxazol-2-ylcarbonyl-amino)propanamide

[1043] 1246

[1044] TLC: Rf 0.48 (methylene chloride:ethyl acetate=4:1);

[1045] NMR (CDCl3): δ 8.18 (2H, d, J=8.8 Hz), 7.81 (1H, d, J=7.4 Hz), 7.46 (2H, d, J=8.8 Hz), 7.06 (1H, t, J=5.4 Hz), 6.88 (1H, d, J=1.2 Hz), 4.75-4.49 (3H, m), 3.09 (1H, dd, J=5.8, 13.8 Hz), 2.90 (1H, dd, J=7.6, 13.8 Hz), 2.59-2.46 (2H, m), 2.41 (3H, d, J=1.2 Hz), 1.88-1.37 (6H, m), 1.34-0.81 (5H, m).

Example 6(60)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(3-t-butoxycarbonyl-thiazolidin-2-ylcarbonylamino)propanamide

[1046] 1247

[1047] (The absolute configuration of * carbon is not determined, but the above compound is a single optical isomer.)

[1048] [α]D=−40.4 (c 0.1, CHCl3);

[1049] TLC: Rf 0.19 (hexane:ethyl acetate=2:1);

[1050] NMR (CDCl3): δ 7.21 (2H, d, J=8.4 Hz), 7.13-6.85 (2H, br), 6.84 (2H, d, J=8.4 Hz), 5.24 (1H, s), 4.57-4.46 (1H, m), 4.37 (2H, d, J=5.6 Hz), 3.90-3.80 (2H, m), 3.79 (3H, s), 3.22-3.03 (2H, m), 2.95 (1H, dt, J=5.2, 11.0 Hz), 2.81 (1H, dd, J=7.0, 14.0 Hz), 2.50-2.32 (2H, m), 1.85-1.56 (6H, m), 1.41 (9H, s), 1.30-0.77 (5H, m).

Example 6(61)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(3-t-butoxycarbonyl-thiazolidin-2-ylcarbonylamino)propanamide

[1051] 1248

[1052] (The absolute configuration of * carbon is not determined, but the above compound is a single optical isomer.)

[1053] [α]D=+22.0 (c 0.11, CHCl3);

[1054] TLC: Rf 0.19 (hexane:ethyl acetate=2:1);

[1055] NMR (CDCl3): δ 7.43-7.25 (1H, br), 7.21 (2H, d, J=8.8 Hz), 6.90-6.78 (3H, m), 5.16 (1H, s), 4.61-4.20 (3H, m), 3.94-3.81 (2H, br), 3.79 (3H, s), 3.40-3.02 (2H, br), 2.96 (1H, dt, J=5.0, 11.0 Hz), 2.76 (1H, dd, J=7.0, 13.8 Hz), 2.50-2.31 (2H, m), 1.83-1.57 (6H, m), 1.42 (9H, s), 1.29-0.77 (5H, m).

Example 6(62)

(2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-cyclohexyl-carbonylaminopropanamide

[1056] 1249

[1057] TLC: Rf 0.58 (ethyl acetate:hexane=1:1);

[1058] NMR (CDCl3): δ 7.17-7.13 (2H, m), 6.79-6.69 (3H, m), 6.51 (1H, d, J=6.6 Hz), 4.50-4.44 (1H, m), 4.34 (2H, d, J=5.4 Hz), 2.96-2.90 (7H, m), 2.74 (1H, dd, J=13.5, 8.1 Hz), 2.49 (1H, dd, J=12.9, 6.9 Hz), 2.44 (1H, dd, J=12.9, 6.6 Hz), 2.18-2.08 (1H, m), 1.98-0.83 (21H, m).

Example 6(63)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(3-t-butoxycarbonyl-thiazolidin-2-ylcarbonylamino)propanamide

[1059] 1250

[1060] (The absolute configuration of * carbon is not determined, but the above compound is a single optical isomer.)

[1061] [α]D=+31.11 (c 1.08, CHCl3);

[1062] TLC: Rf 0.19 (ethyl acetate:hexane=1:2);

[1063] NMR (CDCl3): δ 7.21 (2H, d, J=8.7 Hz), 7.10-6.73 (4H, m), 5.24 (1H, s), 4.57-4.45 (1H, m), 4.38 (2H, d, J=5.4 Hz), 3.88-3.73 (5H, m), 3.20-3.11 (2H, m), 2.99-2.92 (1H, m), 2.79 (1H, dd, J=13.8, 7.2 Hz), 2.48-2.35 (2H, m), 1.83-1.58 (5H, m), 1.51-1.37 (10H, m), 1.28-1.05 (3H, m), 0.98-0.83 (2H, m).

Example 6(64)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4S)-3-t-butoxycarbonyl-thiazolidin-4-ylcarbonylamino)propanamide

[1064] 1251

[1065] TLC: Rf 0.57 (ethyl acetate:hexane=1:1)

[1066] NMR (CD3OD): δ 7.25-7.18 (2H, m), 6.88-6.81 (2H, m), 4.65-4.45 (4H, m), 4.35 (1H, d, J=14:6 Hz), 4.26 (1H, d, J=14.6 Hz), 3.75 (3H, s), 3.35 (1H, dd, J=12.2, 7.4 Hz), 3.11 (1H, dd, J=12.2, 4.8 Hz), 2.98-2.72 (2H, m), 2.41 (2H, d, J=6.6 Hz), 1.88-0.80 (20H, m).

Example 6(65)

(2S)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonyl-thiazolidin-4-ylcarbonylamino)propanamide

[1067] 1252

[1068] TLC: Rf 0.61 (ethyl acetate:hexane=1:1);

[1069] NMR (CD3OD): δ 7.25-7.17 (2H, m), 6.88-6.81 (2H, m), 4.64-4.44 (4H, m), 4.32 (2H, br. s), 3.75 (3H, s), 3.35 (1H, dd, J=12.2, 7.4 Hz), 3.13 (1H, dd, J=12.2, 5.4 Hz), 2.97 (1H, br. s), 2.76 (1H, dd, J=13.6, 8.4 Hz), 2.40 (2H, d, J=7.0 HZ), 1.88-0.80 (20H, m).

Example 6(66)

(2R)-N-methyl-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide

[1070] 1253

[1071] TLC: Rf 0.28 (ethyl acetate:hexane=1:2);

[1072] NMR (CDCl3): δ 7.24-7.02 (3H, m), 6.90-6.83 (2H, m), 5.16-5.06 (1H, m), 4.90-4.38 (5H, m), 3.80-3.79 (3H, m), 3.39-3.16 (2H, m), 3.03-2.69 (5H, m), 2.44-2.23 (2H, m), 1.85-0.76 (20H, m).

Example 6(67)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-N′-methyl-N′-(3-t-butoxycarbonylthiazolidin-4-ylcarbonyl)amino)propanamide

[1073] 1254

[1074] TLC: Rf 0.37 (ethyl acetate:hexane=1:2)

[1075] NMR (CD3OD): δ 7.23-7.17 (2H, m), 6.86-6.82 (2H, m), 5.18-5.00 (2H, m), 4.70-4.66 (1H, m), 4.49-4.18 (3H, m), 3.76 and 3.75 (3H, s), 3.54-2.68 (7H, m), 2.47-2.43 (2H, m), 1.90-1.60 (5H, m), 1.50-1.05 (4H, m), 1.44 and 1.33 (9H, m), 1.05-0.87 (2H, m).

Example 6(68)

(2R)-N-(4-penoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonyl-thiazolidin-4-ylcarbonylamino)propanamide

[1076] 1255

[1077] TLC: Rf 0.58 (ethyl acetate:hexane=1:11);

[1078] NMR (CDCl3): δ 7.36-7.23 (5H, m), 7.15-7.07 (2H, m), 7.01-6.91 (4H, m), 4.65-4.32 (6H, m), 3.33-3.13 (3H, m), 2.79 (1H, dd, J=14.1, 6.3 Hz), 2.45-2.30 (2H, m), 1.83-0.78 (20H, m).

Example 6(69)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS,4R)-3-t-butoxy-carbonyl-2-(2-methylpropyl)thiazolidin-4-ylcarbonylamino)propanamide

[1079] 1256

[1080] TLC: Rf 0.32 (ethyl acetate:hexane=1:2);

[1081] NMR (CDCl3): δ 7.40-7.19 (3H, m), 7.14 (1H, d, J=8 Hz), 6.86-6.80 (2H, m), 5.20-5.07 (1H, m), 4.64 (1H, t, J=7 Hz), 4.63-4.52 (1H, m), 4.43 (1H, dd, J=15, 6 Hz), 4.32 (1H, dd, J=15, 6 Hz), 3.78 (3H, s), 3.36-3.15 (3H, m), 2.78 (1H, dd, J=14, 6 Hz), 2.46-2.24 (2H, m), 1.91-1.53 (8H, m), 1.50-1.30 (10H, m), 1.30-1.03 (3H, m), 1.00-0.78 (8H, m).

Example 6(70)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(pyridin-3-ylcarbonyl-amino)propanamide

[1082] 1257

[1083] TLC: Rf 0.19 (ethyl acetate:hexane=3:1);

[1084] NMR (CDCl3): δ 9.04 (1H, dd, J=3, 1 Hz), 8.75 (1H, dd, J=5, 2 Hz), 8.10 (1H, ddd, J=8, 3, 2 Hz), 7.39 (1H, ddd, J=8, 5, 1 Hz), 7.43-7.36 (1H, m), 7.26-7.19 (2H, m), 6.97-6.90 (1H, m), 6.90-6.83 (2H, m), 4.72-4.63 (1H, m), 4.43 (1H, dd, J=15, 6 Hz), 4.42 (1H, dd, J=15, 6 Hz), 3.79 (3H, s), 3.09 (1H, dd, J=14, 5 Hz), 2.84 (1H, dd, J=14, 8 Hz), 2.54 (1H, dd, J=12, 7 Hz), 2.52 (2H, dd, J=12, 7 Hz), 1.86-1.59 (5H, m), 1.56-1.39 (1H, m), 1.30-1.03 (3H, m), 1.00-0.85 (2H, m).

Example 6(71)

(2R)-N-(4-benzyloxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxy-carbonylthiazolidin-4-ylcarbonylamino)propanamide

[1085] 1258

[1086] TLC: Rf 0.63 (ethyl acetate:hexane=1:1);

[1087] NMR (CDCl3): δ 7.44-7.18 (8H, m), 7.13 (1H, d, J=7.8 Hz), 6.93-6.88 (2H, m), 5.04 (2H, s), 4.65-4.21 (6H, m), 3.32-3.12 (3H, m), 2.78 (1H, dd, J=13.8, 6.3 Hz), 2.44-2.30 (2H, m), 1.80-0.78 (20H, m).

Example 6(72)

(2R)-N-(3-benzyloxy-4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide

[1088] 1259

[1089] TLC: Rf 0.46 (hexane:ethyl acetate=1:1);

[1090] NMR (CD3OD): δ 7.47-7.25 (5H, m), 7.00 (1H, d, J=1.4 Hz), 6.92-6.83 (2H, m), 5.09 (2H, s), 4.63-4.42 (4H, m), 4.35 (1H, d, J=14.8 Hz), 4.24 (1H, d, J=14.8 Hz), 3.81 (3H, s), 3.41-3.30 (1H, m), 3.12 (1H, dd, J=5.0, 12.2 Hz), 3.00-2.71 (2H, br), 2.40 (2H, d, J=7.0 Hz), 1.89-1.59 (5H, m), 1.54-1.31 (10H, m), 1.29-1.08 (3H, m), 1.04-0.76 (2H, m).

Example 6(73)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(pyridin-4-ylcarbonyl-amino)propanamide

[1091] 1260

[1092] TLC: Rf 0.23 (ethyl acetate:methylene chloride=1:1);

[1093] NMR (CDCl3): δ 8.79-8.72 (2H, m), 7.66-7.61 (2H, m), 7.47 (1H, d, J=6 Hz), 7.26-7.19 (2H, m), 6.96-6.84 (3H, m), 4.69-4.61 (1H, m), 4.43 (1H, dd, J=15, 6 Hz), 4.42 (1H, dd, J=15, 6 Hz), 3.80 (3H, s), 3.08 (1H, dd, J=14, 5 Hz), 2.82 (1H, dd, J=14, 9 Hz), 2.54 (1H, dd, J=14, 7 Hz), 2.53 (2H, dd, J=14, 7 Hz), 1.86-1.75 (2H, m), 1.75-1.59 (3H, m), 1.55-1.39 (1H, m), 1.30-1.03 (3H, m), 1.03-0.85 (2H, m).

Example 6(74)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS,4R)-3-t-butoxycarbonyl-2-phenylthiazolidin-4-ylcarbonylamino)propanamide

[1094] 1261

[1095] TLC: Rf 0.26 (ethyl acetate:hexane=2:3);

[1096] NMR (CDCl3): δ 7.53-7.20 (m, 9H), 6.85-6.79 (m, 2H), 5.99 (bs, 1H), 4.80 (dd, J=8, 5 Hz, 1H), 4.72-4.60 (b, 1H), 4.44 (dd, J=15, 6 Hz, 1H), 4.31 (dd, J=15, 6 Hz, 1H), 3.77 (s, 3H), 3.47 (dd, J=12, 5 Hz, 1H), 3.36 (dd, J=12, 8 Hz, 1H), 3.25-3.10 (b, 1H), 2.85-2.73 (m, 1H), 2.38 (dd, J=12, 6 Hz, 1H), 2.29 (dd, J=12, 8 Hz, 1H), 1.78-1.56 (m, 5H), 1.47-1.00 (m, 13H), 0.94-0.74 (m, 2H).

Example 6(75)

(4R)-N-((1R)-2-cyclohexylmethylthio-1-(4-phenylpiperazin-1-ylcarbonyl)ethyl)-3-t-butoxycarbonylthiazolidin-4-ylcarboxamide

[1097] 1262

[1098] TLC: Rf 0.57 (ethyl acetate:hexane=1:1);

[1099] NMR (CDCl3): δ 7.32-7.26 (m, 2H), 7.20-7.05 (br. s, 1H), 6.95-6.89 (m, 2H), 5.14-5.07 (m, 1H), 4.80-4.58 (m, 2H), 4.40 (d, J=9.3 Hz, 1H), 3.88-3.66 (m, 4H), 3.38 (dd, J=11.7, 2.7 Hz 1H), 3.25-3.16 (m, 5H), 2.91 (dd, J=13.8, 7.2 Hz, 1H), 2.77 (dd, J=13.8, 5.7 Hz, 1H), 2.44 (d, J=6.6 Hz, 2H), 1.86-1.59 (m, 5H), 1.54-1.34 (m, 10H), 1.30-1.04 (m, 3H), 0.99-0.84 (m, 2H).

Example 6(76)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((3RS)-4-t-butoxy-carbonylthiomorpholin-3ylcarbonylamino)propanamide

[1100] 1263

[1101] TLC: Rf 0.34 (ethyl acetate:hexane=2:3),

[1102] NMR (CDCl3): δ 7.26-7.18 (m, 2H), 7.06-6.82 (m, 4H), 5.00 (bs, 1H), 4.63-4.52 (m, 1H), 4.50-4.10 (m, 3H), 3.79 (s, 3H), 3.30-3.05 (m, 3H), 2.89-2.57 (m, 3H), 2.53-2.28 (m, 3H), 1.85-1.56 (m, 5H), 1.55-1.35 (m, 1 OH), 1.30-1.03 (m, 3H), 1.00-0.81 (m, 2H).

Example 6(77)

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((3RS)-4-t-butoxy-carbonylthiomorpholin-3-ylcarbonylamino)propanamide

[1103] 1264

[1104] TLC: Rf 0.27 (ethyl acetate:hexane=1:2);

[1105] NMR (CDCl3): “ 7.37-7.29 (m, 2H), 7.29-7.22 (m, 2H), 7.14-7.07 (m, 1H), 7.05-6.90 (m, 6H), 5.06-4.93 (m, 11H), 4.65-4.10 (m, 4H), 3.35-3.00 (m, 3H), 2.91-2.57 (m, 3H), 2.55-2.30 (m, 3H), 1.84-1.56 (m, 5H), 1.56-1.35 (m, 10H), 1.30-1.03 (m, 3H), 1.00-0.83 (m, 2H).

Example 6(78)

(2R)-N-(2-phenoxypyride-5-yl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxy-carbonylthiazolidin-4-ylcarbonylamino)propanamide

[1106] 1265

[1107] TLC: Rf 0.57 (ethyl acetate:hexane=1:1);

[1108] NMR (CDCl3): δ 8.93 (br. s, 1H), 8.49 (br. s, 1H), 8.20 (d, J=7.5 Hz, 1H), 7.42-7.35 (m, 2H), 7.24-7.08 (m, 4H), 6.86 (d, J=9.0 Hz, 1H), 4.80-4.70 (m, 1H), 4.66 (dd, J=7.2, 3.9 Hz, 1H), 4.60 (d, J=9.9 Hz, 1H), 4.55 (d, J=9.9 Hz, 1H), 3.41-3.27 (m, 3H), 2.84 (dd, J=13.8, 5.7 Hz, 1H), 2.48-2.33 (m, 2H), 1.82-1.58 (m, 5H), 1.54-1.35 (m, 10H), 1.28-1.02 (m, 3H), 0.96-0.78 (m, 2H).

Example 6(79)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-4-t-butoxy-carbonylthiomorpholin-2-ylcarbonylamino)propanamide

[1109] 1266

[1110] TLC: Rf 0.27 (ethyl acetate:hexane=2:3);

[1111] NMR (CDCl3): δ 7.65-7.30 (b, 1H), 7.24-7.18 (m, 2H), 6.90-6.83 (m, 2H), 6.77-6.67 (b, 1H), 4.51-4.04 (m, 4H), 3.92-3.46 (m, 3H), 3.80 (s, 3H), 3.40-3.29 (m, 1H), 3.03-2.92 (m, 1H), 2.90-2.67 (m, 2H), 2.60-2.49 (m, 1H), 2.49-2.42 (m, 2H), 1.94-1.55 (m, 5H), 1.53-1.33 (m, 10H), 1.30-1.04 (m, 3H), 1.00-0.83 (m, 2H).

Example 6(80)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4RS)-3-t-butoxycarbonyl-1,3-perhydrothiazin-4-ylcarbonylamino)propanamide

[1112] 1267

[1113] TLC: Rf 0.38 (ethyl acetate:hexane=2:3);

[1114] NMR (CDCl3): δ 7.24-7.17 (m, 2H), 7.04-6.93 and 6.79-6.68 (m, 2H), 6.90-6.82 (m, 2H), 4.86-4.20 (m, 6H), 3.79 (s, 3H), 3.04-2.70 (m, 3H), 2.66-2.37 (m, 4H), 2.07-1.85 (m, 1H), 1.85-1.55 (m, 5H), 1.53-1.33 (m, 10H), 1.30-1.04 (m, 3H), 1.00-0.83 (m, 2H).

Example 6(81)

(2R)-N-(2-phenoxypyridin-5-ylmethyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide

[1115] 1268

[1116] TLC: Rf 0.56 (ethyl acetate:hexane=2:1);

[1117] NMR (CDCl3): δ 8.11 (d, J=2.4 Hz, 1H), 7.68 (dd, J=8.4, 2.4 Hz, 1H), 7.50-7.35 (m, 3H), 7.22-7.16 (m, 1H), 7.14-7.08 (m, 3H), 6.84 (d, J=8.4 Hz, 1H), 4.68-4.31 (m, 6H), 3.35-3.20 (m, 3H), 2.78 (dd, J=13.8, 6.0,1H), 2.44-2.28 (m, 2H), 1.82-1.60 (m, 5H), 1.51-1.36 (m, 10H), 1.32-1.08 (m, 3H), 0.98-0.80 (m, 2H).

Example 6(82)

(2R)-N-(4-(morpholin-4-yl)benzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxy-carbonylthiazolidin-4-ylcarbonylamino)propanamide

[1118] 1269

[1119] TLC: Rf 0.34 (ethyl acetate:hexane=1:1);

[1120] NMR (CDCl3): δ 7.20 (d, J=8.7 Hz, 1H), 7.17-7.12 (m, 2H), 6.84 (d, J=8.7 Hz, 2H), 4.64 (dd, J=6.6, 4.2 Hz, 1H), 4.58 (br. s, 2H), 4.44 (d, J=9.3 Hz, 1H), 4.41-4.28 (m, 2H), 3.87-3.84 (m, 4H), 3.31 (dd, J=12.3, 3.9,1H), 3.26 (dd, J=12.3,6.6 Hz, 1H), 3.20 (br. s, 1H), 3.19-3.11 (m, 4H), 2.78 (dd, J=13.5, 6.3 Hz, 1H), 2.44-2.28 (m, 2H), 1.82-1.60 (m, 5H), 1.5-1.34 (m, 10H), 1.31-1.04 (m, 3H), 0.96-0.80 (m, 2H).

Example 6(83)

(2R)-N-(4-Phenoxybenzyl)-3cyclohexylmethylthio-2-((4RS)-3-t-butoxycarbonyl-1,3-perhydrothiazin-4-ylcarbonylamino)propanamide

[1121] 1270

[1122] TLC: Rf 0.33 ethyl acetate:hexane=1:2);

[1123] NMR (CD3OD) δ 7.37-7.25 (m, 4H), 7.13-7.06 (m, 1H), 6.99-6.89 (m, 4H), 4.94-4.30 (m, 6H), 3.08-2.87 (m, 2H), 2.87-2.76 (m, 1H), 2.68-2.50 (m, 1H), 2.50-2.30 (m, 3H), 2.08-1.76 (m, 3H), 1.76-1.60 (m, 3H), 1.60-1.35 (m, 1 OH), 1.35-1.07 (m, 3H), 1.03-0.85 (m, 2H).

Example 6(84)

(2R)-N-(1-phenylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxy-carbonylthiazolidin-4-ylcarbonylamino)propanamide

[1124] 1271

[1125] TLC: Rf 0.46 (hexane:ethyl acetate=1:1);

[1126] NMR (CD3OD): δ 7.24-7.18 (m, 2H), 6.97 (dd, J=8.7, 0.9 Hz, 2H), 6.81 (t, J=7.5 Hz, 1H), 4.65-4.56 (m, 2H), 4.50-4.45 (m, 2H), 3.86-3.76 (m, 1H), 3.68-3.57 (br, 2H), 3.43-3.32 (br, 1H), 3.16 (dd, J=12.0, 4.8 Hz, 1H), 2.94-2.77 (m, 4H), 2.46 (d, J=6.6 Hz, 2H), 2.00-1.79 (br, 4H), 1.78-1.59 (m, 5H), 1.52-1.38 (m, 10H), 1.33-1.09 (m, 3H), 1.01-0.89 (m, 2H).

Example 6(85)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-2-oxothiazolidin-4-ylcarbonylamino)propanamide

[1127] 1272

[1128] TLC: Rf 0.30 (ethyl acetate:hexane=2:1);

[1129] NMR (CDCl3): δ 7.72-7.58 (1H, m), 7.30-7.11 (3H, m), 7.11-6.96 (1H, m), 6.89-6.79 (2H, m), 4.59 (1H, q, J=7 Hz), 4.45-4.18 (3H, m), 3.78 (3H, s), 3.69 (1H, dd, J=11, 8 Hz), 3.57 (1H, dd, J=11, 5 Hz), 2.86 (2H, d, J=7 Hz), 2.43 (2H, d, J=7 Hz), 1.86-0.75 (11 Hz m).

Example 6(86)

(2R)-N-(1-methylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxy-carbonylthiazolidin-4-ylcarbonylamino)propanamide

[1130] 1273

[1131] TLC: Rf 0.44 (chloroform:methanol=9:1);

[1132] NMR (CD3OD): δ 4.65-4.56 (m, 2H), 4.49-4.43 (m, 2H), 3.72-3.62 (m, 1H), 3.42-3.33 (m, 1H), 3.14 (dd, J=12.0, 4.8 Hz, 1H), 2.93-2.70 (br, 4H), 2.45 (d, J=6.9 Hz, 2H), 2.30 (s, 3H), 2.26-2.14 (br, 2H), 1.93-1.79 (br, 4H), 1.76-1.37 (m, 15H), 1.33-1.09 (m, 3H), 1.02-0.88 (m, 2H).

Example 7

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-t-butoxycarbonyl-aminopropanamide

[1133] 1274

[1134] A solution of the compound prepared in Example 2(80) (147 mg) in methylene chloride (5 ml) was cooled to −78° C. and m-chloroperbenzoic acid (117 mg) was added thereto. The mixture was stirred for 70 minutes. The reaction mixture was warmed to room temperature with stirring for 3.5 hours. To the reaction mixture, m-chloroperbenzoic acid (10 mg) was added. The reaction mixture was stirred for 1 hour. The reaction mixture was diluted with chloroform, washed with saturated aqueous sodium hydrogencarbonate, saturated aqueous sodium thiosulfate and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by recrystallization (ethyl acetate) to give the compound of the present invention (101 mg) having the following physical data.

[1135] TLC: Rf 0.25 (ethyl acetate:hexane=1:2);

[1136] NMR (CDCl3): δ 7.24-7.17 (2H, m), 7.00 (1H, t, J=5.6 Hz), 6.89-6.82 (2H, m), 5.84 (1H, d, J=8.2 Hz), 4.66 (1H, dt, J=8.0, 5.0 Hz), 4.47 (1H, dd, J=15.0, 5.8 Hz), 4.31 (1H, dd, J=15.0, 5.6 Hz), 3.79 (3H, s), 3.70 (1H, dd, J=14.6, 5.0 Hz), 3.39 (1H, dd, J=14.6, 5.2 Hz), 3.09-2.91 (2H, m), 2.16-0.96 (20H, m).

Example 7(1)˜7(4)

[1137] By the same desired procedure as Example 7, using the compounds prepared in Example 2(80), Example 2(90), Example 2(95) and Example 6(31), the following compounds of the present invention were obtained.

Example 7(1)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfinyl-2-t-butoxycarbonyl-aminopropanamide

[1138] 1275

[1139] TLC: Rf 0.51 (methanol:chloroform=1:19);

[1140] NMR (CDCl3): δ 7.65 (0.33H, br.s), 7.37-7.17 (2.67H, m), 6.89-6.81 (2H, m), 6.39-6.27 (0.67H, m), 5.87 (0.33H, d, J=5.8 Hz), 4.80-4.60 (1H, m), 4.51-4.28 (2H, m), 3.79 (3H, s), 3.34-3.21 (1H, m), 3.01-2.86 (1H, m), 2.78-2.66 (1H, m); 2.55-2.45 (1H, m), 2.02-0.92 (20H, m).

Example 7(2)

(2R)-N-(4-methoxybenzyl)-3-cyclopentylmethylsulfonyl-2-t-butoxycarbonyl-aminopropanamide

[1141] 1276

[1142] TLC: Rf 0.21 (ethyl acetate:hexane=1:2);

[1143] NMR (CDCl3): δ 7.25-7.18 (2H, m), 6.99 (1H, t, J=4.8 Hz), 6.90-6.82 (2H, m), 5.84 (1H, d, J=8.0 Hz), 4.71-4.62 (1H, m), 4.47 (1H, dd, J=14.6, 6.2 Hz), 4.32 (1H, dd, J=14.6, 5.4 Hz), 3.81-3.68 (4H, m), 3.40 (1H, dd, J=15.0, 5.2 Hz), 3.20 (1H, dd, J=14.2, 6.8 Hz), 3.11 (1H, dd, J=14.2, 6.8 Hz), 2.46-2.26 (1H, m), 2.05-1.91 (2H, m), 1.75-1.19 (15H, m).

Example 7(3)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-cyclohexylcarbonyl-aminopropanamide

[1144] 1277

[1145] TLC: Rf 0.18 (chloroform: ethyl acetate=100:15);

[1146] NMR (CDCl3): δ 7.26-7.15 (3H, m), 6.93-6.82 (3H, m), 4.84 (1H, td, J=6.6, 4.4 Hz), 4.44 (1H, dd, J=14.6, 5.8 Hz), 4.31 (1H, dd, J=14.6, 5.4 Hz), 3.79 (3H, s), 3.63 (1H, dd, J=15.0, 4.4 Hz), 3.30 (1H, dd, J=15.0, 6.2 Hz), 3.17 (1H, dd, J=14.2, 6.6 Hz), 3.07 (1H, dd, J=14.2, 6.2 Hz), 2.24-1.00 (22H, m).

Example 7(4)

(2S)-N-(4-methoxybenzyl)-3-cyclopentylmethylsulfonyl-2-t-butoxycarbonyl-aminopropanamide

[1147] 1278

[1148] TLC: Rf 0.22 (ethyl acetate:hexane=1:2);

[1149] NMR (CDCl3): δ 7.25-7.17 (2H, m), 6.97 (1H, t, J=5.4 Hz), 6.90-6.82 (2H, m), 5.82 (1H, d, J=8.4 Hz), 4.71-4.62 (1H, m), 4.48 (1H, dd, J=14.8, 6.4 Hz), 4.32 (1H, dd, J=14.8, 5.4 Hz), 3.79-3.68 (4H, m), 3.39 (1H, dd, J=14.6, 5.0 Hz), 3.21 (1H, dd, J=14.2, 7.4 Hz), 3.11 (1H, dd, J=14.2, 7.0 Hz), 2.46-2.30 (1H, m), 2.05-1.91 (2H, m), 1.75-1.17 (15H, m);

Example 8˜Example 8(12)

[1150] By the same desired procedure as Example 6, using the compounds prepared in Example 7 and Example 7(1), the following compounds of the present invention were obtained.

[1151] Also, (+)-3-t-butoxycarbonylthiazolidin-2-ylcarboxylic acid was used for the preparation of the compound of Example 8(8).

Example 8

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(4-methoxy-cyclohexylcarbonylamino)propanamide

[1152] 1279

[1153] (The relative configuration of cyclohexyl ring substituted by methoxy group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 8(1).) more polar

[1154] TLC: Rf 0.68 (ethyl acetate)

[1155] NMR (CDCl3): δ 7.30-7.24 (1H, m), 7.22-7.15 (2H, m), 6.97 (1H, d, J=6.6 Hz), 6.89-6.82 (2H, m), 4.90-4.81 (1H, m), 4.42 (1H, dd, J=4.6, 5.8 Hz), 4.30 (1H, dd, J=14.6, 5.6 Hz), 3.79 (3H, s), 3.60 (1H, dd, J=15.0, 4.8 Hz), 3.45-3.26 (5H, m), 3.15(1H, dd, J=140, 6.2 Hz), 3.05(1H, dd, J=14.0, 6.2 Hz), 2.28-1.00 (20H, m).

Example 8(1)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(4-methoxy-cyclohexylcarbonylamino)propanamide

[1156] 1280

[1157] (The relative configuration of cyclohexyl ring substituted by methoxy group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 8.) less polar

[1158] TLC: Rf 0.59 (ethyl acetate)

[1159] NMR (CDCl3): δ 7.28-7.14 (3H, m), 6.94 (1H, d, J=7.0 Hz), 6.89-6.82 (2H, m), 4.91-4.82 (1H, m), 4.42 (1H, dd, J=14.6, 5.8 Hz), 4.30 (1H, dd, J-14.6, 5.4 Hz), 3.79 (3H, s), 3.60 (1H, dd, J=15.0, 4.8 Hz), 3.38-3.24 (4H, m), 3.18-2.99 (3H, m), 2.21-1.00 (20H, m).

Example 8(2)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmehtylsulfonyl-2-cyclobutyl-carbonylaminopropanamide

[1160] 1281

[1161] TLC: Rf 0.26 (ethyl acetate:hexane=1:1);

[1162] NMR (CDCl3): δ 7.30-7.15 (3H, m), 6.89-6.78 (3H, m), 4.89-4.80 (1H, m), 4.43 (1H, dd, J=14.6, 5.8 Hz), 4.31 (1H, dd, J=14.6, 5.6 Hz), 3.79 (3H, s), 3.62 (1H, dd, J=15.0, 4.2 Hz), 3.31 (1H, dd, J=15.0, 6.6 Hz), 3.23-2.98 (3H, m), 2.38-1.01 (17H, m).

Example 8(3)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(tetrahydrofuran-2-ylcarbonylamino)propanamide

[1163] 1282

[1164] TLC: Rf 0.14 (ethyl acetate:hexane=1:1);

[1165] NMR (CDCl3): δ 7.82-7.77 (1H, m), 7.23-7.05 (3H, m), 6.89-6.82 (2H, m), 4.99-4.90 (0.5H, m), 4.85-4.75 (0.5H, m), 4.49-4.27 (3H, m), 4.09-3.79 (5H, m), 3.73-3.33 (2H, m), 3.21-2.94 (2H, m), 2.38-0.98 (15H, m).

Example 8(4)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-cycloheptylcarbonyl-aminopropanamide

[1166] 1283

[1167] TLC: Rf 0.14 (ethyl acetate:hexane=1:2);

[1168] NMR (CDCl3): δ 7.26-7.15 (3H, m), 6.89-6.82 (3H, m), 4.88-4.79 (1H, m), 4.44 (1H, dd, J=14.8, 6.0 Hz), 4.30 (1H, dd, J=14.8, 5.6 Hz), 3.79 (3H, s), 3.61 (1H, dd, J=15.0, 4.4 Hz), 3.31 (1H, dd, J=15.0, 6.2 Hz), 3.17 (1H, dd, J=14.0, 6.2 Hz), 3.06 (1H, dd, J=14.0, 5.8 Hz), 2.38-1.00 (24H, m).

Example 8(5)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(tetrahydrofuran-3-ylcarbonylamino)propanamide

[1169] 1284

[1170] TLC: Rf 0.08 (ethyl acetate:hexane=1:1);

[1171] NMR (CD3OD): δ 7.25-7.15 (3H, m), 7.02 (1H, d, J=7.0 Hz), 6.90-6.82 (2H, m), 4.88-4.80 (1H, m), 4.43 (1H, dd, J=14.8, 6.0 Hz), 4.31 (1H, dd, J=14.8, 5.6 Hz), 4.01-3.73 (7H, m), 3.64-3.54 (1H, m), 3.39-3.27 (1H, m), 3.21-2.89 (3H, my, 2.20-1.00 (13H, m).

Example 8(6)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-((2RS)-3-t-butoxy-carbonylthiazolidin-2-ylcarbonylamino)propanamide

[1172] 1285

[1173] TLC: Rf 0.32 (ethyl acetate:hexane=1:1);

[1174] NMR (CD3OD): δ 7.23 (2H, d, J=9 Hz), 6.85 (2H, d, J=9 Hz), 5.20 (s) and 5.16 (bs) (1H), 4.97-4.84 (1H, m), 4.42-4.23 (2H, m), 4.02-3.85 (1H, m), 3.84-3.60 (2H, m), 3.77 (3H, s), 3.53-3.10 (2H, m), 3.08-2.90 (3H, m), 2.20-1.58 (6H, m), 1.44 and 1.40 (9H, s), 1.35-1.00 (5H, m).

Example 8(7)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-((4R)-3-t-butoxy-carbonylthiazolidin-4-ylcarbonylamino)propanamide

[1175] 1286

[1176] TLC: Rf 0.61 (methylene chloride:ethyl acetate=2:1);

[1177] NMR (CDCl3): δ 7.96 (1H, brs), 7.67 (1H, brs), 7.25-7.22 (2H, m), 6.84-6.82 (2H, m), 5.02-4.91 (1H, m), 4.62-4.42 (4H, m), 4.30 (1H, dd, J=14.4, 5.0 Hz), 4.06-3.92 (1H, m), 3.78 (3H, s), 3.34-3.15 (3H, m), 2.93-2.72 (2H, m), 2.10-1.59 (6H, m), 1.40 (9H, s), 1.50-0.85 (5H, m).

Example 8(8)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(3-t-butoxycarbonyl-thiazolidin-2-ylcarbonylamino)propanamide

[1178] 1287

[1179] (The absolute configuration of * carbon is not determined, but the above compound is a single optical isomer.)

[1180] [α]D=+1.23 (c 1.31, CHCl3)

[1181] TLC: Rf 0.63 (methylene chloride:ethyl acetate=2:1);

[1182] NMR (CD3OD): δ 7.23-7.18 (2H, m), 6.86-6.81 (2H, m), 5.16 (1H. br), 4.96-4.84 (1H, m), 4.40-4.23 (2H, m), 4.00-3.82 (1H, m), 3.80-3.50 (2H, m), 3.75 (3H, s), 3.50-3.10 (2H, m), 3.09-2.95 (1H, m), 3.00 (2H, d, J=6.2 Hz), 2.17-1.80 (3H, m), 1.80-1.55 (3H, m), 1.39 (9H, s), 1.42-1.00 (5H, m).

Example 8(9)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfinyl-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide

[1183] 1288

[1184] TLC: Rf 0.65 (chloroform:methanol=14:1);

[1185] NMR (CD3OD): δ 7.23-7.18 (2H, m), 6.87-6.83 (2H, m), 4.90-4.75 (1H, m), 4.63-4.45 (3H, m), 4.34-4.32 (2H, m), 3.76 (3H, s), 3.41-3.05 (4H, m), 2.84-2.59 (2H, m), 2.01-1.60 (6H, m), 1.43 and 1.42 (9H, s), 1.43-1.00 (5H, m).

Example 8(10)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(1-t-butoxycarbonylapiperidin-4-ylcarbonylamino)propanamide

[1186] 1289

[1187] TLC: Rf 0.25 (ethyl acetate:chloroform=2:3);

[1188] NMR (CDCl3): δ 7.28-7.15 (3H, m), 6.97 (1H, d, J=6.6 Hz), 6.90-6.82 (2H, m), 4.88-4.79 (1H, m), 4.43 (1H, dd, J=4.2, 5.8 Hz), 4.31 (1H, dd, J=14.2, 5.4 Hz), 4.22-4.04 (2H, m), 3.79 (3H, s), 3.61 (1H, dd, J=15.2, 4.8 Hz), 3.30 (1H, dd, J=15.2, 6.6 Hz), 3.16 (1H, dd, J=14.4, 6.6 Hz), 3.06 (1H, dd, J=14.4, 6.2 Hz), 2.79-2.66 (2H, m), 2.39-1.00 (25H, m).

Example 8(11)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(4-t-butozycarbonylaminocyclohexylcarbonylamino)propanamide

[1189] 1290

[1190] (The relative configuration of cyclohexyl ring substituted by t-butoxycarbonylamino group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 8(12).)

[1191] TLC: Rf 0.17 (ethyl acetate:chloroform=3:7);

[1192] NMR (CDCl3): δ 7.27-7.15 (3H, m), 6.97 (1H, d, J=7.0 Hz), 6.90-6.82 (2H, m), 4.90-4.81 (1H, m), 4.67 (1H, d, J=7.6 Hz), 4.43 (1H, dd, J=14.6, 5.8 Hz), 4.31 (1H, dd, J=14.6, 6.0 Hz), 3.79-3.57 (5H, m), 3.32 (1H, dd, J=15.0, 6.2 Hz), 3.17 (1H, dd, J=14.2, 6.6 Hz), 3.05 (1H, dd, J=14.2, 6.2 Hz), 2.34-1.00 (29H, m).

Example 8(12)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(4-t-butoxycarbonylaminocyclohexylcarbonylamino)propanamide

[1193] 1291

[1194] (The relative configuration of cyclohexyl ring substituted by t-butoxycarbonylamino group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 8(11).)

[1195] TLC: Rf 0.17 (ethyl acetate:chloroform=3:7);

[1196] NMR (CDCl3): δ 7.28-7.14 (3H, m), 6.95 (1H, d, J=6.6 Hz), 6.89-6.82 (2H, m), 4.88-4.79 (1H, m), 4.47-4.24 (3H, m), 3.79 (3H, s), 3.60 (1H, dd, J=15.0, 4.8 Hz), 3.50-3.25 (2H, m), 3.15 (1H, dd, J=14.4, 6.4 Hz), 3.05 (1H, dd, J=14.4, 6.2 Hz), 2.18-0.96 (29H, m).

Example 9˜Example 9(16)

[1197] By the same desired procedure as Reference Example 4, using the compounds prepared in Example 6(36), Example 6(39), Example 6(40), Example 6(41), Example 6(44), Example 6(47), Example 6(50)˜Example 6(52), Example 6(54)˜Example 6(56), Example 6(71), Example 6(72), Example 6(84) and Example 8(6), the following compounds of the present invention were obtained.

Example 9

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-thoazolidin-2-ylcarbonylamino)propanamide.hydrochloride

[1198] 1292

[1199] TLC: Rf 0.27 (methylene chloride:methanol=97:3);

[1200] NMR (CD3OD) δ 7.22 (2H, d, J=9 Hz), 6.85 (2H, d, J=9 Hz), 5.41 and 5.39 (1H, s), 4.55-4.44 (1H, m), 4.36-4.26 (2H, m), 3.85-3.70 (1H, m), 3.76 (3H, s), 3.70-3.52 (1H, m), 3.40-3.10 (2H, m), 3.00-2.84 (1H, m), 2.84-2.68 (1H, m), 2.46-2.38 (2H, m), 1.90-1.55 (5H, m), 1.55-1.08 (4H, m), 1.07-0.77 (2H, m).

Example 9(1)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-((2RS)-thoazolidin-2-ylcarbonylamino)propanamide.hydrochloride

[1201] 1293

[1202] TLC: Rf 0.25 (methylene chloride:methanol=97:3);

[1203] NMR (CD3OD) δ 7.22 (2H, d, J=9 Hz), 6.86 (2H, d, J=9 Hz), 5.44 (s) and 5.37 (1H, s), 5.03-4.93 (1H, m), 4.42-4.22 (2H, m), 3.84-3.34 (4H, m), 3.77 (3H, s), 3.34-3.12 (2H, m), 3.05 (2H, d, J=6 Hz), 2.10-1.83 (3H, m), 1.83-1.58 (3H, m), 1.50-1.00 (5H, m).

Example 9(2)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(piperidin-4-ylcarbonylamino)propanamide.hydrochloride

[1204] 1294

[1205] TLC: Rf 0.19 (chloroform:methanol=9:1);

[1206] NMR (DMSO-d6): δ 9.06-8.90 (1H. br), 8.74-8.52 (2H, m), 8.19 (1H, d, J=8.4 Hz), 7.18 (2H, d, J=8.8 Hz), 6.86 (2H, d, J=8.8 Hz), 4.48-4.37 (1H, m), 4.21 (2H, d, J=6.0 Hz), 3.73 (3H, s), 3.33-3.23 (2H, br), 2.96-2.76 (3H, m), 2.59 (1H, dd, J=8.8, 13.4 Hz), 2.55-2.43 (1H, m), 2.39 (2H, d, J=7.0 Hz), 1.94-1.52 (9H, m), 1.49-1.03 (4H, m), 0.99-0.77 (2H, m).

Example 9(3)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(4-aminocyclohexyl-carbonylamino)propanamide.hydrochloride

[1207] 1295

[1208] (The relative configuration of cyclohexyl ring substituted by amino group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 9(4).)

[1209] TLC: Rf 0.16 (chloroform:methanol=9:1);

[1210] NMR (DMSO-d6): δ 8.49 (1H, d, J=6.0 Hz), 8.06-7.85 (4H, m), 7.18 (2H, d, J=8.8 Hz), 6.86 (2H, d, J=8.8 Hz), 4.47-4.36 (1H, m), 4.21 (2H, d, J=6.0 Hz), 3.73 (3H, s), 3.17-3.04 (1H, br), 2.82 (1H, dd, J=5.6, 13.4 Hz), 2.64 (1H—, dd, J=8.6, 13.4 Hz), 2.44-2.31 (3H, m), 1.99-1.49 (12H, m), 1.46-1.03 (5H, m), 0.98-0.76 (2H, m).

Example 9(4)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(4-aminocyclohexyl-carbonylamino)propanamide.hydrochloride

[1211] 1296

[1212] (The relative configuration of cyclohexyl ring substituted by amino group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 9(3).)

[1213] TLC: Rf 0.11 (chloroform:methanol=9:1);

[1214] NMR (DMSO-d6): δ 8.53-8.47 (1H, br), 8.05-7.94 (4H, br), 7.17 (2H, d, J=8.4 Hz), 6.85 (2H, d, J=8.4 Hz), 4.45-4.35 (1H, br), 4.19 (2H, br), 3.72 (3H, s), 3.16 (1H, d, J=5.2 Hz), 3.04-2.88 (1H, br), 2.78 (1H, dd, J=5.8, 13.2 Hz), 2.59 (1H, dd, J=8.2, 13.2 Hz), 2.38 (2H, d, J=6.6 Hz), 2.35-2.08 (2H, br), 1.98-1.55 (8H, m), 1.49-1.02 (7H, m), 0.99-0.77 (2H, m).

Example 9(5)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide.hydrochloride

[1215] 1297

[1216] TLC: Rf 0.26 (methylene chloride:methanol=97:3);

[1217] NMR (CD3OD): δ 7.27-7.17 (2H, m), 6.93-6.80 (2H, m), 4.61-4.47 (2H, m), 4.41 (2H, s), 4.33 (1H, d, J=14 Hz), 4.31 (1H, d, J=14 Hz), 3.77 (3H, s), 3.55 (1H, dd, J=12, 7), 3.22 (1H, dd, J=12, 7 Hz), 2.92 (1H, dd, J=14, 7 Hz), 2.80 (1H, dd, J=14, 8 Hz), 2.43 (2H, d, J=6 Hz), 1.90-0.80 (11H, m).

Example 9(6)

(2R)-N-((1R)-1-(4-nitrophenyl)ethyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide.hydrochloride

[1218] 1298

[1219] TLC: Rf 0.74 (methanol:chloroform=5:95);

[1220] NMR (CD3OD) δ 8.92 (1H, d, J=7.2 Hz), 8.21-8.14 (2H, m), 7.60-7.54 (2H, m), 5.12-4.98 (1H, m), 4.55 (2H, t, J=7.0 Hz), 4.44 (1H, d, J=10.2 Hz), 4.38 (1H, d, J=10.2 Hz) 3.51 (1H, dd, J=12.2, 7.4 Hz), 3.12 (1H, dd, J=12.2, 7.0 Hz), 2.94 (1H, dd, J=13.6, 6.6 Hz), 2.80 (1H, dd, J=13.4, 8.2 Hz), 2.50 (2H, d, J=6.6 Hz), 1.93-0.85 (14H, m).

Example 9(7)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4S)-thiazolidin-4-ylcarbonylamino)propanamide.hydrochloride

[1221] 1299

[1222] TLC: Rf 0.44 (methylene chloride:methanol=19:1);

[1223] NMR (CD3OD): δ 7.29-7.18 (2H, m), 6.91-6.81 (2H, m), 4.65-4.51 (2H, m), 4.44 (1H, d, J=11 Hz), 4.43 (1H, d, J=11 Hz), 4.32 (2H, m), 3.77 (3H, s), 3.59 (1H, dd, J=12, 8 Hz), 3.38-3.26 (1H, m), 2.97 (1H, dd, J=14, 5 Hz), 2.76 (1H, dd, J=14, 9 Hz), 2.42 (2H, d, J=7 Hz), 1.89-0.80 (11H, m).

Example 9(8)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide.hydrochloride

[1224] 1300

[1225] TLC: Rf 0.43 (methylene chloride:methanol=19:1);

[1226] NMR (CD3OD): δ 8.25-8.15 (2H, m), 7.62-7.50 (2H, m), 4.63-4.49 (4H, m), 4.43, (1H, d, J=10 Hz), 4.41 (1H, d, J=10 Hz), 3.56 (1H, dd, J=12, 7 Hz), 3.26 (1H, dd, J=12, 7 Hz), 2.96 (1H, dd, J=13, 7 Hz), 2.85 (1H, dd, J=13, 8 Hz), 2.46 (2H, d, J=7 Hz), 1.91-0.80 (11H, m).

Example 9(9)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((2RS)-thiazolidin-2-ylcarbonylamino)propanamide.hydrochloride

[1227] 1301

[1228] TLC: Rf 0.41 (methylene chloride:methanol=19:1);

[1229] NMR (DMSO-d,): δ 9.10-8.93 (2H, m), 8.24-8.14 (2H, m), 7.62-7.52 (2H, m), 5.35 and 5.27 (1H, s), 4.58-4.39 (3H, m), 3.72-3.46 (2H, m), 3.28-3.03 (2H, m), 2.94-2.64 (2H, m), 2.44 (2H, d, J=7 Hz), 1.94-0.75 (11H, m).

Example 9(10)

(2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-(imidazol-4-ylcarbonylamino)propanamide.hydrochloride

[1230] 1302

[1231] TLC: Rf 0.31 (chloroform:methanol=9:1);

[1232] NMR (DMSO-d6): δ 9.10-9.01 (3H, m), 8.28 (1H, s), 8.18 (2H, d, J=8.8 Hz), 7.56 (2H, d, J=8.8 Hz), 4.73-4.61 (1H, m), 4.40 (2H, d, J=6.0 Hz), 2.98 (1H, dd, J=6.0, 13.6 Hz), 2.82 (1H, dd, J=8.4, 13.6 Hz), 2.45 (2H, d, J=7.0 Hz), 1.80-1.30 (6H, m), 1.28-0.78 (5H, m).

Example 9(11)

(2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide.2 hydrochloride

[1233] 1303

[1234] TLC: Rf 0.42 (methylene chloride:methanol=19:1);

[1235] NMR (CD3OD): δ 7.67-7.60 (2H, m), 7.60-7.50 (2H, m), 4.66-4.37 (6H, m), 3.59 (1H, dd, J=12, 8 Hz), 3.33-3.21 (1H, m), 3.28 (6H, s), 2.94 (1H, dd, J=16, 7 Hz), 2.84 (1H, dd, J=16, 8 Hz), 2.48 (2H, d, J=7 Hz), 1.93-0.83 (11H, m).

Example 9(12)

(2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-((2RS)-thiazolidin-2-ylcarbonylamino)propanamide.2 hydrochloride

[1236] 1304

[1237] TLC: Rf 0.40 (methylene chloride:methanol=19:1);

[1238] NMR (CD3OD): δ 7.68-7.59 (2H, m), 7.59-7.51 (2H, m), 5.47 and 5.42 (1H, s), 4.59-4.43 (3H, m), 3.92-3.76 (1H, m), 3.72-3.68 (1H, m), 3.39-3.17 (2H, m), 3.29 (6H, m), 3.07-2.73 (2H, m), 2.47 (2H, d, J=7 Hz), 1.93-0.83 (11H, m).

Example 9(13)

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide.hydrochloride

[1239] 1305

[1240] TLC: Rf 0.65 (ethyl acetate)

[1241] NMR (CD3OD): δ 8.71 (1H, t, J=5.7 Hz), 7.36-7.28 (4H, m), 7.09 (1H, t, J=7.2 Hz), 6.96-6.89 (4H, m), 4.59-4.51 (2H, m), 4.44-4.30 (4H, m), 3.55 (1H, dd, J=11.7, 7.5 Hz), 3.24 (1H, dd, J=11.7, 6.9 Hz), 2.93 (1H, dd, J=13.5, 6.3 Hz), 2.81 (1H, dd, J=13.5, 7.5 Hz), 2.46 (1H, dd, J=12.6, 6.9 Hz), 2.42 (1H, dd, J=12.6, 6.6 Hz), 1.88-1.79 (2H, m), 1.74-1.61 (3H, m), 1.53-1.36 (1H, m), 1.31-1.08 (3H, m), 1.00-0.88 (2H, m).

Example 9(14)

(2R)-N-(4-benzyloxybenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide.hydrochloride

[1242] 1306

[1243] TLC: Rf 0.30 (ethyl acetate:hexane=1:1);

[1244] NMR (CD3OD): δ 8.81 (1H, d, J=8.1 Hz), 8.63 (1H, t, J=7.5 Hz), 7.43-7.19 (7H, m), 6.95-6.69 (2H, m), 5.05 (2H, s), 4.60-4.25 (6H, m), 3.56 (1H, dd, J=12.3, 7.5 Hz), 3.21 (1H, dd, J=12.3, 7.2 Hz), 2.91 (1H, dd, J=13.8, 6.6 Hz), 2.78 (1H, dd, J=13.8, 7.5 Hz), 2.44 (1H, dd, J=2.6, 6.9 Hz), 2.40 (1H, dd, J=12.6, 6.6 Hz), 1.86-0.83 (11H, m).

Example 9(15)

(2R)-N-(3-benzyloxy-4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide.hydrochloride

[1245] 1307

[1246] TLC: Rf 0.27 (hexane:ethyl acetate=1:1);

[1247] NMR (CD3OD): δ 7.47-7.26 (m, 5H), 7.00 (d, J=1.8 Hz, 1H), 6.91 (d, J=8.2 Hz, 1H), 6.88 (dd, J=8.2, 1.8 Hz, 1H), 5.08 (s, 2H), 4.60-4.48 (m, 2H), 4.39 (s, 2H), 4.36 (d, J=14.8 Hz, 1H), 4.23 (d, J=14.8 Hz, 1H), 3.82 (s, 3H), 3.56 (dd, J=12.2, 7.4 Hz, 1H), 3.22 (dd, J=12.2, 7.0 Hz, 1H), 2.91 (dd, J=13.8, 6.6 Hz, 1H), 2.77 (dd, J=13.8, 7.8 Hz, 1H), 2.42 (d, J=6.8 Hz, 2H), 1.85-1.56 (m, 5H), 1.54-0.80 (m, 6H).

Example 9(16)

(2R)-N-(1-phenylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide.2 hydrochloride

[1248] 1308

[1249] TLC: Rf 0.26 (hexane:ethyl acetate=1:1);

[1250] NMR (CD3OD) δ 7.80-7.76 (m, 2H), 7.65-7.54 (m, 3H), 4.63 (t, J=7.2 Hz, 1H), 4.54 (t, J=7.2 Hz, 1H), 4.45 (d, J=9.9 Hz, 1H), 4.42 (d, J=9.9 Hz, 1H), 4.20-4.10 (m, 1H), 3.87-3.70 (br, 4H), 3.61 (dd, J=12.0, 7.5 Hz, 1H), 3.29 (dd, J=0.12.0, 6.9 Hz, 1H), 2.95 (dd, J=13.2, 6.6 Hz, 1H), 2.83 (dd, J=13.2, 7.8 Hz, 1H), 2.57-2.46 (m, 2H), 2.32-2.14 (m, 4H), 1.90-1.81 (br, 2H), 1.77-1.63 (m, 3H), 1.54-1.40 (m, 1H), 1.36-1.10 (m, 3H), 1.03-0.91 (m, 2H).

Reference Example 5

Bis((2R)-2-(4-methoxybenzylcarbamoyl)-2-t-butoxycarbonylaminoethyl)-disulfide

[1251] 1309

[1252] Bis((2R)-carboxy-2-t-butoxycarbonylaminoethyl)disulfide (5 g), 4-methoxybenzylamine (3.7 ml) and 1-hydroxybenzotriazole (3.84 g) were dissolved in a mixture of methylene chloride (50 ml) and DMF (10 ml). The solution was cooled with ice and EDC-HCl (5.45 g) was added thereto. The mixture was stirred for 12 hours. The reaction mixture was diluted with chloroform, washed with 1N hydrochloric acid, saturated aqueous sodium hydrogencarbonate and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was washed with diehylether to give the title compound (8.15 g) having the following physical data.

[1253] TLC: Rf 0.16 (ethyl acetate:hexane=1:2);

[1254] NMR (CDCl3): 8.03 (2H, t, J=6.3 Hz), 7.23-7.15 (4H, m), 6.87-6.80 (4H, m), 5.54 (2H, d, J=9.6 Hz), 4.94-4.82 (2H, m), 4.46 (2H, dd, J=14.6, 6.2 Hz), 4.30 (2H, dd, J=14.6, 5.8 Hz), 3.78 (6H, s), 3.04-2.82 (4H, m), 1.26 (18H, s).

Reference Example 6

(2R)-N-(4-methoxybenzyl)-3-mercapto-2-t-butoxycarbonylaminopropanamide

[1255] 1310

[1256] The compound prepared in Reference Example 5 (315 mg), tributylphosphine (103 mg) and acetic acid (15 drops) were dissolved in a mixture of dioxane (8 ml) and water (2 ml). The mixture was stirred for 3 days at room temperature. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography (ethyl acetate:chloroform=1:19) to give the title compound (242 mg) having the following physical data.

[1257] TLC: Rf 0.47 (ethyl acetate:chloroform=1:4);

[1258] NMR (CDCl3): δ 7.24-7.16 (2H, m), 6.90-6.82 (2H, m), 6.70-6.51 (1H, m), 5.41 (1H, d, J=7.6 Hz), 4.49-4.29 (3H, m), 3.80 (3H, s), 3.14 (1H, ddd, J=14.0, 7.8, 4.4 Hz), 2.73 (1H, ddd, J=14.0, 10.2, 5.8 Hz), 1.59-1.50 (1H, m), 1.43 (9H, s).

Example 10

(2R)-N-(4-methoxybenzyl)-3-(tetrahydropyran-2-yl)methylthio-2-t-butoxycarbonylaminopropanamide

[1259] 1311

[1260] A solution of the compound prepared in Reference Example 6 (103 mg), 2-(bromomethyl)tetrahydropyran (0.05 ml) and potassium carbonate (168 mg) in DMF (5 ml) was degassed and stirred for 15 hours at room temperature. The reaction mixture was concentrated. The residue was diluted with 1 N hydrochloric acid and extraced with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (ethyl acetate:hexane=1:6) to give the compound of the present invention (68 mg) having the following physical data.

[1261] TLC: Rf 0.40 (ethyl acetate:chloroform=1:4);

[1262] NMR (CDCl3): δ 7.28-7.20 (2H, m), 7.09-6.95 (1H, m), 6.90-6.82 (2H, m), 5.88-5.78 (1H, m), 4.42-4.38 (2H, m), 4.32-4.20 (1H, m), 3.96-3.76 (4H, m), 3.52-3.18 (2H, m), 3.13-3.01 (1H, m), 2.84-2.51 (3H, m), 1.88-1.74 (1H, m), 1.65-1.08 (14H, m).

Example 10(1)˜Example 10(11)

[1263] By the same desired procedure as Example 10, using the compound prepared in Reference Example 6, the following compounds of the present invention were obtained.

Example 10(1)

(2R)-N-(4-methoxybenzyl)-3-(bicyclo[2.2.1]heptan-2-ylmethylthio)-2-t-butoxycarbonylaminopropanamide

[1264] 1312

[1265] TLC: Rf 0.81 (ethyl acetate:chloroform=1:4);

[1266] NMR (CDCl3): δ 7.25-7.18 (2H, m), 6.90-6.82 (2H, m), 6.68-6.58 (1H, m), 5.35 (1H, d, J=6.6 Hz), 4.40 (2H, d, J=6.0 Hz), 4.29-4.19 (1H, m), 3.80 (3H, s), 3.05-2.94 (1H, m), 2.90-2.78 (1H, m), 2.65-2.25 (2H, m), 2.24-0.60 (20H, m).

Example 10(2)

(2R)-N-(4-methoxybenzyl)-3-(4-methoxycyclohexylmethylthio)-2-t-butoxycarbonylaminopropanamide

[1267] 1313

[1268] (The relative configuration of cyclohexyl ring substituted by methoxy group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 10(3).) less polar

[1269] TLC: Rf 0.41 (ethyl acetate:chloroform=1:4);

[1270] NMR (CDCl3): δ 7.25-7.17 (2H, m), 6.89-6.82 (2H, m), 6.62 (1H, t, J=5.4 Hz), 5.34 (1H, d, J=7.2 Hz), 4.39 (2H, d, J=5.8 Hz), 4.28-4.18 (1H, m), 3.79 (3H, s), 3.44-3.37 (1H, m), 3.29 (3H, s), 2.99 (1H, dd, J=14.0, 6.0 Hz), 2.82 (1H, dd, J=14.0, 7.0 Hz), 2.53-2.37 (2H, m), 1.94-1.80 (2H, m), 1.68-1.20 (16H, m).

Example 10(3)

(2R)-N-(4-methoxybenzyl)-3-(4-methoxycyclohexylmethylthio)-2-t-butoxycarbonylaminopropanamide

[1271] 1314

[1272] (The relative configuration of cyclohexyl ring substituted by methoxy group is not determined, but the above compound is a single compound. This compound is the isomer of the compound prepared in Example 10(2).) more polar

[1273] TLC: Rf 0.38 (ethyl acetate:chloroform=1:4);

[1274] NMR (CDCl3): δ 7.25-7.17 (2H, m), 6.89-6.82 (2H, m), 6.62 (1H, t, J=5.0 Hz), 5.34 (1H, d, J=7.8 Hz), 4.39 (2H, d, J=5.8 Hz), 4.28-4.18 (1H, m), 3.80 (3H, s), 3.34 (3H, s), 3.14-2.93 (2H, m), 2.83 (1H, dd, J=13.8, 6.6 Hz), 2.47 (1H, dd, J=2.8, 7.0 Hz), 2.40 (1H, dd, J=12.8, 6.8 Hz), 2.13-1.98 (2H, m), 1.85-1.81 (2H, m), 1.54-0.84 (14H, m).

Example 10(4)

(2R)-N-(4-methoxybenzyl)-3-(1-methylpeperidin-2-ylmethylthio)-2-t-butoxycarbonylaminopropanamide

[1275] 1315

[1276] TLC: Rf 0.45 (methanol:chloroform=1:9);

[1277] NMR (CDCl3): δ 7.27-7.13 (2.5H, m), 6.89-6.74 (2.5H, m), 6.05 (0.5H, d, J=6.8 Hz), 5.69 (0.5H, d, J=7.0 Hz), 4.49-4.15 (3H, m), 3.80 (3H, s), 3.15-1.18 (25H, m).

Example 10(5)

(2R)-N-(4-methoxybenzyl)-3-(pyridin-4-ylmethylthio)-2-t-butoxycarbonyl-aminopropanamide

[1278] 1316

[1279] TLC: Rf 0.12 (ethyl acetate:chloroform=1:4);

[1280] NMR (CDCl3): δ 8.54-8.51 (2H, m), 7.27-7.17 (4H, m), 6.89-6.82 (2H, m), 6.58 (1H, t, J=5.4 Hz), 5.30 (1H, d, J=7.6 Hz), 4.39 (2H, d, J=5.4 Hz), 4.32-4.22 (1H, m), 3.79 (3H, s), 3.70 (1H, d, J=13.8 Hz), 3.62 (1H, d, J=13.8 Hz), 2.89 (1H, dd, J=14.0, 5.6 Hz), 2.76 (1H, dd, J=14.0, 6.6 Hz), 1.43 (9H, s).

Example 10(6)

(2R)-N-(4-methoxybenzyl)-3-(quinolin-2-ylmethylthio)-2-t-butoxycarbonyl-aminopropanamide

[1281] 1317

[1282] TLC: Rf 0.50 (ethyl acetate:chloroform=1:4);

[1283] NMR (CDCl3): δ 8.13 (1H, d, J=8.4 Hz), 7.94 (1H, d, J=8.2 Hz), 7.80 (1H, dd, J=8.0, 1.4 Hz), 7.68-7.43 (3H, m), 7.17-7.10 (2H, m), 7.05-6.90 (1H, m), 6.82-6.74 (2H, m), 6.19 (1H, d, J=7.8 Hz), 4.51-4.36 (2H, m), 4.30 (1H, dd, J=11.4, 5.4 Hz), 4.06 (2H, s), 3.78 (3H, s), 2.96 (1H, dd, J=14.4, 6.6 Hz), 2.79 (1H, dd, J=14.4, 5.8 Hz), 1.43 (9H, s).

Example 10(7)

(2R)-N-(4-methoxybenzyl)-3-(imidazol-4-ylmethylthio)-2-t-butoxycarbonyl-aminopropanamide

[1284] 1318

[1285] TLC: Rf 0.61 (methanol:chloroform=1:9)

[1286] NMR (CDCl3): δ 7.63 (1H, br. s), 7.34 (1H, s), 7.24-7.18 (2H, m), 6.90-6.81 (2H, m), 5.81 (1H, dd, J=7.6 Hz), 4.46-4.30 (3H, m), 3.82-3.66 (5H, m), 2.96 (1H, d, J=14.2, 5.4 Hz), 2.78 (1H, dd, J=14.2, 7.2 Hz), 1.44 (9H, s).

Example 10(8)

(2R)-N-(4-methoxybenzyl)-3-((1R,4R,5R)-bicyclo[2.2.1]hept-2-en-5-ylmethylthio)-2-t-butoxycarbonylaminopropanamide

[1287] 1319

[1288] TLC: Rf 0.25 (ethyl acetate:chloroform=1:19);

[1289] NMR (CDCl3): δ 7.27-7.16 (2H, m), 6.92-6.82 (2H, m), 6.67-6.55 (1H, m), 6.17 (1H, dd, J=6, 3 Hz), 5.92 (1H, dd, J=6, 3 Hz), 5.33 (1H, d, J=7 Hz), 4.39 (2H, d, J=6 Hz), 4.29-4.16 (1H, m), 3.81 (3H, s), 2.98 (1H, dd, J=14, 6 Hz), 2.91-2.75 (3H, m), 2.38-2.14 (3H, m), 1.98-1.82 (1H, m), 1.55-1.38 (1H, m), 1.45 (9H, s), 1.29-1.21 (1H, m), 0.63-0.52 (1H, m).

Example 10(9)

(2R)-N-(4-methoxybenzyl)-3-((1S,4S,5S)-bicyclo[2.2.1]hept-2-en-5-ylmethylthio)-2-t-butoxycarbonylaminopropanamide

[1290] 1320

[1291] TLC: Rf 0.38 (ethyl acetate:hexane=1:2);

[1292] NMR (CDCl3): δ 7.27-7.17 (2H, m), 6.93-6.81 (2H, m), 6.70-6.55 (1H, m), 6.16 (1H, dd, J=6, 3 Hz), 5.94 (1H, dd, J=6, 3 Hz), 5.33 (1H, d, J=7 Hz), 4.39 (2H, d, J=6 Hz), 4.29-4.15 (1H, m), 3.81 (3H, s), 2.96 (1H, dd, J=14, 6 Hz), 2.92-2.74 (3H, m), 2.37-2.13 (3H, m), 1.97-1.82 (1H, m), 1.55-1.38 (1H, m), 1.44 (9H, s), 1.29-1.20 (1H, m), 0.63-0.51 (1H, m).

Example 10(10)

(2R)-N-(4-methoxybenzyl)-3-((1S,2R,4R)-bicyclo[2.2.1]heptan-2-ylmethylthio)-2-t-butoxycarbonylaminopropanamide

[1293] 1321

[1294] TLC: Rf 0.48 (ethyl acetate:hexane=1:2);

[1295] NMR (CDCl3): δ 7.27-7.17 (2H, m), 6.93-6.83 (2H, m), 6.71-6.57 (1H, m), 5.35 (1H, d, J=7 Hz), 4.40 (2H, d, J=6 Hz), 4.32-4.19 (1H, m), 3.81 (3H, s), 2.99 (1H, dd, J=14, 6 Hz), 2.86 (1H, dd, J=14, 7 Hz), 2.58 (1H, dd, J=12, 8 Hz), 2.55 (1H, dd, J=12, 8 Hz), 2.23-2.13 (2H, m), 2.13-1.88 (1H, m), 1.88-1.70 (1H, m), 1.64-1.18 (5H, m), 1.45 (9H, s), 1.16-1.01 (1H, m), 0.66 (1H, ddd, J=12, 5, 2 Hz).

Example 10(11)

(2R)-N-(4-methoxybenzyl)-3-((1R,2S,4S)-bicyclo[2.2.1]heptan-2-ylmethylthio)-2-t-butoxycarbonylaminopropanamide

[1296] 1322

[1297] TLC: Rf 0.23 (ethyl acetate:hexane=1:3);

[1298] NMR (CDCl3): δ 7.27-7.16 (2H, m), 6.93-6.81 (2H, m), 6.73-6.57 (1H, m), 5.36 (1H, d, J=7 Hz), 4.40 (2H, d, J=6 Hz), 4.31-4.18 (1H, m), 3.81 (3H, s), 2.98 (1H, dd, J=14, 6 Hz), 2.87 (1H, dd, J=14, 7 Hz), 2.58 (1H, dd, J=12, 8 Hz), 2.55 (1H, dd, J=12, 8 Hz), 2.24-2.13 (2H, m), 2.10-1.88 (1H, m), 1.87-1.69 (1H, m), 1.60-1.20 (5H, m), 1.43 (9H, s), 1.16-1.01 (1H, m), 0.66 (1H, ddd, J=12, 5, 2 Hz).

Reference Example 7

(2S)-4-hydroxy-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester

[1299] 1323

[1300] Under cooling with ice, isobutyl chloroformate (0.35 ml) was added dropwise to a solution of (2S)-3-carboxy-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester-dicyclohexylamine salt (1350 mg) and N-methylmorpholine (0.32 ml) in tetrahydrofuran (6 ml). The mixture was stirred for 45 minutes. The reaction mixture was filtered through Celite. Under cooling with ice, sodium borohydride (229 mg) was added to the filtrate and methanol (1.2 ml) was added dropwise thereto for 1 hour. One normal hydrochloric acid was added to the reaciton mixture. The mixture was extracted with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride, successively, and concentrated. The residue was purified by silica gel column chromatography (ethyl acetate hexane=1:2) to give the title compound (180 mg) having the following physical data.

[1301] TLC: Rf 0.42 (methanol:chloroform=1:9);

[1302] NMR (CDCl3): δ 7.30 (2H, d, J=8.7 Hz), 6.89 (2H, d, J=8.7 Hz), 5.38 (1H, brd, J=8.4 Hz), 5.13 (2H, s), 4.55-4.43,(1H, m), 3.82 (3H, s), 3.75-3.55 (2H, m), 3.24-3.05 (1H, m), 2.23-2.06 (1H, m), 1.69-1.56 (1H, m).

Reference Example 8

(2S)-3-formyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester

[1303] 1324

[1304] The compound prepared in Reference Example 7 (162 mg) and triethylamine (0.40 ml) were dissolved in a mixture of methylene chloride (4 ml) and dimethylsulfoxide (4 ml). Under cooling with ice, sulfur trioxide pyridine complex (228 mg) was added to the mixure. The mixture was warmed to room temperature. The reaction mixture was diluted with water and extracted with ethyl acetate. The extract was washed with 1N hydrochloric acid, water and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The obtained title compound (180 mg) was used for the next reaction without purification.

Example 11

(2S)-4-cyclopentylamino-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester

[1305] 1325

[1306] Under cooling with ice, sodium cyanoborohydride (74 mg) was added to a solution of the compound prepared in Reference Example 8 (180 mg), cyclopentylamine (0.10 ml) and acetic acid (0.04 ml) in methanol (5 ml). The mixture was stirred for 6.5 hours under cooling with ice and stirred for 12 hours at room temperature. The reaction mixture was diluted with water and methanol was distilled off under reduced pressure. The aqueous layer was extracted with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (ethyl acetate:hexane=1:1) to give the compound of the present invention (35 mg) having the following physical data.

[1307] TLC: Rf 0.17 (methanol:chloroform=1:9);

[1308] NMR (CD3OD): δ 7.31 (2H, d, J=8.4 Hz), 6.89 (2H, d, J=8.4 Hz), 5.17 (1H, d, J=11.8 Hz), 5.04 (1H, d, J=11.8 Hz), 4.26-4.14 (1H, m), 3.78 (3H, s), 3.27-3.12 (1H, m), 2.77 (2H, t, J=6.2 Hz), 2.12-1.49 (10H, m), 1.42 (9H, s).

Example 12

(2S)-N-(4-methoxybenzyl)-3-cyclohexylsulfonylamino-2-t-butoxycarbonyl-aminopropanamide

[1309] 1326

[1310] (2S)-N-(4-methoxybenzyl)-3-amino-2-t-butoxycarbonylaminopropanamide (98 mg) was dissolved in a mixture of pyridine (3 ml) and methylene chloride (5 ml). Under cooling with ice, cyclohexylsulfonyl chloride (166 mg) was added thereto and dimethylaminopyridine (3 mg) was added thereto. The mixture was stirred for 1 hour. The reaction mixture was diluted with water and extracted with ethyl acetate. The extract was washed with 1N hydrochloric acid, water and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (ethyl acetate:hexane=1:2) to give the compound of the present invention (25 mg) having the following physical data.

[1311] TLC: Rf 0.43 (ethyl acetate:hexane=1:1);

[1312] NMR (CDCl3): δ 7.22-7.14 (2H, m), 7.12-7.00 (1H, m), 6.89-6.81 (2H, m), 5.75 (1H, d, J=7.2 Hz), 5.34-5.20 (1H, m), 4.46-4.21 (3H, m), 3.79 (3H, s), 3.60 (1H, dt, J=14.0, 4.8 Hz), 3.38 (1H, ddd, J=14.0, 8.6,4.2 Hz), 2.97-2.82 (1H, m), 2.24-1.08 (19H, m).

Reference Example 9

(2R)-2-t-butoxycarbonylamino-2-(4-methoxybenzylcarbomoyl)ethansulfonic acid sodium salt

[1313] 1327

[1314] Under cooling with ice, dicyclohexylcarbodiimide (823 mg) was added to a solution of (2R)-2-t-butoxycarbonylamino-2-carboxyethansulfonic acid sodium salt (893 mg) and p-nitrophenol (470 mg) in DMF (15 ml). The mixture was stirred for 30 minutes. The reaction mixture was allowed to stand for 4 days at 5° C. Acetic acid was added to the reaction mixture for treating with an excess amount of-dicyclohexylcarbodiimide. The mixture was filtered. The filtrate was concentrated. Under cooling with ice, 4-methoxybenzylamine (0.40 ml) was added to a solution of the residue in DMF (10 ml). The mixture was stirred for 2 hours. The reaction mixture was concentrated. The residue was diluted with water. The aqueous layer was washed with ethyl acetate. The aqueous layer was concentrated under reduced pressure to give the compound of the present invention (610 mg) having the following physical data.

[1315] TLC: Rf 0.33 (methanol:chloroform=1:4);

[1316] NMR (CD3OD): δ 7.24-7.18 (2H, m), 6.87-6.81 (2H, m), 4.42-4.21 (3H, m), 3.75 (3H, s), 3.22-3.16 (2H, m), 1.41 (9H, s).

Example 13

(2R)-N-(4-methoxybenzyl)-3-cyclohexylsulfamoyl-2-t-butoxycarbonyl-aminopropanamide

[1317] 1328

[1318] Under cooling with ice, sulfuryl chloride (0.045 ml) was added dropwise to a solution of triphenylphosphine (127 mg) in methylene chloride (1 ml). The mixture was stirred and allowed to warm to room temperature. A solution of the compound prepared in Reference Example 9 (100 mg) in methylene chloride (2 ml) was added to the reaction mixture. The mixture was stirred for 1 hour at room temperature. The mixture of cyclohexylamine (0.14 ml) and triethylamine (0.17 ml) was added to the reaction mixture. The mixture was stirred for 1 hour. The reaction mixture was diluted with saturated aqueous sodium hydrogencarbonate and extracted with chloroform. The extract was washed with 1N hydrochloric acid, water and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (ethyl acetate:hexane=1:2) to give the compound of the present invention (15 mg) having the following physical data.

[1319] TLC: Rf 0.56 (ethyl acetate:hexane=1:1);

[1320] NMR (CDCl3): δ 7.24-7.15 (2H, m), 6.90-6.81 (3H, m), 5.72 (1H, d, J=8.4 Hz), 4.75 (1H, d, J=7.4 Hz), 4.69-4.60 (1H, m), 4.43 (1H, dd, J=14.0, 5.4 Hz), 4.33 (1H, dd, J=14.0, 5.8 Hz), 3.79 (3H, s), 3.60 (1H, dd, J=15.0, 6.2 Hz), 3.50 (1H, dd, J=15.0, 4.8 Hz), 3.38-3.19 (1H, m), 2.04-1.08 (19H, m).

Example 13(1)

(2R)-N-(4-methoxybenzyl)-3-(piperidin-1-ylsul (2R)-N-(4-methoxybenzyl)-3-(piperidin-1-ylsulfonyl)-2-t-butoxycarbonyl-aminopropanamide

[1321] 1329

[1322] By the same desired procedure as Example 13, using the compound prepared in Reference Example 9, the compound of the present invention having the following physical data was obtained.

[1323] TLC: Rf 0.41 (ethyl acetate:hexane=1:1);

[1324] NMR (CDCl3): δ 7.25-7.17 (2H, m), 6.89-6.82 (3H, m), 5.64 (1H, d, J=7.4 Hz), 4.61-4.51 (1H, m), 4.45 (1H, dd, J=15.0, 6.2 Hz), 4.35 (1H, dd, J=15.0, 5.4 Hz), 3.79 (3H, s), 3.54 (1H, dd, J=13.2, 5.8 Hz), 3.39 (1H, dd, J=13.2, 5.4 Hz), 3.26-3.21 (4H, m), 1.75-1.50 (6H, m), 1.44 (9H, s).

Example 14

(2S)-3-cyclohexyloxycarbonyl-2-(N-benzyl-N-t-butoxycarbonylamino)-prpanoic acid.4-methoxybenzyl ester

[1325] 1330

[1326] Under cooling with ice, sodium hydride (60%, 13 mg) was added to a solution of the compound prepared in Example 2(4) (122 mg) in DMF (3 ml). The mixture was stirred for 30 minutes at 0° C. Benzyl bromide (37 μl) was added to the reaction mixture. The mixture was stirred for 3 hours at 0° C. The reaction mixture was acidified by adding 1N hydrochloric acid, diluted with water and extracted with ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (ethyl acetate:hexane=1:8) to give the compound of the present invention (52 mg) having the following physical data.

[1327] TLC: Rf 0.44 (ethyl acetate:hexane=1:4);

[1328] NMR (CDCl3): δ 7.34-7.14 (7H, m), 6.89-6.82 (2H, m), 5.10-4.25 (6H, m), 3.81 (3H, s), 3.25-3.03 (1H, m), 2.72-2.46 (1H, m), 1.84-1.22 (19H, m).

Example 15

(2S)-3-cyclohexyloxycarbonyl-2-benzylaminopropanoic acid.4-methoxybenzyl ester

[1329] 1331

[1330] P-toluenesulfonic acid monohydrate (42 mg) was added to a solution of the compound prepared in Example 14 (115 mg) in diethylether (0.5 ml). The mixture was stirred for 19 hours at room temperature. The reaction mixture was washed with diethylether. The obtained cyrstal was dissolved in ethyl acetate, washed with saturated aqueous sodium hydrogencarbonate and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated to give the compound of the present invention (89 mg) having the following physical data.

[1331] TLC: Rf 0.63 (ethyl acetate:hexane=1:2);

[1332] NMR (CDCl3): δ 7.34-7.22 (7H, m), 6.93-6.85 (2H, m), 5.11 (2H, s), 4.80-4.66 (1H, m), 3.85 (1H, d, J=12.8 Hz), 3.81 (3H, s), 3.69 (1H, d, J=12.8 Hz), 3.68 (1H, dd, J=6.8, 6.2 Hz), 2.73 (1H, dd, J=15.8, 6.2 Hz), 2.63 (1H, dd, J=15.8, 6.8 Hz), 1.95 (1H, br. s), 1.84-1.19 (10H, m).

Example 16

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide

[1333] 1332

[1334] A solution of the compound prepared in Example 9(13) (107 mg) in ethyl acetate (10 ml) was washed with saturated aqueous sodium hydrogencarbonate (5 ml) and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated to give the compound of the present invention (96 mg) having the following physical data.

[1335] TLC: Rf 0.39 (ethyl acetate:hexane=1:1);

[1336] NMR (CDCl3): δ 7.88 (d, J=7.5 Hz, 1H), 7.37-7.30 (m, 2H), 7.25-7.21 (m, 2H), 7.14-7.08 (m, 1H), 7.02-6.94 (m, 4H), 6.84-6.80 (m, 1H), 4.49-4.36 (m, 3H), 4.26 (d, J=9.9 Hz, 1H), 4.19-4.15 (m, 1H), 4.05 (d, J=9.9 Hz, 1H), 3.42 (dd, J=11.1, 4.2 Hz, 1H), 3.10 (dd, J=11.1, 7.5 Hz, 1H), 2.93 (dd, J=13.8, 6.3 Hz, 2H), 2.83 (dd, J=13.8, 7.2 Hz, m), 2.45 (d, J=6.6 Hz, 2H), 1.86-1.58 (m, 5H), 1.51-1.36 (m, 1H), 1.29-1.05 (3H, m), 0.98-0.85 (m, 2H).

Example 16(1)

(2R)-N-(1-phenylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide

[1337] 1333

[1338] By the same desired procedure as Example 16, using the compound prepared in Example 9(16), the compound of the present invention having the following physical data was obtained.

[1339] TLC: Rf 0.26 (hexane:ethyl acetate=1:1)

[1340] NMR (CDCl3): δ 7.86 (d, J=7.5 Hz, 1H), 7.29-7.23 (m, 2H), 6.95-6.91 (m, 2H), 6.88-6.83 (m, 1H), 6.47 (d, J=8.1 Hz, 1H), 4.37 (dd, J=14.1, 7.5 Hz, 1H), 4.27 (d, J=9.9 Hz, 1H), 4.18 (dd, J=7.8, 4.2 Hz, 1H), 4.05 (d, J=9.9 Hz, 1H), 4.00-3.88 (m, 1H), 3.63-3.51 (m, 2H), 3.43 (dd, J=11.1, 4.2 Hz, 1H), 3.12 (dd, J=11.1, 7.8 Hz, 1H), 2.95-2.86 (m, 3H), 2.79 (dd, J=13.8, 7.5 Hz, 1H), 2.48 (d, J=6.9 Hz, 2H), 2.08-1.98 (m, 2H), 1.84-1.39 (m, 8H), 1.31-1.06 (m, 3H), 1.00-0.87 (m, 2H).

Example 17˜Example 17(16)

[1341] By the same desired procedure as Example 9→Example 16, using the comounds prepared in Example 6(36), Example 6(44), Example 6(49), Example 6(60), Example 6(61), Example 6(69), Example 6(74)˜Example 6(83) and Example 6(86), the following compounds of the present invention were obtained.

Example 17

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-thiazolidin-2-ylcarbonylamino)propanamide

[1342] 1334

[1343] TLC: Rf 0.45 (methylene chloride:methanol=19:1);

[1344] NMR (CD3OD): δ 7.27-7.17 (2H, m), 6.92-6.82 (2H, m), 5.01 and 4.98 (1H, s), 4.49 and 4.48 (1H, t, J=7 Hz), 4.34 (1H, d, J=15 Hz), 4.28 (1H, d, J=15 Hz), 3.77 (3H, s), 3.48-3.02 (2H, m), 3.00-2.71 (4H, m), 2.41 and 2.39 (2H, d, J=7 Hz), 1.90-0.78 (11H, m).

Example 17(1)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide

[1345] 1335

[1346] TLC: Rf 0.59 (methylene chloride:methanol=9:1);

[1347] NMR (CDCl3): δ 7.87 (1H, d, J=8 Hz), 7.25-7.18 (2H, m), 6.90-6.83 (2H, m), 6.78-6.70 (1H, m), 4.48-4.31 (3H, m), 4.30-4.21 (1H, m), 4.20-4.12 (1H, m), 4.10-4.00 (1H, m), 3.80 (3H, s), 3.41 (1H, dd, J=11, 4 Hz), 3.10 (1H, dd, J=11, 8 Hz), 2.92 (1H, dd, J=14, 6 Hz), 2.83 (1H, dd, J=14, 7 Hz), 2.50-2.38 (1H, b), 2.44 (2H, d, J=7 Hz), 1.85-1.55 (5H, m), 1.50-1.35 (1H, m), 1.31-1.03 (3H, m), 0.98-0.84 (2H, m).

Example 17(2)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(2-aminothiazol-4-ylcarbonylamino)propanamide

[1348] 1336

[1349] TLC: Rf 0.30 (methylene chloride:methanol=19:1);

[1350] (CDCl3+3drops of CD3OD) δ 7.33 (1H, s), 7.27-7.17 (2H, m), 6.90-6.80 (2H, m), 4.64 (1H, t, J=6 Hz), 4.41 (1H, d, J=15 Hz), 4.35 (1H, d, J=15 Hz), 3.80 (3H, s), 3.08-2.84 (2H, m), 2.44 (2H, d, J=7 Hz), 1.87-0.78 (11H, m).

Example 17(3)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(thiazolidin-2-ylcarbonylamino)propanamide

[1351] 1337

[1352] (The absolute configuration of * carbon is not determined, but the above compound is a single optical isomer.)

[1353] [α]D=−71.7 (c 0.21, CHCl3);

[1354] TLC: Rf 0.27 (hexane:ethyl acetate=1:2);

[1355] NMR (CDCl3): δ 7.65 (1H, d, J=7.4 Hz), 7.21 (2H, d, J=8.8 Hz), 6.86 (2H, d, J=8.8 Hz), 6.80-6.73 (1H, br), 4.99 (1H, s), 4.50-4.38 (3H, m), 3.80 (3H, s), 3.51-3.40 (1H, m), 3.15-2.94 (3H, m), 2.88-2.75 (2H, m), 2.44 (2H, d, J=7.0 Hz), 1.83-1.30 (6H, m), 1.28-0.78 (5H, m).

Example 17(4)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(thiazolidin-2-ylcarbonylamino)propanamide

[1356] 1338

[1357] (The absolute configuration of * carbon is not determined, but the above compound is a single optical isomer.)

[1358] [α]D=+51.5 (c 0.19, CHCl3);

[1359] TLC: Rf 0.16 (hexane:ethyl acetate=1:2);

[1360] NMR (CDCl3): δ 7.69 (1H, d, J=7.0 Hz), 7.21 (2H, d, J=8.8 Hz), 6.86 (2H, d, J=8.8 Hz), 6.81-6.69 (1H, br), 5.01 (1H, s), 4.51-4.37 (3H, m), 3.80 (3H, s), 3.52-3.39 (1H, m), 3.08-2.91 (3H, m), 2.89-2.73 (2H, m), 2.53-2.40 (2H, m), 1.83-1.37 (6H, m), 1.34-0.79 (5H, m).

Example 17(5)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS,4R)-2-(2-methylpropyl)thiazolidin-4-ylcarbonylamino)propanamide

[1361] 1339

[1362] TLC: Rf 0.41 (methanol:methylene chloride=1:19);

[1363] NMR (CD3OD): δ 7.25-7.18 (2H, m), 6.89-6.82 (2H, m), 4.61-4.46 (2H, m), 4.39-4.24 (2H, m), 4.39-4.24 (m) and 3.84 (t, J=8 Hz) (1H), 3.76 (3H, s), 3.39 (dd, J=10, 3 Hz) and 3.19 (dd, J=10, 8 Hz) (1H), 3.09 (dd, J=10, 8 Hz) and 2.99-2.90 (m) (1H), 2.90-2.76 (2H, m), 2.38 and 2.41 (2H, d, J=6 Hz), 1.90-1.55 (8H, m), 1.49-1.33 (1H, m), 1.33-1.06 (3H, m), 1.06-0.83 (8H, m).

Example 17(6)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS,4R)-2-phenylthiazolidin-4-ylcarbonylamino)propanamide

[1364] 1340

[1365] TLC: Rf 0.43 (methanol:methylene chloride=1:19);

[1366] NMR (CDCl3+5 drops of CD3OD): δ 7.57-7.48 (m, 2H), 7.45-7.33 (m, 3H), 7.25-7.18 (m, 2H), 6.90-6.83 (m, 2H), 5.60 and 5.53 (s, 1H), 4.53-4.29 and 3.99-3.90 (m, 4H), 3.79 (s, 3H), 3.43-3.35 (m) and 3.64 (dd, J=11, 3 Hz) (1H), 3.19 and 3.39 (dd, J=11, 8 Hz, 1H), 2.73 and 2.92 (d, J=7 Hz, 2H), 2.40 and 2.43 (d, J=7 Hz, 2H), 1.85-1.58 (m, 5H), 1.51-1.34 (m, 1H), 1.31-1.03 (m, 3H), 1.00-0.80 (m, 2H).

Example 17(7)

(4R)-N-((1R)-2-cyclohexylmethylthio-1-(4-phenylpiperazin-1-ylcarbonyl)ethyl)-thiazolidin-4-ylcarboxamide

[1367] 1341

[1368] TLC: Rf 0.55 (methanol:chloroform=1:9);

[1369] NMR (CDCl3): δ 7.85 (d, J=8.7 Hz, 1H), 7.32-7.26 (m, 2H), 6.94-6.89 (m, 3H), 5.12-5.04 (m, 1H), 4.27 (d, J=9.9 Hz, 1H), 4.15 (dd, J=7.5, 4.2 Hz, 1H), 4.07 (d, J=9.9 Hz, 1H), 3.89-3.74 (m, 4H), 3.44 (dd, J=10.8, 4.2 Hz, 1H), 3.32-3.09 (m, 5H), 2.91 (dd, J=13.5, 3.9 Hz, 1H), 2.76 (dd, J=13.5, 6.3 Hz, 1H), 2.54-2.34 (m, 3H), 1.86-1.60 (m, 5H), 1.50-1.35 (m, 1H), 1.30-1.04 (m, 3H), 1.02-0.84 (m, 2H).

Example 17(8)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((3RS)-thiomorpholin-3-ylcarbonylamino)propanamide

[1370] 1342

[1371] TLC: Rf 0.31 and 0.27 (methylene chloride:methanol=19:1);

[1372] NMR (CD3OD): δ 7.26-7.18 (m, 2H), 6.88-6.83 (m, 2H), 4.54-4.46 (m, 1H), 4.38-4.24 (m, 2H), 3.76 (s, 3H), 3.60-3.52 (m, 1H), 3.36-3.28 (m, 1H), 3.02-2.60 (m, 6H), 2.44-2.32 (m, 3H), 1.86-1.60 (m, 5H), 1.50-1.34 (m, 1H), 1.34-1.07 (m, 3H), 1.00-0.83 (m, 2H).

Example 17(9)

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((3RS)-thiomorpholin-3-ylcarbonylamino)propanamide

[1373] 1343

[1374] TLC: Rf 0.14 and 0.16 (methylene chloride:methanol=19:1);

[1375] NMR (CDCl3): δ 7.69 and 7.62 (d, J=8 Hz, 1H), 7.38-7.30 (m, 2H), 7.28-7.21 (m, 2H), 7.15-7.08 (m, 1H), 7.03-6.93 (m, 4H), 6.91-6.77 (m, 1H), 4.54-4.35 (m, 4H), 3.60-3.51 (m, 1H), 3.38-3.23 (m, 1H), 3.10-2.90 (m, 2H), 2.88-2.76 (m, 2H), 2.75-2.37 (m, 5H), 1.86-1.52 (m, 5H), 1.52-1.35 (m, 1H), 1.30-1.04 (m, 3H), 1.00-0.84 (m, 2H).

Example 17(10)

(2R)-N-(2-phenoxypyridin-5-yl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide

[1376] 1344

[1377] TLC: Rf 0.18 (methanol:chloroform=1:19);

[1378] NMR (CDCl3): δ 8.94-8.82 (m, 1H), 8.23 (d, J=2.4 Hz, 1H), 8.05-8.00 (m, 2H), 7.42-7.35 (m, 2H), 7.21-7.16 (m, 1H), 7.12-7.07 (m, 2H), 6.86 (d, J=8.7 Hz, 1H), 4.64-4.57 (m, 1H), 4.30 (d, J=9.9 Hz, 1H), 4.29-4.26 (m, H), 4.07 (d, J=9.9 Hz, 1H), 3.48 (dd, J=10.8, 3.3 Hz, 1H), 3.14 (dd, J=10.8, 8.1, 1H), 3.00 (dd, J=13.8, 7.2 Hz, 1H), 2.92 (dd, J=13.8, 6.9 Hz, 1H), 2.48 (d, J=6.6 Hz, 2H), 1.88-1.60 (m, 5H), 1.54-1.39 (m, 1H), 1.32-1.04 (m, 3H), 1.01-0.84 (m, 2H).

Example 17(11)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-thiomorpholin-2-ylcarbonylamino)propanamide

[1379] 1345

[1380] TLC: Rf 0.46 and 0.41 (methylene chloride:methanol=9:1);

[1381] NMR (CDCl3): δ 8.92 and 8.62 (d, J=8 Hz, 1H), 7.25-7.17 (m, 2H), 6.90-6.82 (m, 2H), 4.66-4.52 (m, 1H), 4.48-4.29 (m, 2H), 3.79 (s, 3H), 3.61-3.53 (m, 1H), 3.31-2.81 (m, 7H), 2.55-2.40 (m, 2H), 2.36-2.24 (m, 1H), 1.86-1.58 (m, 5H), 1.53-1.35 (m, 1H), 1.31-1.04 (m, 3H), 1.00-0.83 (m, 2H).

Example 17(12)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4RS)-1,3-perhydrothiazin-4-ylcarbonylamino)propanamide

[1382] 1346

[1383] TLC: Rf 0.22 and 0.19 (methylene chloride:methanol=49:1);

[1384] NMR (CDCl3): δ 7.66-7.56 (m, 1H), 7.24-7.16 (m, 2H), 6.90-6.82 (m, 2H), 6.78-6.65 (m, 1H), 4.52-4.41 (m, 1H), 4.41-4.30 (m, 2H), 4.17-4.01 (m, 2H), 3.80 (s, 3H), 3.36-3.28 (m, 1H), 2.99-2.73 (m, 4H), 2.49-2.42 (m, 2H), 2.31-2.20 (m, 1H), 1.85-1.35 (m, 7H), 1.30-1.03 (m, 3H), 1.00-0.83 (m, 2H).

Example 17(13)

(2R)-N-(2-phenoxypyridin-5-ylmethyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-+B4-ylcarbonylamino)propanamide

[1385] 1347

[1386] TLC: Rf 0.41 (methanol:chloroform=1:19);

[1387] NMR (CDCl3): δ 8.09 (d, J=2.1 Hz, 1H), 7.87 (d, J=7.5 Hz, 1H), 7.64 (dd, J=8.4, 2.4 Hz, 1H), 7.43-7.37 (m, 2H), 7.20 (it, J=7.2, 1.2 Hz, 1H), 7.14-7.09 (m, 2H), 6.94 (t, J=6.0 Hz, 1H), 6.87 (d, J=8.4 Hz, 1H), 4.43 (dd, J=13.8, 7.2, 1H), 4.40 (d, J=6.0 Hz, 2H), 4.27 (d, J=9.9 Hz, 1H), 4.18 (dd, J=7.8, 4.2 Hz, 1H), 4.04 (d, J=9.9 Hz, 1H), 3.42 (dd, J=11.1, 3.9 Hz, 1H), 3.10 (dd, J=11.1, 7.8 Hz, 1H), 2.92 (dd, J=13.8, 6.6 Hz, 1H), 2.82 (dd, J=13.8, 7.2 Hz, 1H), 2.43 (d, J=9.3 hz, 2H), 1.86-1.58 (m, 5H), 1.48-1.35 (m, 1H), 1.30-1.04 (m, 3H), 0.98-0.82 (m, 2H).

Example 17(14)

(2R)-N-(4-(morpholin-4-yl)benzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide

[1388] 1348

[1389] TLC: Rf 0.46 (methanol:chloroform=1:19);

[1390] NMR (CDCl3): δ 7.86 (d, J=7.5 Hz, 1H), 7.21-7.16 (m, 2H), 6.89-6.84 (m, 2H), 6.71 (t, J=5.1 Hz, 1H), 4.44 (dd, J=13.8, 6.9 Hz, 1H), 4.40 (dd, J=14.7, 5.7 Hz, 1H), 4.34 (dd, J=14.7, 5.4 Hz, 1H), 4.26 (d, J=9.9 Hz, 1H), 4.14 (dd, J=7.5, 3.9 Hz, 1H), 4.04 (d, J=9.9 Hz, 1H), 3.87-3.84 (m, 4H), 3.40 (dd, J=11.1, 4.2 Hz, 1H), 3.16-3.12 (m, 4H), 3.09 (dd, J=11.1, 7.8 Hz, 1H), 2.92 (dd, J=13.8, 6.3 Hz, 1H), 2.82 (dd, J=13.8, 7.2 Hz, 1H), 2.43 (d, J=6.9 Hz, 2H), 1.85-1.58 (m, 5H), 1.51-1.35 (m, 1H), 1.30-1.04 (m, 3H), 0.98-0.82 (m, 2H).

Example 17(15)

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4RS)-1,3-perhydrothiazin-4-ylcarbonylamino)propanamide

[1391] 1349

[1392] TLC: Rf 0.39 and 0.30 (methylene chloride:methanol=19:1),

[1393] NMR (CDCl3): δ 7.68-7.56 (m, 1H), 7.38-7.29 (m, 2H), 7.29-7.20 (m, 2H), 7.14-7.07 (m, 1H), 7.05-6.90 (m, 4H), 6.87-6.82 (m, 1H), 4.54-4.34 (m, 3H), 4.18-4.00 (m, 2H), 3.37-3.29 (m, 1H), 3.00-2.74 (m, 4H), 2.50-2.43 (m, 2H), 2.32-2.20 (m, 1H), 1.86-1.35 (m, 8H), 1.31-1.03 (m, 3H), 1.03-0.83 (m, 2H).

Example 17(16)

(2R)-N-(1-methylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide

[1394] 1350

[1395] TLC: Rf 0.24 (chloroform:methanol=9:1);

[1396] NMR (CD3OD): δ 4.46-4.39 (m, 1H), 4.23-4.09 (m, 3H), 3.75-3.64 (m, 1H), 3.23 (dd, J=10.2, 4.4 Hz, 1H), 3.03 (dd, J=10.2, 7.2 Hz, 1H), 2.93-2.70 (m, 4H), 2.43 (d, J=6.6 Hz, 2H), 2.27 (s, 3H), 2.22-2.06 (m, 2H), 1.94-1.10 (m, 13H), 1.03-0.82 (m, 2H).

Example 18

(2R)-N-((1R)-1-(4-nitrophenyl)ethyl)-3-cyclohexylmethylthio-2-((4R)-3-(2-methylpropylcarbonyl)thiazolidin-4-ylcarbonylamino)propanamide

[1397] 1351

[1398] Under cooling with ice, isovaleryl chloride (0.025 ml) was added to a solution of the compound prepared in Example 9(6) (98 mg) and triethylamine (0.06 ml) in methylene chloride (3 ml). The mixture was stirred for 1 hour. The reaction mixture was washed with saturated aqueous sodium hydrogencarbonate, 1N hydrochloric acid, water and saturated aqueous sodium chloride, successively, dried over anhydrous magnesium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (ethyl acetate:hexane=1:2) to give the compound of the present invention (81 mg) having the following physical data.

[1399] TLC: Rf 0.48 (ethyl acetate:hexane=1:1);

[1400] NMR (CDCl3): δ 8.16 (2H, d, J=8.8 Hz), 7.56 (2H, d, J=8.8 Hz), 7.45 (1H, d, J=7.6 Hz), 6.95 (1H, d, J=8.2 Hz), 5.20-5.06 (1H, m), 4.87 (1H, t, J=5.6 Hz), 4.66-4.56 (3H, m) 3.33 (2H, d, J=5.6 Hz), 3.23 (1H, dd, J=13.8, 4.0 Hz), 2.75 (1H, dd, J=13.8, 5.8 Hz), 2.34 (2H, d, J=7.0 Hz), 2.24-2.01 (3H, m), 1.72-0.60 (20H, m).

Example 18(1)˜Example 18(5)

[1401] By the same desired procedure as Example 18, using the compounds prepared in Example 16, Example 17 and Example 17(1), the following compouns of the present invention were obtained.

Example 18(1)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-3-acetylthiazolidin-2-ylcarbonylamino)propanamide

[1402] 1352

[1403] TLC: Rf 0.40 (ethyl acetate)

[1404] NMR (CDCl3): δ 7.46 (1H, t, J=6.2 Hz), 7.27-7.21 (2H, m), 6.89-6.77 (3H, m), 5.49-5.29 (1H, m), 4.62-4.34 (3H, m), 4.06-3.94 (1H, m), 3.88-3.72 (4H, m), 3.64-3.00 (3H, m), 2.85-2.74 (1H, m), 2.49-2.27 (2H, m), 2.18-2.03 (3H, m), 1.85-0.74 (11H, m).

Example 18(2)

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-methoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide

[1405] 1353

[1406] TLC: Rf 0.39 (hexane:ethyl acetate=1:1);

[1407] NMR (CDCl3): δ 7.37-6.93 (m, 1 1H), 4.73-4.32 (m, 6H), 3.67 (s, 3H), 3.32 (dd, J=12.0, 3.9 Hz, 1H), 3.28 (dd, J=12.0, 6.9 Hz, 1H), 3.23-3.01 (br, 1H), 2.82 (dd, J=13.8, 6.6 Hz, 1H), 2.48-2.34 (m, 2H), 1.82-1.52 (m, 5H), 1.49-1.04 (m, 4H), 0.96-0.81 (m, 2H).

Example 18(3)

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-(2-methylpropoxycarbonyl)thiazolidin-4-ylcarbonylamino)propanamide

[1408] 1354

[1409] TLC: Rf 0.32 (hexane:ethyl acetate=2:1);

[1410] NMR (CDCl3): δ 7.37-6.92 (m, 11H), 4.73-4.29 (m, 6H), 3.84 (d, J=6.6 Hz, 2H), 3.32 (dd, J=12.3, 4.5 Hz, 1H), 3.29 (dd, J=12.3, 6.6 Hz, 1H), 3.24-3.17 (br, 1H), 2.81 (dd, J=13.5, 6.6 Hz, 1H), 2.44-2.32 (m, 2H), 1.99-1.54 (m, 6H), 1.49-1.04 (m, 4H), 0.95-0.86 (m, 8H).

Example 18(4)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-methoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide

[1411] 1355

[1412] TLC: Rf 0.31 (hexane:ethyl acetate=1:1);

[1413] NMR (CDCl3): δ 7.22 (d, J=8.7 Hz, 2H), 7.10 (d, J=7.8 Hz, 2H), 6.85 (d, J=8.7 Hz, 2H), 4.72-4.24 (m, 6H), 3.79 (s, 3H), 3.65 (brs, 3H), 3.31 (dd, J=12.0, 4.2 Hz, 1H), 3.26 (dd, J=12.0, 6.9 Hz, 1H), 3.18-3.00 (br, 1H), 2.81 (dd, J=13.8, 6.6 Hz, 1H), 2.46-2.32 (m, 2H), 1.78-1.60 (m, 5H), 1.48-1.04 (m, 4H), 0.94-0.80 (m, 2H).

Example 18(5)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-(2-methylpropoxycarbonyl)thiazolidin-4-ylcarbonylamino)propanamide

[1414] 1356

[1415] TLC: Rf 0.17 (hexane:ethyl acetate=2:1);

[1416] NMR (CDCl3): δ 7.21 (d, J=8.4 Hz, 2H), 7.11 (d, J=8.1 Hz, 2H), 6.84 (d, J=8.4 Hz, 2H), 4.72-4.21 (m, 6H), 3.78 (s, 5H), 3.31 (dd, J=12.3, 4.2 Hz, 1H), 3.28 (dd, J=12.3, 6.6 Hz, 1H), 3.25-3.17 (br, 1H), 2.80 (dd, J=13.8, 6.6 Hz, 1H), 2.45-2.30 (m, 2H), 1.94-1.62 (m, 6H), 1.47-1.04 (m, 4H), 0.98-0.80 (br, 8H).

Example 19˜Example 19(1)

[1417] By the same desired procedure as Reference Example 4→Example 5→Example 17, using the compound prepared in Example 2(99), the following compounds of the present invention were obtained.

[1418] Also, (−)-3-t-butoxycarbonylthiazolidin-2-ylcarboxylic acid was used for the preparation of the compound of Example 19.

[1419] (+)-3-t-butoxycarbonylthiazolidin-2-ylcarboxylic acid was used for the preparation of the compound of Example 19 (1).

Example 19

(2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-(thiazolidin-2-ylcarbonylamino)propanamide

[1420] 1357

[1421] (The absolute configuration of * carbon is not determined, but the above compound is a single optical isomer.)

[1422] [α]D=−77.07 (c 0.99, CHCl3);

[1423] TLC: Rf 0.46 (ethyl acetate:hexane=2:1)

[1424] NMR (CDCl3): δ 7.68 (1H, d, J=7.2 Hz), 7.19-7.12 (2H, m), 6.73-6.65 (3H, m), 4.98 (1H, s), 4.49-4.39 (1H, m), 4.34 (2H, d, J=5.4 Hz), 3.51-3.39 (1H, m), 3.15-2.74 (11H, m) 2.44 (2H, d, J=6.6 Hz), 1.88-0.77 (11H, m).

Example 19(1)

(2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-(thiazolidin-2-ylcarbonylamino)propanamide

[1425] 1358

[1426] (The absolute configuration of * carbon is not determined, but the above compound-is a single optical isomer.)

[1427] [α]D=+70.27 (c 1.06, CHCl3);

[1428] TLC: Rf 0.41 (ethyl acetate:hexane=2:1);

[1429] NMR (CDCl3): δ 7.69 (1H, d, J=7.4 Hz), 7.19-7.12 (2H, m), 6.73-6.65 (2H, m), 6.60 (1H, d, J=5.2 Hz), 5.00 (1H, s), 4.49-4.39 (1H, m), 4.34 (2H, d, J=5.4 Hz), 3.49-3.38 (1H, m), 3.09-2.72 (11H, m) 2.51 (1H, dd, J=12.4, 6.6 Hz), 2.44 (1H, dd, J=12.4, 7.0 Hz), 1.88-0.77 (11H, m).

Example 20

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(((4R)-3-t-butoxycarbonylthiazolidin-4-ylmethyl)amino)propanamide

[1430] 1359

[1431] N-methyl morpholine (0.18 ml), (4R)-3-t-butoxycarbonyl-4-formylthiazolidine (355 mg) and sodium cyanoborohydride (206 mg) were added to a suspention of the compound (611 mg) (obtained by the same desired procedure as Reference Example 4 using the compound prepared in Example 2(80)) in ethanol (2 ml). The mixture was stirred for 3.5 hours at room temperature. The reaction mixture was concentrated. Saturated aqueous sodium hydrogencarbonate was added to the residue. The mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium chloride, dried over anhydrous sodium sulfate. The organic layer was concentrated and the residue was purified by silica gel column chromatography (ethyl acetate:hexane=2:1→1:1) to give the compound of the present invention (637.5 mg) having the following physical data.

[1432] TLC: Rf 0.30 (ethyl acetate:hexane=1:2);

[1433] NMR (CD3OD) δ 7.27-7.20 (m, 2H), 6.89-6.83 (m, 2H), 4.54 (d, J=9 Hz, 1H), 4.37 (d, J=14 Hz, 1H), 4.33-4.21 (m, 2H), 4.17 (d, J=9 Hz, 1H), 3.77 (3H, s), 3.25 (dd, J=8, 5 Hz), 3.14-3.05 (m, 1H), 2.98-2.80 (m, 2H), 2.77-2.60 (m, 3H), 2.41 (dd, J=12, 8 Hz, 1H), 2.40 (dd, J=12, 8 Hz, 1H), 1.88-1.60 (m, 5H), 1.55-1.35 (m, 10H), 1.35-1.07 (m, 3H), 1.03-0.85 (2H, m).

Example 20(1)˜Example 20(7)

[1434] By the same desired procedure as Example 20, using the compound (obtained by the same desired procedure as Reference Example 4, using the compound prepared in Example 2(103)) or the compound (obtained by the same desired procedure as Reference Example 4, using the compound prepared in Example 2 (80)), the following compounds of the present invention were obtained.

Example 20(1)

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-(((4R)-3-t-butoxycarbonylthiazolidin-4-ylmethyl)amino)propanamide

[1435] 1360

[1436] TLC: Rf 0.60 (methylene chloride:ethyl acetate=9:1),

[1437] NMR (CD3OD): δ 7.39-7.28 (m, 4H), 7.14-7.04 (m, 1H), 6.99-6.88 (m, 4H), 4.54 (d, J=9.0 Hz, 1H), 4.43 (d, J=14.7 Hz, 1H), 4.37-4.21 (m, 1H), 4.33 (d, J=14.7 Hz, 1H), 4.15 (d, J=9.0 Hz, 1H), 3.26 (dd, J=7.6, 5.4 Hz, 1H), 3.16-2.60 (m, 6H), 2.41 (d, J=6.6 Hz, 2H), 1.45 (s, 9H), 1.90-0.80 (m, 11H).

Example 20(2)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((thiophen-2-ylmethyl)amino)propanamide

[1438] 1361

[1439] TLC: Rf 0.19 (hexane:ethyl acetate=4:1);

[1440] NMR (CDCl3): δ 7.64 (t, J=5.4 Hz, 1H), 7.22-7.18 (m, 3H), 6.95-6.84 (m, 4H), 4.39 (dd, J=14.4, 6.0 Hz, 1H), 4.37 (dd, J=14.4, 6.0 Hz, 1H), 3.93 (s, 2H), 3.80 (s, 3H), 3.30 (dd, J=9.3, 3.9 Hz, 1H), 3.03 (dd, J=13.8, 3.9 Hz, 1H), 2.63 (dd, J=13.8, 9.3 Hz, 1H), 2.31 (dd, J=12.3, 6.9 Hz, 1H), 2.25 (dd, J=12.3, 6.9 Hz, 1H), 1.83-1.32 (m, 6H), 1.28-1.04 (m, 3H), 0.95-0.80 (m, 2H).

Example 20(3)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((cyclohexylmethyl)-amino)propanamide

[1441] 1362

[1442] TLC: Rf 0.24 (hexane:ethyl acetate=4:1);

[1443] NMR (CDCl3): δ 7.67 (t, J=5.5 Hz, 1H), 7.23-7.16 (m, 2H), 6.90-6.83 (m, 2H), 4.40 (dd, J=14.4, 6.2 Hz, 1H), 4.35 (dd, J=14.6, 5.8 Hz, 1H), 3.80 (s, 3H), 3.17-3.02 (m, 2H), 2.60-2.24 (m, 5H), 1.87-0.70 (m, 22H).

Example 20(4)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(((4RS)-3-t-butoxycarbonyl-1,3-perhydrothiazin-4-ylmethyl)amino)propanamide

[1444] 1363

[1445] TLC: Rf 0.17 (ethyl acetate:hexane=1:2);

[1446] NMR (CD3OD) δ 7.29-7.20 (m, 2H), 6.91-6.81 (m, 2H), 4.71-4.50 (m, 1H), 4.41-4.22 (m, 4H), 3.77 (s, 3H), 3.28-3.19 (m, 1H), 3.03-2.75 (m, 3H), 2.71-2.35 (m, 5H), 2.00-1.60 (m, 7H), 1.52-1.34 (m, 1 OH), 1.33-1.10 (m, 3H), 1.02-0.84 (m, 2H).

Example 20(5)

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((thiophen-2-ylmethyl)-amino)propanamide

[1447] 1364

[1448] TLC: Rf 0.41 (hexane:ethyl acetate=2:1);

[1449] NMR (CD3OD): δ 7.37-7.25 (m, 5H), 7.12-7.05 (m, 1H), 7.00-6.91 (m, 6H), 4.42 (d, J=14.6 Hz, 1H), 4.34 (d, J=14.6 Hz, 1H), 3.98 (d, J=14.1 Hz, 1H), 3.86 (d, J=14.1 Hz, 1H), 3.33-3.28 (m, 1H), 2.83 (dd, J=13.4, 6.0 Hz, 1H), 2.68 (dd, J=13.4, 7.4 Hz, 1H), 2.32 (dd, J=12.6, 6.9 Hz, 1H), 2.26 (dd, J=12.6, 6.9 Hz, 1H), 1.84-1.59 (m, 5H), 1.47-1.06 (m, 4H), 0.99-0.80 (m, 2H).

Example 20(6)

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((cyclohexylmethyl)-amino)propanamide

[1450] 1365

[1451] TLC: Rf 0.52 (hexane:ethyl acetate=2:1)

[1452] NMR (CD3OD) δ 7.38-7.27 (m, 4H), 7.13-7.04 (m, 1H), 6.98-6.89 (m, 4H), 4.45 (d, J=14.6 Hz, 1H), 4.30 (d, J=14.6 Hz, 1H), 3.17 (dd, J=7.4, 6.2 Hz, 1H), 2.83 (dd, J=13.2, 6.2 Hz, 1H), 2.65 (dd, J=13.2, 7.4 Hz, 1H), 2.42-2.23 (m, 0.4H) 1.90-0.70 (m, 22H).

Example 20(7)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(((4R)-3-(3-methylbutyryl)-thiazolidin-4-ylmethyl)amino)propanamide

[1453] 1366

[1454] TLC: Rf 0.33 (hexane:ethyl acetate=1:1);

[1455] NMR (DMSO-d6) δ 8.06-8.00 (br, 1H), 7.20 (d, J=8.0 Hz, 2H), 6.85 (d, J=8.0 Hz, 2H), 4.76-4.68 (br, 1H), 4.53-4.42 (br, 1H), 4.28-4.18 (m, 3H), 3.74 (s, 3H), 3.24-3.21 (m, 1H), 3.09-2.95 (m, 2H), 2.77-2.60.(m, 4H), 2.45-2.38.(m, 2H), 2.28-2.17 (m, 3H), 2.09-2.00 (m, 1H), 1.79-1.73 (m, 2H), 1.69-1.58 (m, 3H), 1.46-1.38 (m, 1H), 1.26-1.10 (m, 3H), 0.99-0.91 (m, 8H).

Example 21˜Example 21 (2)

[1456] By the same desired procedure as Example 17, using the compounds prepared in Example 20 Example 20(1) and Example 20(4), the following compounds of the present invention were obtained.

Example 21

(2R)-N-(4-methoxybenzyl)-3-cycloyhexylmethylthio-2-(((4R)-thiazolidin-4-ylmethyl)amino)propanamide

[1457] 1367

[1458] TLC: Rf 0.34 (methylene chloride:methanol=19:1);

[1459] NMR (CDCl3): δ 7.76-7.66 (m, 1H), 7.23-7.16 (m, 2H), 6.89-6.83 (m, 2H), 4.37 (d, J=6 Hz, 2H), 4.16 (d, J=10 Hz, 1H), 4.10 (d, J=10 Hz, 1H), 3.80 (3H, s), 3.39 (quintet, J=7 Hz, 1H), 3.19 (dd, J=10, 3 Hz, 1H), 3.08 (dd, J=14, 3 Hz, 1H), 2.96 (dd, J=10, 7 Hz, 1H), 2.68 (d, J=7 Hz, 2H), 2.61 (dd, J. 14,10 Hz, 1H), 2.47(dd, J=10, 7 Hz, 1H), 2.42 (dd, J=13, 7 Hz, 1H), 2.39(dd, J=13, 7 Hz, 1H), 2.00-1.58 (m, 7H), 1.53-1.36 (m, 1H), 1.32-1.05 (m, 3H), 1.02-0.83 (2H, m).

Example 21 (1)

(2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-(((4R)-thiazolidin-4-ylmethyl)amino)propanamide

[1460] 1368

[1461] TLC: Rf 0.47 (chloroform:methanol=19:1);

[1462] NMR (CD3OD): δ 7.40-7.29 (m, 4H), 7.15-7.04 (m, 1H), 7.00-6.90 (m, 4H), 4.43 (d, J=14.6 Hz, 1H), 4.34 (d, J=14.6 Hz, 1H), 4.13 (d, J=9.2 Hz, 1H), 4.02 (d, J=9.2 Hz, 1H), 3.78-3.54 (m, 1H), 3.33-3.23 (m, 1H), 2.99-2.60 (m, 6H), 2.52 (dd, J=9.8, 7.0 Hz, 1H), 2.41 (d, J=6.6 Hz, 2H), 1.90-0.80 (m, 11H).

Example 21 (2)

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(((4RS)-1,3-perhydrothiazin-4-ylmethyl)amino)propanamide

[1463] 1369

[1464] TLC: Rf 0.37 (methylene chloride:methanol=9:1);

[1465] NMR (CD3OD) δ 7.28-7.21 (m, 2H), 6.90-6.83 (m, 2H), 4.42-4.25 (m, 2H), 4.08-3.97 (m, 1H), 3.95-3.86 (m, 1H), 3.77 (s, 3H), 3.23-3.13 (m, 1H), 3.01-2.76 (m, 2H), 2.76-2.56 (m, 3H), 2.56-2.32 (m, 4H), 1.87-1.60 (m, 6H), 1.50-1.08 (m, 5H), 1.03-0.84 (m, 2H).

Example 22

(2R)-N-(4-methoxybenzyl)-3-((1S,2R,4R)-bicyclo[2.2.1]heptan-2-ylmethylthio)-2-((4R)-3-t-butoxycarbonylthiazolidin+4-ylcarbonylamino)propanamide

[1466] 1370

[1467] By the same desired procedure as Example 6, using the compound prepared in Example 10(10), the compound of the present invention having the following physical data was obtained.

[1468] TLC: Rf 0.50 (ethyl acetate:hexane=1:1);

[1469] NMR (CD3OD): δ 7.27-7.15 (2H, m), 6.90-6.79 (2H, m), 4.67-4.43 (4H, m), 4.33 (1H, d, J=15 Hz), 4.31 (1H, d, J=15 Hz), 3.76 (3H, s), 3.43-3.25 (1H, m), 3.14 (1H, dd, J=12, 4 Hz), 3.02-2.70 (2H, m), 2.57 (1H, dd, J=12, 8 Hz), 2.55 (1H, dd, J=12, 8 Hz), 2.22-2.10 (2H, m), 2.10-1.69 (2H, m), 1.61-1.03 (6H, m), 1.45 (9H, s), 0.68 (1H, ddd, J=12, 5, 2 Hz).

Example 23

(2R)-N-(4-methoxybenzyl)-3-((1S,2R,4R)-bicyclo[2.2.1]heptan-2-ylmethylthio)-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide-hydrochloride

[1470] 1371

[1471] By the same desired procedure as Example 9, using the compound prepared in Example 22, the compound of the present invention having the following physical data was obtained.

[1472] TLC: Rf 0.51 (methylene chloride:methanol=19:1);

[1473] NMR (CD3OD): δ 7.30-7.18 (2H, m), 6.93-6.83 (2H, m), 4.60-4.46 (2H, m), 4.39 (2H, s), 4.36-4.24 (2H, m), 3.78 (3H, s), 3.50 (1H, dd, J=12, 7 Hz), 3.24 (1H, dd, J=12, 7 Hz), 2.94 (1H, dd, J=13, 6 Hz), 2.82 (1H, dd, J=13, 8 Hz), 2.59 (1H, dd, J=12, 8 Hz), 2.57 (1H, dd, J=12, 8 Hz), 2.22-2.11 (2H, m), 2.10-1.89 (1H, m), 1.89-1.70 (1H, m), 1.62-1.03 (6H, m), 0.68 (1H, ddd, J=12, 5, 2 Hz).

FORMULATION EXAMPLE

Fomulation Example 1

[1474] The following components were admixed in conventional method and punched out to obtain 100 tablets each containing 50 mg of active ingredient.

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t- 5.0 g
butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide
carboxymethylcellulose calcium (disintegrating agent) 0.2 g
Magnesium stearate (Lubricating agent) 0.1 g
Microcrystaline cellulose        4.7 g

Formulation Example 2

[1475] The following components were admixed in conventional manner. The solution was sterilized in conventional manner, placed 5 ml portions into ampoules and freezed-dried to obtain 100 ampouls each containing 20 mg of active ingredient.

(2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-	2.00	g
t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide
mannitol	20	g
distilled water	500	ml

Claims

1. An N-type calcium channel blocker comprising, as an active ingredient, an amino acid derivative of the formula (I):

2. A pharmaceutical composition comprising a compound depicted in claim 1 as an active ingredient for the prevention and/or treatment of cerebral infarct, transient ischemic attack, encephalomyelopathy after cardiac operation, spinal angiopathy, hypertension with stress, neurosis or epilepsy.

3. A pharmaceutical composition comprising a compound depicted in claim 1 as an active ingredient for the treatment of pain.

4. An amino acid derivative of the formula (I):

5. A compound according to claim 4, wherein E is —S—, —SO—, or —SO2—.

6. A compound according to claim 4, wherein E is —O—.

7. A compound according to claim 4, wherein E is —COO—.

8. A compound according to claim 4, wherein E is —OCO—, —CONR8—, —NR9CO—, —NR10—, —CO—, —SO2NR11—, or NR12SO2— (in which R8, R9, R10, R11 and R12 are the same meanings as described in claim 4.).

9. A compound according to claim 5, which is (1) (2R)-3-(4-methoxybenzylthio)-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester, (2) (2R)-N-(4-methoxybenzyl)-3-(4-methoxybenzylthio)-2-t-butoxycarbonylaminopropanamide, (3) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylaminopropanamide, (4) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylaminopropanamide, (5) (2R)-N-(4-methoxybenzyl)-3-cyclopentylmethylthio-2-t-butoxycarbonylaminopropanamide, (6) (2S)-N-(4-methoxybenzyl)-3-cyclopentylmethylthio-2-t-butoxycarbonylaminopropanamide, (7) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylaminopropanamide, (8) (2R)-N-(furan-2-ylmethyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylaminopropanamide, (9) (2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-t-butoxycarbonylaminopropanamide, (10) (2R)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanoic acid.4-methoxybenzyl ester, (11) (2R)-N-(4-methoxycyclohexylmethyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (12) (2R)-N-(4-methoxycyclohexylmethyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (13) (2R)-N-(4-phenoxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexylmethyl-thiopropanamide, (14) (2R)-N-((1S)-1-(4-nitrophenyl)ethyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (15) (2R)-N-((1R)-1-(4-nitrophenyl)ethyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (16) (2R)-N-methyl-N-(4-nitrobenzyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (17) (2R)-N-(1-(4-methoxyphenyl)-1-methylethyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (18) (2R)-N-(1-methyl-1-(4-nitrophenyl)ethyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (19) (2S)-N-((1R)-1-(4-nitrophenyl)ethyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (20) (2R)-N-methyl-N-(4-methoxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (21) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(N′-methyl-N′-(t-butoxycarbonyl)amino)propanamide, (22) (2R)-N-(4-benzyloxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (23) (2R)-N-(3-benzyloxy-4-methoxybenzyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (24) N-((1R)-2-cyclohexylmethylthio-1-(4-phenylpiperazin-1-ylcarbonyl)ethyl)carbamide acid.t-butyl ester, (25) (2R)-N-(2-phenoxypyridin-5-yl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (26) (2R)-N-(2-phenoxypyridin-5-ylmethyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (27) (2R)-N-(4-(morpholin-4-yl)benzyl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (28) (2R)-N-(1-phenylpiperidin-4-yl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (29) (2R)-N-(1-methylpiperidin-4-yl)-2-t-butoxycarbonylamino-3-cyclohexylmethylthiopropanamide, (30) (2R)-N-(4-methoxybenzyl)3-cyclohexylmethylthio-2-cyclopentylcarbonylaminopropanamide, (31) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-cyclohexylcarbonylaminopropanamide, (32) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-cyclobutylcarbonylaminopropanamide, (33) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-cycloheptylcarbonylaminopropanamide, (34) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(4-methoxycyclohexylcarbonylamino)propanamide, (35) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-3-t-butoxycarbonylthiazolidin-2-ylcarbonylamino)propanamide, (36) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(2-methylpropylcarbonylamino)propanamide, (37) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(2-methylpropyloxycarbonylamino)propanamide, (38) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(1-(t-butoxycarbonyl)piperidin-4-ylcarbonylamino)propanamide, (39) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(4-(t-butoxycarbonylamino)cyclohexylcarbonylamino)propanamide, (40) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(tetrahydrofuran-2-ylcarbonylamino)propanamide, (41) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide, (42) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2S)-1-t-butoxycarbonylpyrrolidin-2-ylcarbonylamino)propanamide, (43) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(thiazol-4-ylcarbonylamino)propanamide, (44) (2R)-N-((1R)-1-(4-nitrophenyl)ethyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide, (45) (2S)-N-((1R)-1-(4-nitrophenyl)ethyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (46) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(2-t-butoxycarbonylaminothiazol-4-ylcarbonylamino) propanamide, (47) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4S)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (48) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (49) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((2RS)-3-t-butoxycarbonylthiazolidin-2-ylcarbonylamino) propanamide, (50) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((4R)-3-methylthiazolidin-4-ylcarbonylamino)propanamide, (51) (2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (52) (2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-((2RS)-3-t-butoxycarbonylthiazolidin-2-ylcarbonylamino) propanamide, (53) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-(1-t-butoxycarbonylimidazol-4-ylcarbonylamino) propanamide, (54) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((4R)-2,2-dimethylthiazolidin-4-ylcarbonylamino)propanamide, (55) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-(thiophen-2-ylcarbonylamino)propanamide, (56) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-(5-methyloxazol-2-ylcarbonylamino)propanamide, (57) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(3-t-butoxycarbonylthiazolidin-2-ylcarbonylamino)propanamide, (58) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(3-t-butoxycarbonylthiazolidin-2-ylcarbonylamino)propanamide, (59) (2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-cyclohexylcarbonylaminopropanamide, (60) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(3-t-butoxycarbonylthiazolidin-2-ylcarbonylamino)propanamide, (61) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4S)3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (62) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin 4-ylcarbonylamino) propanamide, (63) (2R)-N-methyl-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide, (64) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-N′-methyl-N′-(3-t-butoxycarbonylthiazolidin-4-ylcarbonyl)amino)propanamide, (65) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (66) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS, 4R)-3-t-butoxycarbonyl-2-(2-methylpropyl) thiazolidin-4-ylcarbonylamino)propanamide, (67) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(pyridin-3-ylcarbonylamino)propanamide, (68) (2R)-N-(4-benzyloxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (69) (2R)-N-(3-benzyloxy-4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide, (70) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(pyridin-4-ylcarbonylamino)propanamide, (71) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS, 4R)-3-t-butoxycarbonyl-2-phenylthiazolidin-4-ylcarbonylamino)propanamide, (72) (4R)-N-((1R)-2-cyclohexylmethylthio-1-(4-phenylpiperazin-1-ylcarbonyl)ethyl)-3-t-butoxycarbonylthiazolidin-4-ylcarboxamide, (73) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((3RS)-4-t-butoxycarbonylthiomorpholin-3-ylcarbonylamino) propanamide, (74) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((3RS)-4-t-butoxycarbonylthiomorpholin-3-ylcarbonylamino) propanamide, (75) (2R)-N-(2-phenoxypyridin-5-yl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (76) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-4-t-butoxycarbonylthiomorpholin-2-ylcarbonylamino) propanamide, (77) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4RS)-3-t-butoxycarbonyl-1,3-perhydrothiazin-4-ylcarbonylamino) propanamide, (78) (2R)-N-(2-phenoxypyridin-5-ylmethyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (79) (2R)-N-(4-(morpholin-4-yl)benzyl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (80) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4RS)-3-t-butoxycarbonyl-1,3-perhydrothiazin-4-ylcarbonylamino) propanamide, (81) (2R)-N-(1-phenylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (82) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-2-oxothiazolidin-4-ylcarbonylamino)propanamide, (83) (2R)-N-(1-methylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide, (84) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-t-butoxycarbonyl-aminopropanamide, (85) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfinyl-2-t-butoxycarbonylaminopropanamide, (86) (2R)-N-(4-methoxybenzyl)-3-cyclopentylmethylsulfonyl-2-t-butoxycarbonylaminopropanamide, (87) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-cyclohexylcarbonylaminopropanamide, (88) (2S)-N-(4-methoxybenzyl)-3-cyclopentylmethylsulfonyl-2-t-butoxycarbonylaminopropanamide, (89) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyi-2-(4-methoxycyclohexylcarbonylamino)propanamide, (90) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(4-methoxycyclohexylcarbonylamino)propanamide, (91) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-cyclobutylcarbonylaminopropanamide, (92) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(tetrahydrofuran-2-ylcarbonylamino)propanamide, (93) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-cycloheptylcarbonylaminopropanamide, (94) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(tetrahydrofuran-3-ylcarbonylamino) propanamide, (95) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-((2RS)-3-t-butoxycarbonylthiazolidin-2-ylcarbonylamino) propanamide, (96) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (97) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(3-t-butoxycarbonylthiazolidin-2-ylcarbonylamino) propanamide, (98) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfinyl-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino) propanamide, (99) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(1-t-butoxycarbonylpiperidin-4-ylcarbonylamino) propanamide, (100) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-(4-t-butoxycarbonylaminocyclohexylcarbonylamino)propanamide, (101) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylsulfonyl-2-((2RS)-thiazolidin-2-ylcarbonylamino) propanamide, (102) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(piperidin-4-ylcarbonylamino)propanamide, (103) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(4-aminocyclohexylcarbonylamino)propanamide, (104) (2R)-N-((1R)-1-(4-nitrophenyl)ethyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino) propanamide, (105) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4S)-thiazolidin-4-ylcarbonylamino)propanamide, (106) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide, (107) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-((2RS)-thiazolidin-2-ylcarbonylamino)propanamide, (108) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethylthio-2-(imidazol-4-ylcarbonylamino)propanamide, (109) (2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino) propanamide, (110) (2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-((2RS)-thiazolidin-2-ylcarbonylamino) propanamide, (111) (2R)-N-(4-benzyloxybenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino) propanamide, (112) (2R)-N-(3-benzyloxy-4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino) propanamide, (113) (2R)-N-(4-methoxybenzyl)-3-(tetrahydropyran-2-yl)methylthio-2-t-butoxycarbonylaminopropanamide, (114) (2R)-N-(4-methoxybenzyl)-3-(bicyclo[2.2.1]heptan-2-ylmethylthio)-2-t-butoxycarbonylaminopropanamide, (115) (2R)-N-(4-methoxybenzyl)-3-(4-methoxycyclohexylmethylthio)-2-t-butoxycarbonylaminopropanamide, (116) (2R)-N-(4-methoxybenzyl)-3-(1-methylpiperidin-2-ylmethylthio)-2-t-butoxycarbonylaminopropanamide, (117) (2R)-N-(4-methoxybenzyl)-3-(pyridin-4-ylmethylthio)-2-t-butoxycarbonylaminopropanamide, (118) (2R)-N-(4-methoxybenzyl)-3-(quinolin-2-ylmethylthio)-2-t-butoxycarbonylaminopropanamide, (119) (2R)-N-(4-methoxybenzyl)-3-(imidazol-4-ylmethylthio)-2-t-butoxycarbonylaminopropanamide, (120) (2R)-N-(4-methoxybenzyl)-3-((1R, 4R, 5R)-bicyclo[2.2.1]hept-2-en-5-ylmethylthio)-2-t-butoxycarbonylaminopropanamide, (121) (2R)-N-(4-methoxybenzyl)-3-((1S, 4S, 5S)-bicyclo[2.2.1]hept-2-en-5-ylmethylthio)-2-t-butoxycarbonylaminopropanamide, (122) (2R)-N-(4-methoxybenzyl)-3-((1S, 2R, 4R)-bicyclo[2.2.1]heptan-2-ylmethylthio)-2-t-butoxycarbonylaminopropanamide, (123) (2R)-N-(4-methoxybenzyl)-3-((1R, 2S, 4S)-bicyclo[2.2.1]heptan-2-ylmethylthio)-2-t-butoxycarbonylaminopropanamide, (124) (2R)-N-(4-methoxybenzyl)-3-(piperidin-1-ylsulfonyl)-2-t-butoxycarbonylaminopropanamide, (125) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide, (126) (2R)-N-(1-phenylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide, (127) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-thiazolidin-2-ylcarbonylamino) propanamide, (128) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide, (129) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(2-aminothiazol-4-ylcarbonylamino)propanamide, (130) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(thiazolidin-2-ylcarbonylamino)propanamide, (131) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS, 4R)-2-(2-methylpropyl)thiazolidin-4-ylcarbonylamino)propanamide, (132) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS, 4R)-2-phenylthiazolidin-4-ylcarbonylamino)propanamide, (133) (4R)-N-((1R)-2-cyclohexylmethylthio-1-(4-phenylpiperazin-1-ylcarbonyl)ethyl)thiazolidin-4-ylcarboxamide, (134) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((3RS)-thiomorpholin-3-ylcarbonylamino) propanamide, (135) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((3RS)-thiomorpholin-3-ylcarbonylamino) propanamide, (136) (2R)-N-(2-phenoxypyridin-5-yl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide, (137) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-thiomorpholin-2-ylcarbonylamino) propanamide, (138) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4RS)-1,3-perhydrothiazin-4-ylcarbonylamino)propanamide, (139) (2R)-N-(2-phenoxypyridin-5-ylmethyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino) propanamide, (140) (2R)-N-(4-(morpholin-4-yl)benzyl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino) propanamide, (141) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4RS)-1,3-perhydrothiazin-4-ylcarbonylamino)propanamide, (142) (2R)-N-(1-methylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-thiazolidin-4-ylcarbonylamino) propanamide, (143) (2R)-N-((1R)-1-(4-nitrophenyl)ethyl)-3-cyclohexylmethylthio-2-((4R)-3-(2-methylpropylcarbonyl)thiazolidin-4-ylcarbonylamino)propanamide, (144) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((2RS)-3-acetylthiazolidin-2-ylcarbonylamino)propanamide, (145) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-methoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide, (146) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-(2-methylpropoxycarbonyl)thiazolidin-4-ylcarbonylamino)propanamide, (147) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-methoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide, (148) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((4R)-3-(2-methylpropoxycarbonyl)thiazolidin-4-ylcarbonylamino)propanamide, (149) (2R)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethylthio-2-(thiazolidin-2-ylcarbonylamino)propanamide, (150) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(((4R)-3-t-butoxycarbonylthiazolidin-4-ylmethyl)amino)propanamide, (151) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-(((4R)-3-t-butoxycarbonylthiazolidin-4-ylmethyl)amino)propanamide, (152) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((thiophen-2-ylmethyl)amino)propanamide, (153) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-((cyclohexylmethyl)amino)propanamide, (154) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(((4RS)-3-t-butoxycarbonyl-1,3-perhydrothiazin-4-ylmethyl)amino) propanamide, (155) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((thiophen-2-ylmethyl)amino)propanamide, (156) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-((cyclohexylmethyl)amino)propanamide, (157) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(((4R)-3-(3-methylbutyryl)thiazolidin-4-ylmethyl)amino)propanamide, (158) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(((4R)-thiazolidin-4-ylmethyl)amino)propanamide, (159) (2R)-N-(4-phenoxybenzyl)-3-cyclohexylmethylthio-2-(((4R)-thiazolidin-4-ylmethyl)amino) propanamide, (160) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethylthio-2-(((4RS)-1,3-perhydrothiazin-4-ylmethyl)amino)propanamide, (161) (2R)-N-(4-methoxybenzyl)-3-((1S, 2R, 4R)-bicyclo[2.2.1]heptan-2-ylmethylthio)-2-((4R)-3-t-butoxycarbonylthiazolidin-4-ylcarbonylamino)propanamide, or (162) (2R)-N-(4-methoxybenzyl)-3-((1S, 2R, 4R)-bicyclo[2.2.1]heptan-2-ylmethylthio)-2-((4R)-thiazolidin-4-ylcarbonylamino)propanamide, or a non-toxic salt thereof, or a hydrate thereof.

10. A compound according to claim 6, which is (1) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanamide, (2) (2R)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (3) (2S)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (4) (2S)-N-(4-methoxybenzyl)-3-benzyloxy-2-t-butoxycarbonylaminopropanamide, (5) (2S)-N-(4-dimethylaminobenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanamide, (6) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanamide, (7) (2S)-N-methyl-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanamide, (8) (2RS)-N-(4-methoxybenzyl)-4-cyclohexylmethoxy-2-t-butoxycarbonylaminobutanamide, (9) (2S)-N-(4-nitrobenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanamide, (10) (2S)-N-(4-methoxybenzyl)-3-(2-cyclohexenyloxy)-2-t-butoxycarbonylaminopropanamide, (11) (2S)-N-(4-methoxybenzyl)-3-cyclohexyloxy-2-1-butoxycarbonylaminopropanamide, (12) (2S)-N-(4-methoxybenzyl)-3-cyclopentylmethoxy-2-t-butoxycarbonylaminopropanamide, (13) (2S)-N-(4-methoxybenzyl)-4-(2-cyclohexenyloxy)-2-t-butoxycarbonylaminobutanamide, (14) (2S)-N-(4-methoxybenzyl)-4-cyclohexyloxy-2-t-butoxycarbonylaminobutanamide, (15) (2R)-N-(4-nitrobenzyl)-3-cyclohexylmethoxy-2-t-butoxycarbonylaminopropanamide, (16) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-benzoylaminopropanamide, (17) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-phenylsulfonylaminopropanamide, (18) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-pivaloylaminopropanamide, (19) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-(4-methoxybenzoylamino)propanamide, (20) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-(4-nitrobenzoylamino)propanamide, (21) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-(12-methyltridecylcarbonylamino)propanamide, (22) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-cyclohexylcarbonylaminopropanamide, (23) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-(4-methoxyphenylsulfonylamino)propanamide, (24) (2S)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-cyclohexylsulfonylaminopropanamide, or (25) (2R)-N-(4-methoxybenzyl)-3-cyclohexylmethoxy-2-cyclohexylcarbonylaminopropanamide, or a non-toxic salt thereof, or a hydrate thereof.

11. A compound according to claim 7, which is (1) (2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester, (2) (2S)-3-benzyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester, (3) (2S)-3-benzyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.cyclopentyl ester, (4) (2R)-3-benzyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester, (5) (2R)-3-benzyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.cyclopentyl ester, (6) (2R)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester, (7) (2S)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.benzyl ester, (8) (2R)-4-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.benzyl ester, (9) (2R)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.benzyl ester, (10) (2S)-4-benzyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester, (11) (2S)-4-benzyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.cyclopentyl ester, (12) (2R)-4-benzyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester, (13) (2R)-4-benzyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid cyclopentyl ester, (14) (2S)-3-cyclopentyloxycarbonyl-2-(N-t-butoxycarbonyl-N-methylamino)propanoic acid.4-nitrobenzyl ester, (15) (2S)-3-cyclohexyloxycarbonyl-2-(N-t-butoxycarbonyl-N-amino)propanoic acid.4-nitrobenzyl ester, (16) (2S)-3-cyclobutyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester, (17) (2S)-3-(adamantan-2-yloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.benzyl ester, (18) (2S)-3-(adamantan-1-yloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.benzyl ester, (19) (2S)-4-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-nitrobenzyl ester, (20) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-fluorobenzyl ester, (21) (2R)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-fluorobenzyl ester, (22) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (23) (2R)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (24) (2S)-3-cyclohexyloxycarbonyl-2-benzyloxycarbonylaminopropanoic acid.4-nitrobenzyl ester, (25) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 4-nitrophenethyl ester, (26) (2S)-N-benzyl-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide, (27) (2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 4-methoxybenzyl ester, (28) (2S)-3-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester, (29) (2S)-3-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester, (30) (2S)-3-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid cyclopentyl ester, (31) (2S)-3-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid cyclopentyl ester, (32) (2R)-3-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester, (33) (2R)-3-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester, (34) (2R)-3-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.cyclopentyl ester, (35) (2R)-3-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid cyclopentyl ester, (36) (2R)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (37) (2S)-4-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester, (38) (2S)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester, (39) (2S)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-nitrobenzyl ester, (40) (2R)-4-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester, (41) (2R)-4-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid.4-nitrobenzyl ester, (42) (2R)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid 4-methoxybenzyl ester, (43) (2R)-4-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminobutanoic acid 4-nitrobenzyl ester, (44) (2S)-4-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester, (45) (2S)-4-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester, (46) (2S)-4-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclopentyl ester, (47) (2S)-4-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid cyclopentyl ester, (48) (2R)-4-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester, (49) (2R)-4-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclohexyl ester, (50) (2R)-4-(4-methoxybenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclopentyl ester, (51) (2R)-4-(4-nitrobenzyloxycarbonyl)-2-t-butoxycarbonylaminobutanoic acid.cyclopentyl ester, (52) (2S)-N-(4-methoxybenzyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide, (53) (2S)-N-(4-methoxybenzyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide, (54) (2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.2-pyridylmethyl ester, (55) (2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-t-butylbenzyl ester, (56) (2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 2-methoxybenzyl ester, (57) (2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 3-methoxybenzyl ester, (58) (2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 3-pyridylmethyl ester, (59) (2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 4-pyridylmethyl ester, (60) (2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 4-chlorobenzyl ester, (61) (2S)-3-cyclopentyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 4-bromobenzyl ester, (62) (2S)-3-cyclopentyloxycarbonyl-2-(N-methyl-N-t-butoxycarbonylamino)propanoic acid.4-methoxybenzyl ester, (63) (2S)-3-cyclohexyloxycarbonyl-2-(N-methyl-N-t-butoxycarbonylamino)propanoic acid.4-methoxybenzyl ester, (64) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxyphenethyl ester, (65) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid is 3-(4-methoxyphenyl)propyl ester, (66) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.furan-2-ylmethyl ester, (67) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid thiophen-2-ylmethyl ester, (68) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 4-(4-methoxyphenyl)butyl ester, (69) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.cyclohexyl ester, (70) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid methyl ester, (71) (2S)-N-(4-methoxyphenyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide, (72) (2S)-3-cyclobutyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 4-methoxybenzyl ester, (73) (2S)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid diphenylmethyl ester, (74) (2S)-N-((1S)-2-phenyl-1-benzyloxycarbonylethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide, (75) (2S)-N-((1S)-1-benzyloxycarbonylethyl)-3-cyclohexyloxycarbonyl-2-t butoxycarbonylaminopropanamide, (76) (2S)-3-benzyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid 4-methoxybenzyl ester, (77) (2S)-3-cycloheptyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (78) (2S)-3-cyclooctyloxycarbonyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (79) (2S)-3-(adamantan-2-yloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (80) (2S)-3-(adamantan-1-yloxycarbonyl)-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (81) (2S)-N-((1S)-1-(4-methoxybenzyloxycarbonyl)ethyl)-3-cyclohexyloxycarbonyl-2-benzyloxycarbonylaminopropanamide, (82) (2S)-N-((1S)-2-phenyl-1-(4-methoxybenzyloxycarbonyl)ethyl)-3-. cyclohexyloxycarbonyl-2-benzyloxycarbonylaminopropanamide, (83) (3S)-3-t-butoxycarbonylamino-3-(1, 2, 3, 4-tetrahydroquinolin-1-ylcarbonyl)propanoic acid.cyclohexyl ester, (84) (3S)-3-t-butoxycarbonylamino-3-(1, 2, 3, 4-tetrahydroisoquinolin-2-ylcarbonyl)propanoic acid.cyclohexyl ester, (85) (2S)-N-methyl-N-(1,1-dimethyl-2-phenylethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide, (86) (2S)-N-((1S)-1-carboxy-2-phenylethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide, (87) (2S)-N-((1S)-1-carboxyethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide, (88) (2S)-N-((1S)-1-(4-methoxybenzyloxycarbonyl)ethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide, (89) (2S)-N-((l S)-2-phenyl-1-(4-methoxybenzyloxycarbonyl)ethyl)-3-cyclohexyloxycarbonyl-2-t-butoxycarbonylaminopropanamide, (90) (2S)-3-cyclopentyloxycarbonyl-2-methylcarbonylaminopropanoic acid 4-methoxybenzyl ester, (91) (2S)-3-cyclopentyloxycarbonyl-2-benzoylaminopropanoic acid.4-methoxybenzyl ester, (92) (2S)-3-cyclopentyloxycarbonyl-2-pivaloylaminopropanoic acid.4-methoxybenzyl ester, (93) (2S)-3-cyclopentyloxycarbonyl-2-cinnamoylaminopropanoic acid.4-methoxybenzyl ester, (94) (2S)-3-cyclopentyloxycarbonyl-2-valerylaminopropanoic acid.4-methoxybenzyl ester, (95) (2S)-3-cyclopentyloxycarbonyl-2-(octylcarbonylamino)propanoic acid 4-methoxybenzyl ester, (96) (2S)-3-cyclopentyloxycarbonyl-2-mesylaminopropanoic acid 4-methoxybenzyl ester, (97) (2S)-3-cyclopentyloxycarbonyl-2-phenylsulfonylaminopropanoic acid.4-methoxybenzyl ester, (98) (2S)-3-cyclopentyloxycarbonyl-2-(butylsulfonylamino)propanoic acid.4-methoxybenzyl ester, (99) (2S)-3-cyclopentyloxycarbonyl-2-(octylsulfonylamino)propanoic acid.4-methoxybenzyl ester, (100) (2S)-3-cyclopentyloxycarbonyl-2-((E)-styrylsuflonylamino)propanoic acid.4-methoxybenzyl ester, (101) (2S)-3-cyclopentyloxycarbonyl-2-benzyloxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (102) (2S)-3-cyclohexyloxycarbonyl-2-benzoylaminopropanoic acid.4-methoxybenzyl ester, (103) (2S)-3-cyclohexyloxycarbonyl-2-(4-fluorobenzoylamino)propanoic acid.4-methoxybenzyl ester, (104) (2S)-3-cyclohexyloxycarbonyl-2-(4-methoxybenzoyl)propanoic acid 4-methoxybenzyl ester, (105) (2S)-3-cyclohexyloxycarbonyl-2-(4-phenylbenzoylamino)propanoic acid.4-methoxybenzyl ester, (106) (2S)-3-cyclohexyloxycarbonyl-2-(4-nitrobenzoylamino)propanoic acid.4-methoxybenzyl ester, (107) (2S)-3-cyclohexyloxycarbonyl-2-(4-acetylbenzoylamino)propanoic acid.4-methoxybenzyl ester, (108) (2S)-3-cyclohexyloxycarbonyl-2-(4-methylthiobenzoylamino)propanoic acid.4-methoxybenzyl ester, (109) (2S)-3-cyclohexyloxycarbonyl-2-(4-dimethylaminobenzoylamino)propanoic acid.4-methoxybenzyl ester, (110) (2S)-N-((1S)-1-carboxyethyl)-3-cyclohexyloxycarbonyl-2-benzyloxycarbonylaminopropanamide, (111) (2S)-N-((1S)-2-phenyl-1-carboxyethyl)-3-cyclohexyloxycarbonyl-2-benzyloxycarbonylaminopropanamide, (112) (2S)-3-cyclohexyloxycarbonyl-2-(N-benzyl-N-t-butoxycarbonylamino)propanoic acid.4-methoxybenzyl ester, or (113) (2S)-3-cyclohexyloxycarbonyl-2-benzylaminopropanoic acid 4-methoxybenzyl ester, or a non-toxic salt thereof, or a hydrate thereof.

12. A compound according to claim 8, which is (1) (2S)-3-cyclohexylcarbamoyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester, (2) (2S)-3-cyclopentylcarbamoyl-2-t-butoxycarbonylaminopropanoic acid.benzyl ester, (3) (2S)-4-(pyrrolidin-1-ylcarbonyl)-2-t-butoxycarbonylaminobutanoic acid.benzyl ester, (4) (2S)-3-cyclohexylcarbamoyl-2-t-butoxycarbonylaminopropanoic acid 4-methoxybenzyl ester, (5) (2S)-N-(4-methoxybenzyl)-3-cyclohexylcarbamoyl-2-t-butoxycarbonylaminopropanamide, (6) (2S)-3-cyclopentylcarbamoyl-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (7) (2S)-N-(4-methoxybenzyl)-3-cyclopentylcarbamoyl-2-t-butoxycarbonylaminopropanamide, (8) (2S)-4-(pyrrolidin-1-ylcarbonyl)-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester, (9) (2S)-3-cyclohexylcarbonyloxy-2-t-butoxycarbonylaminopropanoic acid.4-methoxybenzyl ester, (10) (2S, 3R)-3-cyclohexylcarbonyloxy-2-t-butoxycarbonylaminobutanoic acid.4-methoxybenzyl ester, (11) (2S)-6-cyclohexylcarbonylamino-2-t-butoxycarbonylaminohexanoic acid.4-methoxybenzyl ester, (12) (2S)-N-(4-methoxybenzyl)-3-cyclohexylcarbonylamino-2-t-butoxycarbonylaminopropanamide, (13) (2S)-4-cyclopentylamino-2-t-butoxycarbonylaminobutanoic acid 4-methoxybenzyl ester, (14) (2S)-N-(4-methoxybenzyl)-3-cyclohexylsulfonylamino-2-t-butoxycarbonylaminopropanamide, or (15) (2R)-N-(4-methoxybenzyl)-3-cyclohexylsulfamoyl-2-t-butoxycarbonylaminopropanamide, or a non-toxic salt thereof, or a hydrate thereof.